U.S. patent application number 17/670252 was filed with the patent office on 2022-06-02 for bispecific t cell activating antigen binding molecules.
The applicant listed for this patent is Hoffmann-La Roche Inc.. Invention is credited to Joaquin ARRIBAS, Marina BACAC, Anne FREIMOSER-GRUNDSCHOBER, Sylvia HERTER, Christian KLEIN, Rocio VICARIO.
Application Number | 20220169748 17/670252 |
Document ID | / |
Family ID | 1000006138585 |
Filed Date | 2022-06-02 |
United States Patent
Application |
20220169748 |
Kind Code |
A1 |
KLEIN; Christian ; et
al. |
June 2, 2022 |
BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
Abstract
The present invention generally relates to novel bispecific
antigen binding molecules for T cell activation and re-direction to
specific target cells. In addition, the present invention relates
to polynucleotides encoding such bispecific antigen binding
molecules, and vectors and host cells comprising such
polynucleotides. The invention further relates to methods for
producing the bispecific antigen binding molecules of the
invention, and to methods of using these bispecific antigen binding
molecules in the treatment of disease.
Inventors: |
KLEIN; Christian;
(Schlieren, CH) ; BACAC; Marina; (Schlieren,
CH) ; FREIMOSER-GRUNDSCHOBER; Anne; (Schlieren,
CH) ; HERTER; Sylvia; (Schlieren, CH) ;
ARRIBAS; Joaquin; (Barcelona, ES) ; VICARIO;
Rocio; (Barcelona, ES) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Hoffmann-La Roche Inc. |
Little Falls |
NJ |
US |
|
|
Family ID: |
1000006138585 |
Appl. No.: |
17/670252 |
Filed: |
February 11, 2022 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
17443893 |
Jul 28, 2021 |
|
|
|
17670252 |
|
|
|
|
17117598 |
Dec 10, 2020 |
|
|
|
17443893 |
|
|
|
|
15718818 |
Sep 28, 2017 |
10882918 |
|
|
17117598 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07K 2317/66 20130101;
C07K 16/30 20130101; C07K 16/468 20130101; C07K 16/2809 20130101;
C07K 2317/14 20130101; C07K 2317/565 20130101; A61P 35/00 20180101;
C07K 2317/24 20130101; C07K 16/28 20130101; C07K 16/46 20130101;
C07K 2317/522 20130101; C07K 2317/34 20130101; C07K 2317/55
20130101; C07K 2317/21 20130101; C07K 2317/56 20130101; C07K 16/32
20130101; C07K 2317/515 20130101; C07K 16/2803 20130101; C07K
2317/31 20130101; A61K 2039/505 20130101; C07K 2317/52
20130101 |
International
Class: |
C07K 16/32 20060101
C07K016/32; C07K 16/28 20060101 C07K016/28; C07K 16/30 20060101
C07K016/30; C07K 16/46 20060101 C07K016/46; A61P 35/00 20060101
A61P035/00 |
Foreign Application Data
Date |
Code |
Application Number |
Sep 30, 2016 |
EP |
16191933.7 |
Claims
1. A T cell activating bispecific antigen binding molecule
comprising (a) a first antigen binding moiety which specifically
binds to a first antigen; (b) a second antigen binding moiety which
specifically binds to a second antigen; wherein the first antigen
is an activating T cell antigen and the second antigen is p95HER2,
or the first antigen is p95HER2 and the second antigen is an
activating T cell antigen; and wherein the antigen binding moiety
which specifically binds to p95HER2 comprises a heavy chain
variable region, particularly a humanized heavy chain variable
region, comprising the heavy chain complementarity determining
region (HCDR) 1 of SEQ ID NO: 14, the HCDR 2 of SEQ ID NO: 15 and
the HCDR 3 of SEQ ID NO: 16, and a light chain variable region,
particularly a humanized light chain variable region, comprising
the light chain complementarity determining region (LCDR) 1 of SEQ
ID NO: 17, the LCDR 2 of SEQ ID NO: 18 and the LCDR 3 of SEQ ID NO:
19.
2. The T cell activating bispecific antigen binding molecule
according to claim 1, wherein the antigen binding moiety which
specifically binds to p95HER2 comprises a heavy chain variable
region comprising an amino acid sequence that is at least about
95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid
sequence of SEQ ID NO: 20 and a light chain variable region
comprising an amino acid sequence that is at least about 95%, 96%,
97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ
ID NO: 21.
3. The T cell activating bispecific antigen binding molecule
according to claim 1 or 2, wherein the first and/or the second
antigen binding moiety is a Fab molecule.
4. The T cell activating bispecific antigen binding molecule
according to any one of claims 1-3, wherein the second antigen
binding moiety is a Fab molecule which specifically binds to a
second antigen, and wherein the variable domains VL and VH or the
constant domains CL and CH1 of the Fab light chain and the Fab
heavy chain are replaced by each other.
5. The T cell activating bispecific antigen binding molecule
according to any one of claims 1-4, wherein the first antigen is
p95HER2 and the second antigen is an activating T cell antigen.
6. The T cell activating bispecific antigen binding molecule
according to any one of claims 1-5, wherein the activating T cell
antigen is CD3, particularly CD3 epsilon.
7. The T cell activating bispecific antigen binding molecule
according to any one of claims 1-6, wherein the antigen binding
moiety which specifically binds to the activating T cell antigen
comprises the heavy chain complementarity determining region (CDR)
1 of SEQ ID NO: 4, the heavy chain CDR 2 of SEQ ID NO: 5, the heavy
chain CDR 3 of SEQ ID NO: 6, the light chain CDR 1 of SEQ ID NO: 8,
the light chain CDR 2 of SEQ ID NO: 9 and the light chain CDR 3 of
SEQ ID NO: 10.
8. The T cell activating bispecific antigen binding molecule
according to any one of claims 1-7, wherein the antigen binding
moiety which specifically binds to the activating T cell antigen
comprises a heavy chain variable region comprising an amino acid
sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100%
identical to the amino acid sequence of SEQ ID NO: 3 and a light
chain variable region comprising an amino acid sequence that is at
least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino
acid sequence of SEQ ID NO: 7.
9. The T cell activating bispecific antigen binding molecule
according to any one of claims 1-8, wherein the first antigen
binding moiety under (a) is a first Fab molecule which specifically
binds to a first antigen, the second antigen binding moiety under
(b) is a second Fab molecule which specifically binds to a second
antigen wherein the variable domains VL and VH of the Fab light
chain and the Fab heavy chain are replaced by each other; and i) in
the constant domain CL of the first Fab molecule under a) the amino
acid at position 124 is substituted independently by lysine (K),
arginine (R) or histidine (H) (numbering according to Kabat), and
wherein in the constant domain CH1 of the first Fab molecule under
a) the amino acid at position 147 or the amino acid at position 213
is substituted independently by glutamic acid (E), or aspartic acid
(D) (numbering according to Kabat EU index); or ii) in the constant
domain CL of the second Fab molecule under b) the amino acid at
position 124 is substituted independently by lysine (K), arginine
(R) or histidine (H) (numbering according to Kabat), and wherein in
the constant domain CH1 of the second Fab molecule under b) the
amino acid at position 147 or the amino acid at position 213 is
substituted independently by glutamic acid (E), or aspartic acid
(D) (numbering according to Kabat EU index).
10. The T cell activating bispecific antigen binding molecule
according to claim 9, wherein in the constant domain CL of the
first Fab molecule under a) the amino acid at position 124 is
substituted independently by lysine (K), arginine (R) or histidine
(H) (numbering according to Kabat), and wherein in the constant
domain CH1 of the first Fab molecule under a) the amino acid at
position 147 or the amino acid at position 213 is substituted
independently by glutamic acid (E), or aspartic acid (D) (numbering
according to Kabat EU index).
11. The T cell activating bispecific antigen binding molecule
according to claim 9 or 10, wherein in the constant domain CL of
the first Fab molecule under a) the amino acid at position 124 is
substituted independently by lysine (K), arginine (R) or histidine
(H) (numbering according to Kabat), and wherein in the constant
domain CH1 of the first Fab molecule under a) the amino acid at
position 147 is substituted independently by glutamic acid (E), or
aspartic acid (D) (numbering according to Kabat EU index).
12. The T cell activating bispecific antigen binding molecule
according to any one of claims 9-11, wherein in the constant domain
CL of the first Fab molecule under a) the amino acid at position
124 is substituted independently by lysine (K), arginine (R) or
histidine (H) (numbering according to Kabat) and the amino acid at
position 123 is substituted independently by lysine (K), arginine
(R) or histidine (H) (numbering according to Kabat), and wherein in
the constant domain CH1 of the first Fab molecule under a) the
amino acid at position 147 is substituted independently by glutamic
acid (E), or aspartic acid (D) (numbering according to Kabat EU
index) and the amino acid at position 213 is substituted
independently by glutamic acid (E), or aspartic acid (D) (numbering
according to Kabat EU index).
13. The T cell activating bispecific antigen binding molecule
according to any one of claims 9-12, wherein in the constant domain
CL of the first Fab molecule under a) the amino acid at position
124 is substituted by lysine (K) (numbering according to Kabat) and
the amino acid at position 123 is substituted by arginine (R)
(numbering according to Kabat), and wherein in the constant domain
CH1 of the first Fab molecule under a) the amino acid at position
147 is substituted by glutamic acid (E) (numbering according to
Kabat EU index) and the amino acid at position 213 is substituted
by glutamic acid (E) (numbering according to Kabat EU index).
14. The T cell activating bispecific antigen binding molecule
according to any one of claims 9-12, wherein in the constant domain
CL of the first Fab molecule under a) the amino acid at position
124 is substituted by lysine (K) (numbering according to Kabat) and
the amino acid at position 123 is substituted by lysine (K)
(numbering according to Kabat), and wherein in the constant domain
CH1 of the first Fab molecule under a) the amino acid at position
147 is substituted by glutamic acid (E) (numbering according to
Kabat EU index) and the amino acid at position 213 is substituted
by glutamic acid (E) (numbering according to Kabat EU index).
15. The T cell activating bispecific antigen binding molecule
according to claim 9, wherein in the constant domain CL of the
second Fab molecule under b) the amino acid at position 124 is
substituted independently by lysine (K), arginine (R) or histidine
(H) (numbering according to Kabat), and wherein in the constant
domain CH1 of the second Fab molecule under b) the amino acid at
position 147 or the amino acid at position 213 is substituted
independently by glutamic acid (E), or aspartic acid (D) (numbering
according to Kabat EU index).
16. The T cell activating bispecific antigen binding molecule
according to claim 9 or 15, wherein in the constant domain CL of
the second Fab molecule under b) the amino acid at position 124 is
substituted independently by lysine (K), arginine (R) or histidine
(H) (numbering according to Kabat), and wherein in the constant
domain CH1 of the second Fab molecule under b) the amino acid at
position 147 is substituted independently by glutamic acid (E), or
aspartic acid (D) (numbering according to Kabat EU index).
17. The T cell activating bispecific antigen binding molecule
according to any one of claims 9, 15 and 16, wherein in the
constant domain CL of the second Fab molecule under b) the amino
acid at position 124 is substituted independently by lysine (K),
arginine (R) or histidine (H) (numbering according to Kabat) and
the amino acid at position 123 is substituted independently by
lysine (K), arginine (R) or histidine (H) (numbering according to
Kabat), and wherein in the constant domain CH1 of the second Fab
molecule under b) the amino acid at position 147 is substituted
independently by glutamic acid (E), or aspartic acid (D) (numbering
according to Kabat EU index) and the amino acid at position 213 is
substituted independently by glutamic acid (E), or aspartic acid
(D) (numbering according to Kabat EU index).
18. The T cell activating bispecific antigen binding molecule
according to any one of claims 9 and 15-17, wherein in the constant
domain CL of the second Fab molecule under b) the amino acid at
position 124 is substituted by lysine (K) (numbering according to
Kabat) and the amino acid at position 123 is substituted by
arginine (R) (numbering according to Kabat), and wherein in the
constant domain CH1 of the second Fab molecule under b) the amino
acid at position 147 is substituted by glutamic acid (E) (numbering
according to Kabat EU index) and the amino acid at position 213 is
substituted by glutamic acid (E) (numbering according to Kabat EU
index).
19. The T cell activating bispecific antigen binding molecule
according to any one of claims 9 and 15-17, wherein in the constant
domain CL of the second Fab molecule under b) the amino acid at
position 124 is substituted by lysine (K) (numbering according to
Kabat) and the amino acid at position 123 is substituted by lysine
(K) (numbering according to Kabat), and wherein in the constant
domain CH1 of the second Fab molecule under b) the amino acid at
position 147 is substituted by glutamic acid (E) (numbering
according to Kabat EU index) and the amino acid at position 213 is
substituted by glutamic acid (E) (numbering according to Kabat EU
index).
20. The T cell activating bispecific antigen binding molecule
according to any one of claims 1-19, further comprising c) a third
antigen binding moiety which specifically binds to the first
antigen.
21. The T cell activating bispecific antigen binding molecule
according to claim 20, wherein the third antigen binding moiety is
a Fab molecule.
22. The T cell activating bispecific antigen binding molecule
according to claim 20 or 21, wherein the third antigen binding
moiety is identical to the first antigen binding moiety.
23. The T cell activating bispecific antigen binding molecule
according to any one of claims 20-22, wherein the first and the
third antigen binding moiety specifically bind to a target cell
antigen, and the second antigen binding moiety specifically binds
to an activating T cell antigen, particularly CD3, more
particularly CD3 epsilon.
24. The T cell activating bispecific antigen binding molecule
according to any one of claims 1 to 23, additionally comprising d)
an Fc domain composed of a first and a second subunit capable of
stable association.
25. The T cell activating bispecific antigen binding molecule
according to any one of claims 1 to 24, wherein the first and the
second antigen binding moiety are fused to each other, optionally
via a peptide linker.
26. The T cell activating bispecific antigen binding molecule
according to any one of claims 1 to 25, wherein the first and the
second antigen binding moieties are Fab molecules and the second
antigen binding moiety is fused at the C-terminus of the Fab heavy
chain to the N-terminus of the Fab heavy chain of the first antigen
binding moiety.
27. The T cell activating bispecific antigen binding molecule of
any one of claims 1 to 25, wherein the first and the second antigen
binding moieties are Fab molecules and the first antigen binding
moiety is fused at the C-terminus of the Fab heavy chain to the
N-terminus of the Fab heavy chain of the second antigen binding
moiety.
28. The T cell activating bispecific antigen binding molecule of
claim 26 or 27, wherein the first and the second antigen binding
moieties are Fab molecules and the Fab light chain of the first
antigen binding moiety and the Fab light chain of the second
antigen binding moiety are fused to each other, optionally via a
peptide linker.
29. The T cell activating bispecific antigen binding molecule
according to claim 24, wherein the first and the second antigen
binding moieties are Fab molecules and the second antigen binding
moiety is fused at the C-terminus of the Fab heavy chain to the
N-terminus of the first or the second subunit of the Fc domain.
30. The T cell activating bispecific antigen binding molecule
according to claim 24, wherein the first and the second antigen
binding moieties are Fab molecules and the first antigen binding
moiety is fused at the C-terminus of the Fab heavy chain to the
N-terminus of the first or the second subunit of the Fc domain.
31. The T cell activating bispecific antigen binding molecule
according to claim 24, wherein the first and the second antigen
binding moieties are Fab molecules and the first and the second
antigen binding moiety are each fused at the C-terminus of the Fab
heavy chain to the N-terminus of one of the subunits of the Fc
domain.
32. The T cell activating bispecific antigen binding molecule
according to any one of claim 24, 29 or 30, wherein the third
antigen binding moiety is a Fab molecule and is fused at the
C-terminus of the Fab heavy chain to the N-terminus of the first or
second subunit of the Fc domain.
33. The T cell activating bispecific antigen binding molecule of
claim 24, wherein the first, second and third antigen binding
moieties are Fab molecules and the second and the third antigen
binding moiety are each fused at the C-terminus of the Fab heavy
chain to the N-terminus of one of the subunits of the Fc domain,
and the first antigen binding moiety is fused at the C-terminus of
the Fab heavy chain to the N-terminus of the Fab heavy chain of the
second antigen binding moiety.
34. The T cell activating bispecific antigen binding molecule
according to claim 24, wherein the first, second and third antigen
binding moieties are Fab molecules and the first and the third
antigen binding moiety are each fused at the C-terminus of the Fab
heavy chain to the N-terminus of one of the subunits of the Fc
domain, and the second antigen binding moiety is fused at the
C-terminus of the Fab heavy chain to the N-terminus of the Fab
heavy chain of the first antigen binding moiety.
35. The T cell activating bispecific antigen binding molecule
according to claim 34, wherein the first and the third antigen
binding moiety and the Fc domain are part of an immunoglobulin
molecule, particularly an IgG class immunoglobulin.
36. The T cell activating bispecific antigen binding molecule
according to any one of claims 24-35, wherein the Fc domain is an
IgG, specifically an IgG.sub.1 or IgG.sub.4, Fc domain.
37. The T cell activating bispecific antigen binding molecule
according to any one of claims 24-36, wherein the Fc domain is a
human Fc domain.
38. The T cell activating bispecific antigen binding molecule
according to any one of claims 24-37, wherein the Fc domain
comprises a modification promoting the association of the first and
the second subunit of the Fc domain.
39. The T cell activating bispecific antigen binding molecule of
claim 38, wherein in the CH3 domain of the first subunit of the Fc
domain an amino acid residue is replaced with an amino acid residue
having a larger side chain volume, thereby generating a
protuberance within the CH3 domain of the first subunit which is
positionable in a cavity within the CH3 domain of the second
subunit, and in the CH3 domain of the second subunit of the Fc
domain an amino acid residue is replaced with an amino acid residue
having a smaller side chain volume, thereby generating a cavity
within the CH3 domain of the second subunit within which the
protuberance within the CH3 domain of the first subunit is
positionable.
40. The T cell activating bispecific antigen binding molecule of
claim 39, wherein said amino acid residue having a larger side
chain volume is selected from the group consisting of arginine (R),
phenylalanine (F), tyrosine (Y), and tryptophan (W), and said amino
acid residue having a smaller side chain volume is selected from
the group consisting of alanine (A), serine (S), threonine (T), and
valine (V).
41. The T cell activating bispecific antigen binding molecule of
claim 39 or 40, wherein in the CH3 domain of the first subunit of
the Fc domain the threonine residue at position 366 is replaced
with a tryptophan residue (T366W), and in the CH3 domain of the
second subunit of the Fc domain the tyrosine residue at position
407 is replaced with a valine residue (Y407V), and optionally in
the second subunit of the Fc domain additionally the threonine
residue at position 366 is replaced with a serine residue (T366S)
and the leucine residue at position 368 is replaced with an alanine
residue (L368A) (numberings according to Kabat EU index).
42. The T cell activating bispecific antigen binding molecule of
any one of claims 39-41, wherein in the first subunit of the Fc
domain additionally the serine residue at position 354 is replaced
with a cysteine residue (S354C) or the glutamic acid residue at
position 356 is replaced with a cysteine residue (E356C), and in
the second subunit of the Fc domain additionally the tyrosine
residue at position 349 is replaced by a cysteine residue (Y349C)
(numberings according to Kabat EU index).
43. The T cell activating bispecific antigen binding molecule of
any one of claims 39-42, wherein the first subunit of the Fc domain
comprises amino acid substitutions S354C and T366W, and the second
subunit of the Fc domain comprises amino acid substitutions Y349C,
T366S, L368A and Y407V (numbering according to Kabat EU index).
44. The T cell activating bispecific antigen binding molecule
according to any one of claims 24-43, wherein the Fc domain
exhibits reduced binding affinity to an Fc receptor and/or reduced
effector function, as compared to a native IgG.sub.1 Fc domain.
45. The T cell activating bispecific antigen binding molecule
according to any one of claims 24-44, wherein the Fc domain
comprises one or more amino acid substitution that reduces binding
to an Fc receptor and/or effector function.
46. The T cell activating bispecific antigen binding molecule
according to claim 45, wherein said one or more amino acid
substitution is at one or more position selected from the group of
L234, L235, and P329 (Kabat EU index numbering).
47. The T cell activating bispecific antigen binding molecule
according to any one of claims 24-46, wherein each subunit of the
Fc domain comprises three amino acid substitutions that reduce
binding to an activating Fc receptor and/or effector function
wherein said amino acid substitutions are L234A, L235A and P329G
(Kabat EU index numbering).
48. The T cell activating bispecific antigen binding molecule of
any one of claims 44 to 47, wherein the Fc receptor is an Fc.gamma.
receptor.
49. The T cell activating bispecific antigen binding molecule of
any one of claims 44 to 48, wherein the effector function is
antibody-dependent cell-mediated cytotoxicity (ADCC).
50. One or more isolated polynucleotide encoding the T cell
activating bispecific antigen binding molecule of any one of claims
1 to 49.
51. One or more vector, particularly expression vector, comprising
the polynucleotide(s) of claim 50.
52. A host cell comprising the polynucleotide(s) of claim 50 or the
vector(s) of claim 51.
53. A method of producing a T cell activating bispecific antigen
binding molecule capable of specific binding to p95HER2 and an
activating T cell antigen, comprising the steps of a) culturing the
host cell of claim 52 under conditions suitable for the expression
of the T cell activating bispecific antigen binding molecule and b)
optionally recovering the T cell activating bispecific antigen
binding molecule.
54. A T cell activating bispecific antigen binding molecule
produced by the method of claim 53.
55. A pharmaceutical composition comprising the T cell activating
bispecific antigen binding molecule of any one of claim 1 to 49 or
54 and a pharmaceutically acceptable carrier.
56. The T cell activating bispecific antigen binding molecule of
any one of claim 1 to 49 or 54 or the pharmaceutical composition of
claim 55 for use as a medicament.
57. The T cell activating bispecific antigen binding molecule of
any one of claim 1 to 49 or 54 or the pharmaceutical composition of
claim 55 for use in the treatment of a disease in an individual in
need thereof.
58. The T cell activating bispecific antigen binding molecule or
the pharmaceutical composition of claim 57, wherein the disease is
cancer.
59. Use of the T cell activating bispecific antigen binding
molecule of any one of claim 1 to 49 or 54 for the manufacture of a
medicament for the treatment of a disease in an individual in need
thereof.
60. A method of treating a disease in an individual, comprising
administering to said individual a therapeutically effective amount
of a composition comprising the T cell activating bispecific
antigen binding molecule of any one of claim 1 to 49 or 54 in a
pharmaceutically acceptable form.
61. The use of claim 59 or the method of claim 60, wherein said
disease is cancer.
62. A method for inducing lysis of a target cell, comprising
contacting a target cell with the T cell activating bispecific
antigen binding molecule of any one of claim 1-49 or 54 in the
presence of a T cell.
63. The invention as described hereinbefore.
Description
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application is a continuation of U.S. application Ser.
No. 17/443,893, filed Jul. 28, 2021, which is a continuation of
U.S. application Ser. No. 17/117,598, filed Dec. 10, 2020, now
abandoned, which is a continuation of U.S. application Ser. No.
15/718,818, filed Sep. 28, 2017, now U.S. Pat. No. 10,882,918,
which claims priority to European Patent Application No. EP
16191933.7, filed Sep. 30, 2016, the disclosure of which is
incorporated herein by reference.
SEQUENCE LISTING
[0002] The present application contains a Sequence Listing, which
has been submitted in ASCII format via EFS-Web and is hereby
incorporated by reference in its entirety. Said ASCII copy, created
on Feb. 9, 2022, is named 51177-021004_Sequence_Listing_2_9_22_ST25
and is 57,756 bytes in size.
FIELD OF THE INVENTION
[0003] The present invention generally relates to bispecific
antigen binding molecules for activating T cells. In addition, the
present invention relates to polynucleotides encoding such
bispecific antigen binding molecules, and vectors and host cells
comprising such polynucleotides. The invention further relates to
methods for producing the bispecific antigen binding molecules of
the invention, and to methods of using these bispecific antigen
binding molecules in the treatment of disease.
BACKGROUND
[0004] The selective destruction of an individual cell or a
specific cell type is often desirable in a variety of clinical
settings. For example, it is a primary goal of cancer therapy to
specifically destroy tumor cells, while leaving healthy cells and
tissues intact and undamaged.
[0005] An attractive way of achieving this is by inducing an immune
response against the tumor, to make immune effector cells such as
natural killer (NK) cells or cytotoxic T lymphocytes (CTLs) attack
and destroy tumor cells. CTLs constitute the most potent effector
cells of the immune system, however they cannot be activated by the
effector mechanism mediated by the Fc domain of conventional
therapeutic antibodies.
[0006] In this regard, bispecific antibodies designed to bind with
one "arm" to a surface antigen on target cells, and with the second
"arm" to an activating, invariant component of the T cell receptor
(TCR) complex, have become of interest in recent years. The
simultaneous binding of such an antibody to both of its targets
will force a temporary interaction between target cell and T cell,
causing activation of any cytotoxic T cell and subsequent lysis of
the target cell. Hence, the immune response is re-directed to the
target cells and is independent of peptide antigen presentation by
the target cell or the specificity of the T cell as would be
relevant for normal MHC-restricted activation of CTLs. In this
context it is crucial that CTLs are only activated when a target
cell is presenting the bispecific antibody to them, i.e. the
immunological synapse is mimicked. Particularly desirable are
bispecific antibodies that do not require lymphocyte
preconditioning or co-stimulation in order to elicit efficient
lysis of target cells.
[0007] Several bispecific antibody formats have been developed and
their suitability for T cell mediated immunotherapy investigated.
Out of these, the so-called BiTE (bispecific T cell engager)
molecules have been very well characterized and already shown some
promise in the clinic (reviewed in Nagorsen and Bauerle, Exp Cell
Res 317, 1255-1260 (2011)). BiTEs are tandem scFv molecules wherein
two scFv molecules are fused by a flexible linker. Further
bispecific formats being evaluated for T cell engagement include
diabodies (Holliger et al., Prot Eng 9, 299-305 (1996)) and
derivatives thereof, such as tandem diabodies (Kipriyanov et al., J
Mol Biol 293, 41-66 (1999)). A more recent development are the
so-called DART (dual affinity retargeting) molecules, which are
based on the diabody format but feature a C-terminal disulfide
bridge for additional stabilization (Moore et al., Blood 117,
4542-51 (2011)). The so-called triomabs, which are whole hybrid
mouse/rat IgG molecules and also currently being evaluated in
clinical trials, represent a larger sized format (reviewed in
Seimetz et al., Cancer Treat Rev 36, 458-467 (2010)).
[0008] The variety of formats that are being developed shows the
great potential attributed to T cell re-direction and activation in
immunotherapy. The task of generating bispecific antibodies
suitable therefor is, however, by no means trivial, but involves a
number of challenges that have to be met related to efficacy,
toxicity, applicability and produceability of the antibodies.
[0009] Small constructs such as, for example, BiTE molecules--while
being able to efficiently crosslink effector and target cells--have
a very short serum half life requiring them to be administered to
patients by continuous infusion. IgG-like formats on the other
hand--while having the great benefit of a long half life--suffer
from toxicity associated with the native effector functions
inherent to IgG molecules. Their immunogenic potential constitutes
another unfavorable feature of IgG-like bispecific antibodies,
especially non-human formats, for successful therapeutic
development. Finally, a major challenge in the general development
of bispecific antibodies has been the production of bispecific
antibody constructs at a clinically sufficient quantity and purity,
due to the mispairing of antibody heavy and light chains of
different specificities upon co-expression, which decreases the
yield of the correctly assembled construct and results in a number
of non-functional side products from which the desired bispecific
antibody may be difficult to separate.
[0010] The choice of target antigens and appropriate binders for
both the T cell antigen and the target cell antigen is a further
crucial aspect in the generation of T cell bispecific (TCB)
antibodies for therapeutic application.
[0011] The tyrosine kinase receptor HER2 is overexpressed in
approximately 20% of breast cancers. Currently HER2-positive breast
cancers are treated with regimens that include monoclonal
antibodies against the extracellular domain of HER2, such as
trastuzumab, or synthetic molecules that inhibit its tyrosine
kinase activity. Despite the success of currently available drugs
targeting HER2, most cases of advanced breast cancer eventually
progress. Furthermore, redirecting T lymphocytes to tumors via
recognition of HER2 may result in severe toxicities, likely due to
the physiologic levels of HER2 in normal epithelia. For example,
severe adverse events were observed during a phase I clinical trial
with a T cell activating bispecific antibody targeting HER2 (Kiewe
et al., Clin Cancer Res (2006) 12, 3085-3091). Therefore,
additional anti-HER2 therapies are needed.
[0012] A subgroup of breast tumors express detectable levels of a
heterogeneous group of HER2 fragments collectively known as p95HER2
(reviewed in Arribas et al., Cancer Res 71 (2011) 1515-1519). One
of these fragments, known as 611-CTF or 100-115 kDa p95HER2 (for
simplicity hereafter referred to as p95HER2), is particularly
oncogenic because of its ability to form homodimers maintained by
intermolecular disulfide bonds (Pedersen et al., Mol Cell Biol 29,
3319-31 (2009)). p95HER2 seems to be expressed in an homogeneous
subgroup of HER2-positive breast cancers (Parra-Palau et al, J Natl
Cancer Inst 106, dju291 (2014)), but is not recognized by e.g.
trastuzumab because the HER2 fragment lacks the epitope recognized
by the antibody (Pedersen et al., Mol Cell Biol 29, 3319-31
(2009)).
[0013] The present invention provides novel bispecific antigen
binding molecules designed for T cell activation and re-direction,
targeting CD3 and p95HER2, that combine good efficacy and
produceability with low toxicity and favorable pharmacokinetic
properties.
SUMMARY OF THE INVENTION
[0014] The present inventors have developed a novel T cell
activating bispecific antigen binding molecule targeting
p95HER2.
[0015] Thus, the present invention provides a T cell activating
bispecific antigen binding molecule comprising
[0016] (a) a first antigen binding moiety which specifically binds
to a first antigen;
[0017] (b) a second antigen binding moiety which specifically binds
to a second antigen;
[0018] wherein the first antigen is an activating T cell antigen
and the second antigen is p95HER2, or the first antigen is p95HER2
and the second antigen is an activating T cell antigen.
[0019] In one aspect the present invention provides a T cell
activating bispecific antigen binding molecule comprising
[0020] (a) a first antigen binding moiety which specifically binds
to a first antigen;
[0021] (b) a second antigen binding moiety which specifically binds
to a second antigen;
[0022] wherein the first antigen is an activating T cell antigen
and the second antigen is p95HER2, or the first antigen is p95HER2
and the second antigen is an activating T cell antigen; and
[0023] wherein the antigen binding moiety which specifically binds
to p95HER2 comprises a heavy chain variable region, particularly a
humanized heavy chain variable region, comprising the heavy chain
complementarity determining region (HCDR) 1 of SEQ ID NO: 14, the
HCDR 2 of SEQ ID NO: 15 and the HCDR 3 of SEQ ID NO: 16, and a
light chain variable region, particularly a humanized light chain
variable region, comprising the light chain complementarity
determining region (LCDR) 1 of SEQ ID NO: 17, the LCDR 2 of SEQ ID
NO: 18 and the LCDR 3 of SEQ ID NO: 19.
[0024] In one embodiment, the antigen binding moiety which
specifically binds to p95HER2 comprises a heavy chain variable
region comprising an amino acid sequence that is at least about
95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid
sequence of SEQ ID NO: 20 and a light chain variable region
comprising an amino acid sequence that is at least about 95%, 96%,
97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ
ID NO: 21.
[0025] In particular embodiments, the first and/or the second
antigen binding moiety is a Fab molecule. In a particular
embodiment, the second antigen binding moiety is a Fab molecule
which specifically binds to a second antigen, and wherein the
variable domains VL and VH or the constant domains CL and CH1 of
the Fab light chain and the Fab heavy chain are replaced by each
other (i.e. according to such embodiment, the second Fab molecule
is a crossover Fab molecule wherein the variable or constant
domains of the Fab light chain and the Fab heavy chain are
exchanged).
[0026] In particular embodiments, the first (and the third, if any)
Fab molecule is a conventional Fab molecule. In a further
particular embodiment, not more than one Fab molecule capable of
specific binding to an activating T cell antigen is present in the
T cell activating bispecific antigen binding molecule (i.e. the T
cell activating bispecific antigen binding molecule provides
monovalent binding to the activating T cell antigen).
[0027] In one embodiment, the first antigen is p95HER2 and the
second antigen is an activating T cell antigen. In a more specific
embodiment, the activating T cell antigen is CD3, particularly CD3
epsilon.
[0028] In a particular embodiment, the T cell activating bispecific
antigen binding molecule of the invention comprises
[0029] (a) a first Fab molecule which specifically binds to a first
antigen;
[0030] (b) a second Fab molecule which specifically binds to a
second antigen, and wherein the variable domains VL and VH or the
constant domains CL and CH1 of the Fab light chain and the Fab
heavy chain are replaced by each other;
[0031] wherein the first antigen is p95HER2 and the second antigen
is an activating T cell antigen;
[0032] wherein the first Fab molecule under (a) comprises a heavy
chain variable region, particularly a humanized heavy chain
variable region, comprising the heavy chain complementarity
determining region (HCDR) 1 of SEQ ID NO: 14, the HCDR 2 of SEQ ID
NO: 15 and the HCDR 3 of SEQ ID NO: 16, and a light chain variable
region, particularly a humanized light chain variable region,
comprising the light chain complementarity determining region
(LCDR) 1 of SEQ ID NO: 17, the LCDR 2 of SEQ ID NO: 18 and the LCDR
3 of SEQ ID NO: 19.
[0033] According to a further aspect of the invention, the ratio of
a desired bispecific antibody compared to undesired side products,
in particular Bence Jones-type side products occurring in
bispecific antibodies with a VH/VL domain exchange in one of their
binding arms, can be improved by the introduction of charged amino
acids with opposite charges at specific amino acid positions in the
CH1 and CL domains (sometimes referred to herein as "charge
modifications").
[0034] Thus, in some embodiments the first antigen binding moiety
under (a) is a first Fab molecule which specifically binds to a
first antigen, the second antigen binding moiety under (b) is a
second Fab molecule which specifically binds to a second antigen
wherein the variable domains VL and VH of the Fab light chain and
the Fab heavy chain are replaced by each other;
[0035] and [0036] i) in the constant domain CL of the first Fab
molecule under a) the amino acid at position 124 is substituted
independently by lysine (K), arginine (R) or histidine (H)
(numbering according to Kabat), and wherein in the constant domain
CH1 of the first Fab molecule under a) the amino acid at position
147 or the amino acid at position 213 is substituted independently
by glutamic acid (E), or aspartic acid (D) (numbering according to
Kabat EU index); or [0037] ii) in the constant domain CL of the
second Fab molecule under b) the amino acid at position 124 is
substituted independently by lysine (K), arginine (R) or histidine
(H) (numbering according to Kabat), and wherein in the constant
domain CH1 of the second Fab molecule under b) the amino acid at
position 147 or the amino acid at position 213 is substituted
independently by glutamic acid (E), or aspartic acid (D) (numbering
according to Kabat EU index).
[0038] In one such embodiment, in the constant domain CL of the
first Fab molecule under a) the amino acid at position 124 is
substituted independently by lysine (K), arginine (R) or histidine
(H) (numbering according to Kabat) (in one preferred embodiment
independently by lysine (K) or arginine (R)), and in the constant
domain CH1 of the first Fab molecule under a) the amino acid at
position 147 or the amino acid at position 213 is substituted
independently by glutamic acid (E), or aspartic acid (D) (numbering
according to Kabat EU index).
[0039] In a further embodiment, in the constant domain CL of the
first Fab molecule under a) the amino acid at position 124 is
substituted independently by lysine (K), arginine (R) or histidine
(H) (numbering according to Kabat), and in the constant domain CH1
of the first Fab molecule under a) the amino acid at position 147
is substituted independently by glutamic acid (E), or aspartic acid
(D) (numbering according to Kabat EU index).
[0040] In yet another embodiment, in the constant domain CL of the
first Fab molecule under a) the amino acid at position 124 is
substituted independently by lysine (K), arginine (R) or histidine
(H) (numbering according to Kabat) (in one preferred embodiment
independently by lysine (K) or arginine (R)) and the amino acid at
position 123 is substituted independently by lysine (K), arginine
(R) or histidine (H) (numbering according to Kabat) (in one
preferred embodiment independently by lysine (K) or arginine (R)),
and in the constant domain CH1 of the first Fab molecule under a)
the amino acid at position 147 is substituted independently by
glutamic acid (E), or aspartic acid (D) (numbering according to
Kabat EU index) and the amino acid at position 213 is substituted
independently by glutamic acid (E), or aspartic acid (D) (numbering
according to Kabat EU index).
[0041] In a particular embodiment, in the constant domain CL of the
first Fab molecule under a) the amino acid at position 124 is
substituted by lysine (K) (numbering according to Kabat) and the
amino acid at position 123 is substituted by lysine (K) (numbering
according to Kabat), and in the constant domain CH1 of the first
Fab molecule under a) the amino acid at position 147 is substituted
by glutamic acid (E) (numbering according to Kabat EU index) and
the amino acid at position 213 is substituted by glutamic acid (E)
(numbering according to Kabat EU index).
[0042] In another particular embodiment, in the constant domain CL
of the first Fab molecule under a) the amino acid at position 124
is substituted by lysine (K) (numbering according to Kabat) and the
amino acid at position 123 is substituted by arginine (R)
(numbering according to Kabat), and in the constant domain CH1 of
the first Fab molecule under a) the amino acid at position 147 is
substituted by glutamic acid (E) (numbering according to Kabat EU
index) and the amino acid at position 213 is substituted by
glutamic acid (E) (numbering according to Kabat EU index).
[0043] In an alternative embodiment, in the constant domain CL of
the second Fab molecule under b) the amino acid at position 124 is
substituted independently by lysine (K), arginine (R) or histidine
(H) (numbering according to Kabat) (in one preferred embodiment
independently by lysine (K) or arginine (R)), and in the constant
domain CH1 of the second Fab molecule under b) the amino acid at
position 147 or the amino acid at position 213 is substituted
independently by glutamic acid (E), or aspartic acid (D) (numbering
according to Kabat EU index).
[0044] In a further embodiment, in the constant domain CL of the
second Fab molecule under b) the amino acid at position 124 is
substituted independently by lysine (K), arginine (R) or histidine
(H) (numbering according to Kabat), and in the constant domain CH1
of the second Fab molecule under b) the amino acid at position 147
is substituted independently by glutamic acid (E), or aspartic acid
(D) (numbering according to Kabat EU index).
[0045] In still another embodiment, in the constant domain CL of
the second Fab molecule under b) the amino acid at position 124 is
substituted independently by lysine (K), arginine (R) or histidine
(H) (numbering according to Kabat) (in one preferred embodiment
independently by lysine (K) or arginine (R)) and the amino acid at
position 123 is substituted independently by lysine (K), arginine
(R) or histidine (H) (numbering according to Kabat) (in one
preferred embodiment independently by lysine (K) or arginine (R)),
and in the constant domain CH1 of the second Fab molecule under b)
the amino acid at position 147 is substituted independently by
glutamic acid (E), or aspartic acid (D) (numbering according to
Kabat EU index) and the amino acid at position 213 is substituted
independently by glutamic acid (E), or aspartic acid (D) (numbering
according to Kabat EU index).
[0046] In one embodiment, in the constant domain CL of the second
Fab molecule under b) the amino acid at position 124 is substituted
by lysine (K) (numbering according to Kabat) and the amino acid at
position 123 is substituted by lysine (K) (numbering according to
Kabat), and in the constant domain CH1 of the second Fab molecule
under b) the amino acid at position 147 is substituted by glutamic
acid (E) (numbering according to Kabat EU index) and the amino acid
at position 213 is substituted by glutamic acid (E) (numbering
according to Kabat EU index).
[0047] In another embodiment, in the constant domain CL of the
second Fab molecule under b) the amino acid at position 124 is
substituted by lysine (K) (numbering according to Kabat) and the
amino acid at position 123 is substituted by arginine (R)
(numbering according to Kabat), and in the constant domain CH1 of
the second Fab molecule under b) the amino acid at position 147 is
substituted by glutamic acid (E) (numbering according to Kabat EU
index) and the amino acid at position 213 is substituted by
glutamic acid (E) (numbering according to Kabat EU index).
[0048] In a particular embodiment, the T cell activating bispecific
antigen binding molecule of the invention comprises
[0049] (a) a first Fab molecule which specifically binds to a first
antigen;
[0050] (b) a second Fab molecule which specifically binds to a
second antigen, and wherein the variable domains VL and VH of the
Fab light chain and the Fab heavy chain are replaced by each
other;
[0051] wherein the first antigen is p95HER2 and the second antigen
is an activating T cell antigen;
[0052] wherein the first Fab molecule under (a) comprises a heavy
chain variable region, particularly a humanized heavy chain
variable region, comprising the heavy chain complementarity
determining region (HCDR) 1 of SEQ ID NO: 14, the HCDR 2 of SEQ ID
NO: 15 and the HCDR 3 of SEQ ID NO: 16, and a light chain variable
region, particularly a humanized light chain variable region,
comprising the light chain complementarity determining region
(LCDR) 1 of SEQ ID NO: 17, the LCDR 2 of SEQ ID NO: 18 and the LCDR
3 of SEQ ID NO: 19; and wherein in the constant domain CL of the
first Fab molecule under a) the amino acid at position 124 is
substituted independently by lysine (K), arginine (R) or histidine
(H) (numbering according to Kabat) (in one preferred embodiment
independently by lysine (K) or arginine (R)) and the amino acid at
position 123 is substituted independently by lysine (K), arginine
(R) or histidine (H) (numbering according to Kabat) (in one
preferred embodiment independently by lysine (K) or arginine (R)),
and in the constant domain CH1 of the first Fab molecule under a)
the amino acid at position 147 is substituted independently by
glutamic acid (E), or aspartic acid (D) (numbering according to
Kabat EU index) and the amino acid at position 213 is substituted
independently by glutamic acid (E), or aspartic acid (D) (numbering
according to Kabat EU index).
[0053] In some embodiments, the T cell activating bispecific
antigen binding molecule according to the invention further
comprises a third antigen binding moiety which specifically binds
to the first antigen. In particular embodiments, the third antigen
binding moiety is identical to the first antigen binding moiety. In
one embodiment, the third antigen binding moiety is a Fab
molecule.
[0054] In particular embodiments, the third and the first antigen
binding moiety are each a Fab molecule and the third Fab molecule
is identical to the first Fab molecule. In these embodiments, the
third Fab molecule thus comprises the same amino acid
substitutions, if any, as the first Fab molecule. Like the first
Fab molecule, the third Fab molecule particularly is a conventional
Fab molecule.
[0055] If a third antigen binding moiety is present, in a
particular embodiment the first and the third antigen moiety
specifically bind to p95HER2, and the second antigen binding moiety
specifically binds to an activating T cell antigen, particularly
CD3, more particularly CD3 epsilon.
[0056] In some embodiments of the T cell activating bispecific
antigen binding molecule according to the invention the first
antigen binding moiety under a) and the second antigen binding
moiety under b) are fused to each other, optionally via a peptide
linker. In particular embodiments, the first and the second antigen
binding moiety are each a Fab molecule. In a specific such
embodiment, the second Fab molecule is fused at the C-terminus of
the Fab heavy chain to the N-terminus of the Fab heavy chain of the
first Fab molecule. In an alternative such embodiment, the first
Fab molecule is fused at the C-terminus of the Fab heavy chain to
the N-terminus of the Fab heavy chain of the second Fab molecule.
In embodiments wherein either (i) the second Fab molecule is fused
at the C-terminus of the Fab heavy chain to the N-terminus of the
Fab heavy chain of the first Fab molecule or (ii) the first Fab
molecule is fused at the C-terminus of the Fab heavy chain to the
N-terminus of the Fab heavy chain of the second Fab molecule,
additionally the Fab light chain of the Fab molecule and the Fab
light chain of the second Fab molecule may be fused to each other,
optionally via a peptide linker.
[0057] In particular embodiments, the T cell activating bispecific
antigen binding molecule according to the invention additionally
comprises an Fc domain composed of a first and a second subunit
capable of stable association.
[0058] The T cell activating bispecific antigen binding molecule
according to the invention can have different configurations, i.e.
the first, second (and optionally third) antigen binding moiety may
be fused to each other and to the Fc domain in different ways. The
components may be fused to each other directly or, preferably, via
one or more suitable peptide linkers. Where fusion of a Fab
molecule is to the N-terminus of a subunit of the Fc domain, it is
typically via an immunoglobulin hinge region.
[0059] In one embodiment, the first and the second antigen binding
moiety are each a Fab molecule and the second antigen binding
moiety is fused at the C-terminus of the Fab heavy chain to the
N-terminus of the first or the second subunit of the Fc domain. In
such embodiment, the first antigen binding moiety may be fused at
the C-terminus of the Fab heavy chain to the N-terminus of the Fab
heavy chain of the second antigen binding moiety or to the
N-terminus of the other one of the subunits of the Fc domain.
[0060] In one embodiment, the first and the second antigen binding
moiety are each a Fab molecule and the first and the second antigen
binding moiety are each fused at the C-terminus of the Fab heavy
chain to the N-terminus of one of the subunits of the Fc domain. In
this embodiment, the T cell activating bispecific antigen binding
molecule essentially comprises an immunoglobulin molecule, wherein
in one of the Fab arms the heavy and light chain variable regions
VH and VL (or the constant regions CH1 and CL in embodiments
wherein no charge modifications as described herein are introduced
in CH1 and CL domains) are exchanged/replaced by each other (see
FIG. 1A, D).
[0061] In alternative embodiments, a third antigen binding moiety,
particularly a third Fab molecule, is fused at the C-terminus of
the Fab heavy chain to the N-terminus of the first or second
subunit of the Fc domain. In a particular such embodiment, the
second and the third antigen binding moiety are each fused at the
C-terminus of the Fab heavy chain to the N-terminus of one of the
subunits of the Fc domain, and the first antigen binding moiety is
fused at the C-terminus of the Fab heavy chain to the N-terminus of
the Fab heavy chain of the second Fab molecule. In this embodiment,
the T cell activating bispecific antigen binding molecule
essentially comprises an immunoglobulin molecule, wherein in one of
the Fab arms the heavy and light chain variable regions VH and VL
(or the constant regions CH1 and CL in embodiments wherein no
charge modifications as described herein are introduced in CH1 and
CL domains) are exchanged/replaced by each other, and wherein an
additional (conventional) Fab molecule is N-terminally fused to
said Fab arm (see FIG. 1B, E). In another such embodiment, the
first and the third antigen binding moiety are each fused at the
C-terminus of the Fab heavy chain to the N-terminus of one of the
subunits of the Fc domain, and the second antigen binding moiety is
fused at the C-terminus of the Fab heavy chain to the N-terminus of
the Fab heavy chain of the first antigen binding moiety. In this
embodiment, the T cell activating bispecific antigen binding
molecule essentially comprises an immunoglobulin molecule with an
additional Fab molecule N-terminally fused to one of the
immunoglobulin Fab arms, wherein in said additional Fab molecule
the heavy and light chain variable regions VH and VL (or the
constant regions CH1 and CL in embodiments wherein no charge
modifications as described herein are introduced in CH1 and CL
domains) are exchanged/replaced by each other (see FIG. 1C, F).
[0062] In a particular embodiment, the immunoglobulin molecule
comprised in the T cell activating bispecific antigen binding
molecule according to the invention is an IgG class immunoglobulin.
In an even more particular embodiment the immunoglobulin is an
IgG.sub.1 subclass immunoglobulin. In another embodiment, the
immunoglobulin is an IgG.sub.4 subclass immunoglobulin.
[0063] In a particular embodiment, the invention provides a T cell
activating bispecific antigen binding molecule comprising
[0064] a) a first Fab molecule which specifically binds to a first
antigen;
[0065] b) a second Fab molecule which specifically binds to a
second antigen, and wherein the variable domains VL and VH or the
constant domains CL and CH1 of the Fab light chain and the Fab
heavy chain are replaced by each other;
[0066] c) a third Fab molecule which specifically binds to the
first antigen; and
[0067] d) an Fc domain composed of a first and a second subunit
capable of stable association;
[0068] wherein the first antigen is p95HER2 and the second antigen
is an activating T cell antigen, particularly CD3, more
particularly CD3 epsilon;
[0069] wherein the third Fab molecule under c) is identical to the
first Fab molecule under a); [0070] wherein
[0071] (i) the first Fab molecule under a) is fused at the
C-terminus of the Fab heavy chain to the N-terminus of the Fab
heavy chain of the second Fab molecule under b), and the second Fab
molecule under b) and the third Fab molecule under c) are each
fused at the C-terminus of the Fab heavy chain to the N-terminus of
one of the subunits of the Fc domain under d), or
[0072] (ii) the second Fab molecule under b) is fused at the
C-terminus of the Fab heavy chain to the N-terminus of the Fab
heavy chain of the first Fab molecule under a), and the first Fab
molecule under a) and the third Fab molecule under c) are each
fused at the C-terminus of the Fab heavy chain to the N-terminus of
one of the subunits of the Fc domain under d); and
[0073] wherein the first Fab molecule under a) and the third Fab
molecule under c) comprise a heavy chain variable region,
particularly a humanized heavy chain variable region, comprising
the heavy chain complementarity determining region (HCDR) 1 of SEQ
ID NO: 14, the HCDR 2 of SEQ ID NO: 15 and the HCDR 3 of SEQ ID NO:
16, and a light chain variable region, particularly a humanized
light chain variable region, comprising the light chain
complementarity determining region (LCDR) 1 of SEQ ID NO: 17, the
LCDR 2 of SEQ ID NO: 18 and the LCDR 3 of SEQ ID NO: 19.
[0074] In another embodiment, the invention provides a T cell
activating bispecific antigen binding molecule comprising
[0075] a) a first Fab molecule which specifically binds to a first
antigen;
[0076] b) a second Fab molecule which specifically binds to a
second antigen, and wherein the variable domains VL and VH or the
constant domains CL and CH1 of the Fab light chain and the Fab
heavy chain are replaced by each other;
[0077] c) an Fc domain composed of a first and a second subunit
capable of stable association;
[0078] wherein the first antigen is p95HER2 and the second antigen
is an activating T cell antigen, particularly CD3, more
particularly CD3 epsilon; [0079] wherein
[0080] (i) the first Fab molecule under a) is fused at the
C-terminus of the Fab heavy chain to the N-terminus of the Fab
heavy chain of the second Fab molecule under b), and the second Fab
molecule under b) is fused at the C-terminus of the Fab heavy chain
to the N-terminus of one of the subunits of the Fc domain under c),
or
[0081] (ii) the second Fab molecule under b) is fused at the
C-terminus of the Fab heavy chain to the N-terminus of the Fab
heavy chain of the first Fab molecule under a), and the first Fab
molecule under a) is fused at the C-terminus of the Fab heavy chain
to the N-terminus of one of the subunits of the Fc domain under c);
and wherein the first Fab molecule under a) comprises a heavy chain
variable region, particularly a humanized heavy chain variable
region, comprising the heavy chain complementarity determining
region (HCDR) 1 of SEQ ID NO: 14, the HCDR 2 of SEQ ID NO: 15 and
the HCDR 3 of SEQ ID NO: 16, and a light chain variable region,
particularly a humanized light chain variable region, comprising
the light chain complementarity determining region (LCDR) 1 of SEQ
ID NO: 17, the LCDR 2 of SEQ ID NO: 18 and the LCDR 3 of SEQ ID NO:
19.
[0082] In a further embodiment, the invention provides a T cell
activating bispecific antigen binding molecule comprising
[0083] a) a first Fab molecule which specifically binds to a first
antigen;
[0084] b) a second Fab molecule which specifically binds to a
second antigen, and wherein the variable domains VL and VH or the
constant domains CL and CH1 of the Fab light chain and the Fab
heavy chain are replaced by each other; and
[0085] c) an Fc domain composed of a first and a second subunit
capable of stable association; wherein
[0086] (i) the first antigen is p95HER2 and the second antigen is
an activating T cell antigen, particularly CD3, more particularly
CD3 epsilon; or
[0087] (ii) the second antigen is p95HER2 and the first antigen is
an activating T cell antigen, particularly CD3, more particularly
CD3 epsilon;
[0088] wherein the first Fab molecule under a) and the second Fab
molecule under b) are each fused at the C-terminus of the Fab heavy
chain to the N-terminus of one of the subunits of the Fc domain
under c); and
[0089] wherein the Fab molecule which specifically binds to p95HER2
comprises a heavy chain variable region, particularly a humanized
heavy chain variable region, comprising the heavy chain
complementarity determining region (HCDR) 1 of SEQ ID NO: 14, the
HCDR 2 of SEQ ID NO: 15 and the HCDR 3 of SEQ ID NO: 16, and a
light chain variable region, particularly a humanized light chain
variable region, comprising the light chain complementarity
determining region (LCDR) 1 of SEQ ID NO: 17, the LCDR 2 of SEQ ID
NO: 18 and the LCDR 3 of SEQ ID NO: 19.
[0090] In all of the different configurations of the T cell
activating bispecific antigen binding molecule according to the
invention, the amino acid substitutions described herein, if
present, may either be in the CH1 and CL domains of the first and
(if present) the third Fab molecule, or in the CH1 and CL domains
of the second Fab molecule. Preferably, they are in the CH1 and CL
domains of the first and (if present) the third Fab molecule. In
accordance with the concept of the invention, if amino acid
substitutions as described herein are made in the first (and, if
present, the third) Fab molecule, no such amino acid substitutions
are made in the second Fab molecule. Conversely, if amino acid
substitutions as described herein are made in the second Fab
molecule, no such amino acid substitutions are made in the first
(and, if present, the third) Fab molecule. No amino acid
substitutions are made in T cell activating bispecific antigen
binding molecules comprising a Fab molecule wherein the constant
domains CL and CH1 of the Fab light chain and the Fab heavy chain
are replaced by each other.
[0091] In particular embodiments of the T cell activating
bispecific antigen binding molecule according to the invention,
particularly wherein amino acid substitutions as described herein
are made in the first (and, if present, the third) Fab molecule,
the constant domain CL of the first (and, if present, the third)
Fab molecule is of kappa isotype. In other embodiments of the T
cell activating bispecific antigen binding molecule according to
the invention, particularly wherein amino acid substitutions as
described herein are made in the second Fab molecule, the constant
domain CL of the second Fab molecule is of kappa isotype. In some
embodiments, the constant domain CL of the first (and, if present,
the third) Fab molecule and the constant domain CL of the second
Fab molecule are of kappa isotype.
[0092] In a particular embodiment, the invention provides a T cell
activating bispecific antigen binding molecule comprising
[0093] a) a first Fab molecule which specifically binds to a first
antigen;
[0094] b) a second Fab molecule which specifically binds to a
second antigen, and wherein the variable domains VL and VH of the
Fab light chain and the Fab heavy chain are replaced by each
other;
[0095] c) a third Fab molecule which specifically binds to the
first antigen; and
[0096] d) an Fc domain composed of a first and a second subunit
capable of stable association;
[0097] wherein the first antigen is p95HER2 and the second antigen
is an activating T cell antigen, particularly CD3, more
particularly CD3 epsilon;
[0098] wherein the third Fab molecule under c) is identical to the
first Fab molecule under a);
[0099] wherein in the constant domain CL of the first Fab molecule
under a) and the third Fab molecule under c) the amino acid at
position 124 is substituted by lysine (K) (numbering according to
Kabat) and the amino acid at position 123 is substituted by lysine
(K) or arginine (R) (numbering according to Kabat), and wherein in
the constant domain CH1 of the first Fab molecule under a) and the
third Fab molecule under c) the amino acid at position 147 is
substituted by glutamic acid (E) (numbering according to Kabat EU
index) and the amino acid at position 213 is substituted by
glutamic acid (E) (numbering according to Kabat EU index); [0100]
wherein
[0101] (i) the first Fab molecule under a) is fused at the
C-terminus of the Fab heavy chain to the N-terminus of the Fab
heavy chain of the second Fab molecule under b), and the second Fab
molecule under b) and the third Fab molecule under c) are each
fused at the C-terminus of the Fab heavy chain to the N-terminus of
one of the subunits of the Fc domain under d), or
[0102] (ii) the second Fab molecule under b) is fused at the
C-terminus of the Fab heavy chain to the N-terminus of the Fab
heavy chain of the first Fab molecule under a), and the first Fab
molecule under a) and the third Fab molecule under c) are each
fused at the C-terminus of the Fab heavy chain to the N-terminus of
one of the subunits of the Fc domain under d); and wherein the
first Fab molecule under a) and the third Fab molecule under c)
comprise a heavy chain variable region, particularly a humanized
heavy chain variable region, comprising the heavy chain
complementarity determining region (HCDR) 1 of SEQ ID NO: 14, the
HCDR 2 of SEQ ID NO: 15 and the HCDR 3 of SEQ ID NO: 16, and a
light chain variable region, particularly a humanized light chain
variable region, comprising the light chain complementarity
determining region (LCDR) 1 of SEQ ID NO: 17, the LCDR 2 of SEQ ID
NO: 18 and the LCDR 3 of SEQ ID NO: 19.
[0103] In an even more particular embodiment, the invention
provides a T cell activating bispecific antigen binding molecule
comprising
[0104] a) a first Fab molecule which specifically binds to a first
antigen;
[0105] b) a second Fab molecule which specifically binds to a
second antigen, and wherein the variable domains VL and VH of the
Fab light chain and the Fab heavy chain are replaced by each
other;
[0106] c) a third Fab molecule which specifically binds to the
first antigen; and
[0107] d) an Fc domain composed of a first and a second subunit
capable of stable association; wherein the first antigen is p95HER2
and the second antigen is an activating T cell antigen,
particularly CD3, more particularly CD3 epsilon;
[0108] wherein the third Fab molecule under c) is identical to the
first Fab molecule under a);
[0109] wherein in the constant domain CL of the first Fab molecule
under a) and the third Fab molecule under c) the amino acid at
position 124 is substituted by lysine (K) (numbering according to
Kabat) and the amino acid at position 123 is substituted by
arginine (R) (numbering according to Kabat), and wherein in the
constant domain CH1 of the first Fab molecule under a) and the
third Fab molecule under c) the amino acid at position 147 is
substituted by glutamic acid (E) (numbering according to Kabat EU
index) and the amino acid at position 213 is substituted by
glutamic acid (E) (numbering according to Kabat EU index);
[0110] wherein the first Fab molecule under a) is fused at the
C-terminus of the Fab heavy chain to the N-terminus of the Fab
heavy chain of the second Fab molecule under b), and the second Fab
molecule under b) and the third Fab molecule under c) are each
fused at the C-terminus of the Fab heavy chain to the N-terminus of
one of the subunits of the Fc domain under d); and wherein the
first Fab molecule under a) and the third Fab molecule under c)
comprise a heavy chain variable region, particularly a humanized
heavy chain variable region, comprising the heavy chain
complementarity determining region (HCDR) 1 of SEQ ID NO: 14, the
HCDR 2 of SEQ ID NO: 15 and the HCDR 3 of SEQ ID NO: 16, and a
light chain variable region, particularly a humanized light chain
variable region, comprising the light chain complementarity
determining region (LCDR) 1 of SEQ ID NO: 17, the LCDR 2 of SEQ ID
NO: 18 and the LCDR 3 of SEQ ID NO: 19.
[0111] In another embodiment, the invention provides a T cell
activating bispecific antigen binding molecule comprising
[0112] a) a first Fab molecule which specifically binds to a first
antigen;
[0113] b) a second Fab molecule which specifically binds to a
second antigen, and wherein the variable domains VL and VH of the
Fab light chain and the Fab heavy chain are replaced by each
other;
[0114] c) an Fc domain composed of a first and a second subunit
capable of stable association;
[0115] wherein the first antigen is p95HER2 and the second antigen
is an activating T cell antigen, particularly CD3, more
particularly CD3 epsilon;
[0116] wherein in the constant domain CL of the first Fab molecule
under a) the amino acid at position 124 is substituted by lysine
(K) (numbering according to Kabat) and the amino acid at position
123 is substituted by lysine (K) or arginine (R) (numbering
according to Kabat), and wherein in the constant domain CH1 of the
first Fab molecule under a) the amino acid at position 147 is
substituted by glutamic acid (E) (numbering according to Kabat EU
index) and the amino acid at position 213 is substituted by
glutamic acid (E) (numbering according to Kabat EU index); [0117]
wherein
[0118] (i) the first Fab molecule under a) is fused at the
C-terminus of the Fab heavy chain to the N-terminus of the Fab
heavy chain of the second Fab molecule under b), and the second Fab
molecule under b) is fused at the C-terminus of the Fab heavy chain
to the N-terminus of one of the subunits of the Fc domain under c),
or
[0119] (ii) the second Fab molecule under b) is fused at the
C-terminus of the Fab heavy chain to the N-terminus of the Fab
heavy chain of the first Fab molecule under a), and the first Fab
molecule under a) is fused at the C-terminus of the Fab heavy chain
to the N-terminus of one of the subunits of the Fc domain under c);
and wherein the first Fab molecule under a) comprises a heavy chain
variable region, particularly a humanized heavy chain variable
region, comprising the heavy chain complementarity determining
region (HCDR) 1 of SEQ ID NO: 14, the HCDR 2 of SEQ ID NO: 15 and
the HCDR 3 of SEQ ID NO: 16, and a light chain variable region,
particularly a humanized light chain variable region, comprising
the light chain complementarity determining region (LCDR) 1 of SEQ
ID NO: 17, the LCDR 2 of SEQ ID NO: 18 and the LCDR 3 of SEQ ID NO:
19.
[0120] In a further embodiment, the invention provides a T cell
activating bispecific antigen binding molecule comprising
[0121] a) a first Fab molecule which specifically binds to a first
antigen;
[0122] b) a second Fab molecule which specifically binds to a
second antigen, and wherein the variable domains VL and VH of the
Fab light chain and the Fab heavy chain are replaced by each other;
and
[0123] c) an Fc domain composed of a first and a second subunit
capable of stable association; wherein
[0124] (i) the first antigen is p95HER2 and the second antigen is
an activating T cell antigen, particularly CD3, more particularly
CD3 epsilon; or
[0125] (ii) the second antigen is p95HER2 and the first antigen is
an activating T cell antigen, particularly CD3, more particularly
CD3 epsilon;
[0126] wherein in the constant domain CL of the first Fab molecule
under a) the amino acid at position 124 is substituted by lysine
(K) (numbering according to Kabat) and the amino acid at position
123 is substituted by lysine (K) or arginine (R) (numbering
according to Kabat), and wherein in the constant domain CH1 of the
first Fab molecule under a) the amino acid at position 147 is
substituted by glutamic acid (E) (numbering according to Kabat EU
index) and the amino acid at position 213 is substituted by
glutamic acid (E) (numbering according to Kabat EU index);
[0127] wherein the first Fab molecule under a) and the second Fab
molecule under b) are each fused at the C-terminus of the Fab heavy
chain to the N-terminus of one of the subunits of the Fc domain
under c); and wherein the Fab molecule which specifically binds to
p95HER2 comprises a heavy chain variable region, particularly a
humanized heavy chain variable region, comprising the heavy chain
complementarity determining region (HCDR) 1 of SEQ ID NO: 14, the
HCDR 2 of SEQ ID NO: 15 and the HCDR 3 of SEQ ID NO: 16, and a
light chain variable region, particularly a humanized light chain
variable region, comprising the light chain complementarity
determining region (LCDR) 1 of SEQ ID NO: 17, the LCDR 2 of SEQ ID
NO: 18 and the LCDR 3 of SEQ ID NO: 19.
[0128] In particular embodiments of the T cell activating
bispecific antigen binding molecule, the Fc domain is an IgG Fc
domain. In a specific embodiment, the Fc domain is an IgG.sub.1 Fc
domain. In another specific embodiment, the Fc domain is an
IgG.sub.4 Fc domain. In an even more specific embodiment, the Fc
domain is an IgG.sub.4 Fc domain comprising the amino acid
substitution S228P (Kabat numbering). In particular embodiments the
Fc domain is a human Fc domain.
[0129] In particular embodiments, the Fc domain comprises a
modification promoting the association of the first and the second
Fc domain subunit. In a specific such embodiment, an amino acid
residue in the CH3 domain of the first subunit of the Fc domain is
replaced with an amino acid residue having a larger side chain
volume, thereby generating a protuberance within the CH3 domain of
the first subunit which is positionable in a cavity within the CH3
domain of the second subunit, and an amino acid residue in the CH3
domain of the second subunit of the Fc domain is replaced with an
amino acid residue having a smaller side chain volume, thereby
generating a cavity within the CH3 domain of the second subunit
within which the protuberance within the CH3 domain of the first
subunit is positionable.
[0130] In a particular embodiment the Fc domain exhibits reduced
binding affinity to an Fc receptor and/or reduced effector
function, as compared to a native IgG.sub.1 Fc domain. In certain
embodiments the Fc domain is engineered to have reduced binding
affinity to an Fc receptor and/or reduced effector function, as
compared to a non-engineered Fc domain. In one embodiment, the Fc
domain comprises one or more amino acid substitution that reduces
binding to an Fc receptor and/or effector function. In one
embodiment, the one or more amino acid substitution in the Fc
domain that reduces binding to an Fc receptor and/or effector
function is at one or more position selected from the group of
L234, L235, and P329 (Kabat EU index numbering). In particular
embodiments, each subunit of the Fc domain comprises three amino
acid substitutions that reduce binding to an Fc receptor and/or
effector function wherein said amino acid substitutions are L234A,
L235A and P329G (Kabat EU index numbering). In one such embodiment,
the Fc domain is an IgG.sub.1 Fc domain, particularly a human
IgG.sub.1 Fc domain. In other embodiments, each subunit of the Fc
domain comprises two amino acid substitutions that reduce binding
to an Fc receptor and/or effector function wherein said amino acid
substitutions are L235E and P329G (Kabat EU index numbering). In
one such embodiment, the Fc domain is an IgG.sub.4 Fc domain,
particularly a human IgG.sub.4 Fc domain. In one embodiment, the Fc
domain of the T cell activating bispecific antigen binding molecule
is an IgG.sub.4 Fc domain and comprises the amino acid
substitutions L235E and S228P (SPLE) (Kabat EU index
numbering).
[0131] In one embodiment the Fc receptor is an Fc.gamma. receptor.
In one embodiment the Fc receptor is a human Fc receptor. In one
embodiment, the Fc receptor is an activating Fc receptor. In a
specific embodiment, the Fc receptor is human Fc.gamma.RIIa,
Fc.gamma.RI, and/or Fc.gamma.RIIIa. In one embodiment, the effector
function is antibody-dependent cell-mediated cytotoxicity
(ADCC).
[0132] In a specific embodiment of the T cell activating bispecific
antigen binding molecule according to the invention, the antigen
binding moiety which specifically binds to an activating T cell
antigen, particularly CD3, more particularly CD3 epsilon, comprises
a heavy chain variable region comprising the heavy chain
complementarity determining region (HCDR) 1 of SEQ ID NO: 4, the
HCDR 2 of SEQ ID NO: 5, the HCDR 3 of SEQ ID NO: 6, and a light
chain variable region comprising the light chain complementarity
determining region (LCDR) 1 of SEQ ID NO: 8, the LCDR 2 of SEQ ID
NO: 9 and the LCDR 3 of SEQ ID NO: 10. In an even more specific
embodiment, the antigen binding moiety which specifically binds to
an activating T cell antigen, particularly CD3, more particularly
CD3 epsilon, comprises a heavy chain variable region comprising an
amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99%
or 100% identical to the amino acid sequence of SEQ ID NO: 3 and a
light chain variable region comprising an amino acid sequence that
is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the
amino acid sequence of SEQ ID NO: 7. In some embodiments, the
antigen binding moiety which specifically binds to an activating T
cell antigen is a Fab molecule. In one specific embodiment, the
second antigen binding moiety, particularly Fab molecule, comprised
in the T cell activating bispecific antigen binding molecule
according to the invention specifically binds to CD3, more
particularly CD3 epsilon, and comprises the heavy chain
complementarity determining region (CDR) 1 of SEQ ID NO: 4, the
heavy chain CDR 2 of SEQ ID NO: 5, the heavy chain CDR 3 of SEQ ID
NO: 6, the light chain CDR 1 of SEQ ID NO: 8, the light chain CDR 2
of SEQ ID NO: 9 and the light chain CDR 3 of SEQ ID NO: 10. In an
even more specific embodiment, said second antigen binding moiety,
particularly Fab molecule, comprises a heavy chain variable region
comprising the amino acid sequence of SEQ ID NO: 3 and a light
chain variable region comprising the amino acid sequence of SEQ ID
NO: 7.
[0133] In a further specific embodiment of the T cell activating
bispecific antigen binding molecule according to the invention, the
antigen binding moiety, particularly Fab molecule, which
specifically binds to p95HER2 comprises the heavy chain
complementarity determining region (CDR) 1 of SEQ ID NO: 14, the
heavy chain CDR 2 of SEQ ID NO: 15, the heavy chain CDR 3 of SEQ ID
NO: 16, the light chain CDR 1 of SEQ ID NO: 17, the light chain CDR
2 of SEQ ID NO: 18 and the light chain CDR 3 of SEQ ID NO: 19. In
an even more specific embodiment, the antigen binding moiety,
particularly Fab molecule, which specifically binds to p95HER2
comprises a heavy chain variable region comprising an amino acid
sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100%
identical to the amino acid sequence of SEQ ID NO: 20 and a light
chain variable region comprising an amino acid sequence that is at
least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino
acid sequence of SEQ ID NO: 21. In one specific embodiment, the
first (and, if present, the third) antigen binding moiety,
particularly Fab molecule, comprised in the T cell activating
bispecific antigen binding molecule according to the invention
specifically binds to p95HER2, and comprises the heavy chain
complementarity determining region (CDR) 1 of SEQ ID NO: 14, the
heavy chain CDR 2 of SEQ ID NO: 15, the heavy chain CDR 3 of SEQ ID
NO: 16, the light chain CDR 1 of SEQ ID NO: 17, the light chain CDR
2 of SEQ ID NO: 18 and the light chain CDR 3 of SEQ ID NO: 19. In
an even more specific embodiment, said first (and, if present, said
third) antigen binding moiety, particularly Fab molecule, comprises
a heavy chain variable region comprising the amino acid sequence of
SEQ ID NO: 20 and a light chain variable region comprising the
amino acid sequence of SEQ ID NO: 21.
[0134] In a particular aspect, the invention provides a T cell
activating bispecific antigen binding molecule comprising
[0135] a) a first Fab molecule which specifically binds to a first
antigen;
[0136] b) a second Fab molecule which specifically binds to a
second antigen, and wherein the variable domains VL and VH or the
constant domains CL and CH1 of the Fab light chain and the Fab
heavy chain are replaced by each other;
[0137] c) a third Fab molecule which specifically binds to the
first antigen; and
[0138] d) an Fc domain composed of a first and a second subunit
capable of stable association;
[0139] wherein
[0140] (i) the first antigen is p95HER2 and the second antigen is
CD3, particularly CD3 epsilon;
[0141] (ii) the first Fab molecule under a) and the third Fab
molecule under c) each comprise the heavy chain complementarity
determining region (CDR) 1 of SEQ ID NO: 14, the heavy chain CDR 2
of SEQ ID NO: 15, the heavy chain CDR 3 of SEQ ID NO: 16, the light
chain CDR 1 of SEQ ID NO: 17, the light chain CDR 2 of SEQ ID NO:
18 and the light chain CDR 3 of SEQ ID NO: 19, and the second Fab
molecule under b) comprises the heavy chain CDR 1 of SEQ ID NO: 4,
the heavy chain CDR 2 of SEQ ID NO: 5, the heavy chain CDR 3 of SEQ
ID NO: 6, the light chain CDR 1 of SEQ ID NO: 8, the light chain
CDR 2 of SEQ ID NO: 9 and the light chain CDR 3 of SEQ ID NO: 10;
and
[0142] (iii) the first Fab molecule under a) is fused at the
C-terminus of the Fab heavy chain to the N-terminus of the Fab
heavy chain of the second Fab molecule under b), and the second Fab
molecule under b) and the third Fab molecule under c) are each
fused at the C-terminus of the Fab heavy chain to the N-terminus of
one of the subunits of the Fc domain under d).
[0143] In one embodiment, in the second Fab molecule under b) the
variable domains VL and VH are replaced by each other and further
(iv) in the constant domain CL of the first Fab molecule under a)
and the third Fab molecule under c) the amino acid at position 124
is substituted by lysine (K) (numbering according to Kabat) and the
amino acid at position 123 is substituted by lysine (K) or arginine
(R), particularly by arginine (R) (numbering according to Kabat),
and in the constant domain CH1 of the first Fab molecule under a)
and the third Fab molecule under c) the amino acid at position 147
is substituted by glutamic acid (E) (numbering according to Kabat
EU index) and the amino acid at position 213 is substituted by
glutamic acid (E) (numbering according to Kabat EU index).
[0144] According to another aspect of the invention there is
provided one or more isolated polynucleotide(s) encoding a T cell
activating bispecific antigen binding molecule of the invention.
The invention further provides one or more expression vector(s)
comprising the isolated polynucleotide(s) of the invention, and a
host cell comprising the isolated polynucleotide(s) or the
expression vector(s) of the invention. In some embodiments the host
cell is a eukaryotic cell, particularly a mammalian cell.
[0145] In another aspect is provided a method of producing the T
cell activating bispecific antigen binding molecule of the
invention, comprising the steps of a) culturing the host cell of
the invention under conditions suitable for the expression of the T
cell activating bispecific antigen binding molecule and b)
recovering the T cell activating bispecific antigen binding
molecule. The invention also encompasses a T cell activating
bispecific antigen binding molecule produced by the method of the
invention.
[0146] The invention further provides a pharmaceutical composition
comprising the T cell activating bispecific antigen binding
molecule of the invention and a pharmaceutically acceptable
carrier.
[0147] Also encompassed by the invention are methods of using the T
cell activating bispecific antigen binding molecule and
pharmaceutical composition of the invention. In one aspect the
invention provides a T cell activating bispecific antigen binding
molecule or a pharmaceutical composition of the invention for use
as a medicament. In one aspect is provided a T cell activating
bispecific antigen binding molecule or a pharmaceutical composition
according to the invention for use in the treatment of a disease in
an individual in need thereof. In a specific embodiment the disease
is cancer.
[0148] Also provided is the use of a T cell activating bispecific
antigen binding molecule of the invention for the manufacture of a
medicament for the treatment of a disease in an individual in need
thereof; as well as a method of treating a disease in an
individual, comprising administering to said individual a
therapeutically effective amount of a composition comprising the T
cell activating bispecific antigen binding molecule according to
the invention in a pharmaceutically acceptable form. In a specific
embodiment the disease is cancer. In any of the above embodiments
the individual preferably is a mammal, particularly a human.
[0149] The invention also provides a method for inducing lysis of a
target cell, particularly a tumor cell, comprising contacting a
target cell with a T cell activating bispecific antigen binding
molecule of the invention in the presence of a T cell, particularly
a cytotoxic T cell.
BRIEF DESCRIPTION OF THE DRAWINGS
[0150] FIG. 1. Exemplary configurations of the T cell activating
bispecific antigen binding molecules (TCBs) of the invention. (A,
D) Illustration of the "1+1 CrossMab" molecule. (B, E) Illustration
of the "2+1 IgG Crossfab" molecule with alternative order of
Crossfab and Fab components ("inverted"). (C, F) Illustration of
the "2+1 IgG Crossfab" molecule. (G, K) Illustration of the "1+1
IgG Crossfab" molecule with alternative order of Crossfab and Fab
components ("inverted"). (H, L) Illustration of the "1+1 IgG
Crossfab" molecule. (I, M) Illustration of the "2+1 IgG Crossfab"
molecule with two CrossFabs. (J, N) Illustration of the "2+1 IgG
Crossfab" molecule with two CrossFabs and alternative order of
Crossfab and Fab components ("inverted"). (O, S) Illustration of
the "Fab-Crossfab" molecule. (P, T) Illustration of the
"Crossfab-Fab" molecule. (Q, U) Illustration of the
"(Fab).sub.2-Crossfab" molecule. (R, V) Illustration of the
"Crossfab-(Fab).sub.2" molecule. (W, Y) Illustration of the
"Fab-(Crossfab).sub.2" molecule. (X, Z) Illustration of the
"(Crossfab).sub.2-Fab" molecule. Black dot: optional modification
in the Fc domain promoting heterodimerization. ++, --: amino acids
of opposite charges optionally introduced in the CH1 and CL
domains. Crossfab molecules are depicted as comprising an exchange
of VH and VL regions, but may--in embodiments wherein no charge
modifications are introduced in CH1 and CL domains--alternatively
comprise an exchange of the CH1 and CL domains.
[0151] FIG. 2. Illustration of the TCBs prepared in the Examples.
(A) Illustration of "2+1 IgG CrossFab, inverted"
anti-p95HER2/anti-CD3 TCB molecule with charge modifications (VH/VL
exchange in CD3 binder, charge modification in p95HER2 binder,
molecule A). (B) Illustration of "2+1 IgG CrossFab, inverted"
anti-p95HER2/anti-CD3 TCB molecule without charge modifications
(CH1/CL exchange in CD3 binder, molecule B). EE=147E, 213E;
RK=123R, 124K.
[0152] FIG. 3. CE-SDS analyses of the TCB molecules prepared in the
Examples (final purified preparations). (A) Electropherogram of
"2+1 IgG CrossFab, inverted" with charge modifications (VH/VL
exchange in CD3 binder, charge modification in p95HER2 binder;
molecule A). (B) Electropherogram of "2+1 IgG CrossFab, inverted"
anti-p95HER2/anti-CD3 TCB molecule without charge modifications
(CH1/CL exchange in CD3 binder, molecule B). Lane A=non reduced,
lane B=reduced.
[0153] FIG. 4. Non-reduced SDS PAGE of fractions from Protein A
chromatography of the TCB molecule A prepared in Example 1 (4-12%
Bis/Tris, NuPage (Invitrogen); Coomassie stained; lane 1=size
marker Mark 12 (Invitrogen)); lanes 2 to 7: fractions from Protein
A chromatography of molecule A.
[0154] FIG. 5. (A) Western blot of MCF10A cells stably expressing
Vector, p95HER2, HER2 or the combination. (B) Cells shown in (A)
were incubated with 2 .mu.g/ml of p95HER2 TCB and analyzed by flow
cytometry. (C) Comparison of p95HER2 expression levels on MCF10A
cells stably expressing p95HER2 ("MCF10A_p95Her2") and HCC-1954
cells analyzed by flow cytometry.
[0155] FIG. 6. Lysis of MCF10A cells stably expressing Vector,
p95HER2, HER2 or the combination after 48 hours incubation with
PBMCs (effector: target ratio 10:1) and increasing concentrations
of p95HER2 TCB antibody ("p95-TCB").
[0156] FIG. 7. Lysis of (A, B) MCF10A cells stably expressing
p95HER2 (A) or Vector (B), or (C) HCC-1954 cells, after incubation
for 46 hours with PBMCs (effector: target ratio 10:1) and
increasing concentrations of p95HER2 TCB or untargeted control
TCB.
[0157] FIG. 8. CD25 (A, B) and CD69 (C, D) expression on CD4+ T
cells upon killing of MCF10A cells expressing p95HER2 or Vector, or
HCC-1954 cells after 46 hours mediated by p95HER2 TCB, analyzed by
flow cytometry. (A, C) Mean fluorescence intensity (MFI), (B, D) %
positive CD4+ T cells.
[0158] FIG. 9. CD25 (A, B) and CD69 (C, D) expression on CD8+ T
cells upon killing of MCF10A expressing p95HER2 or Vector or
HCC-1954 after 46 hours mediated by p95HER2 TCB, analyzed by flow
cytometry. (A, C) Mean fluorescence intensity (MFI), (B, D) %
positive CD8+ T cells.
[0159] FIG. 10. Binding of p95HER2-TCB, HER2-TCB and untargeted
control TCB on MCF10A_p95HER2, MCF10A_Vector, MCF10A_HER2 and
cardiomyocytes analyzed by flow cytometry.
[0160] FIG. 11. CD3 stimulation of Jurkat NFAT cells mediated by
p95HER2 TCB or HER2 TCB in the presence of cardiomyocytes.
[0161] FIG. 12. Lysis of MCF10A cells stably expressing p95HER2
(MCF10A-p95Her2) or HER2 (MCF10A-Her2), and cardiomyocytes after
incubation for .about.48 hours with PBMCs (effector: target ratio
10:1) and with increasing concentrations of p95HER2 TCB or HER2
TCB.
[0162] FIG. 13. CD25 expression level on CD8+(A) and CD4+(B) T
cells upon lysis of MCF10A-p95HER2 or MCF10A-HER2 and
cardiomyocytes after incubation for .about.48 hours with PBMCs
(effector: target ratio 10:1) and increasing concentrations of
p95HER2 TCB or HER2 TCB.
[0163] FIG. 14. (A) Immunohistochemistry with p95HER2 antibody of
the p95HER2 positive (PDX67) and p95HER2 negative (PDX118)
patient-derived xenografts (PDXs) from which primary cultures were
generated. (B) Primary cultures from PDXs shown in (A) and from a
Triple Negative Breast Cancer (TNBC) PDX were incubated with 2
.mu.g/ml of p95HER2-TCB and analyzed by flow cytometry. (C) Primary
cultures from PDXs in (A) were incubated with PBMCs (effector:
target ratio 10:1) and with increasing concentrations of p95HER2
TCB for 48 hours. Cell lysis was determined by LDH release.
[0164] FIG. 15. (A) Experimental workflow for in vivo testing of
p95HER2 TCB. PDX173, p95HER2+, was implanted into the mammary fat
pad of NSG mice. When tumors reached a media of 200 mm.sup.3
animals were humanized with 10.sup.7 freshly isolated PBMCs and
randomized into the 4 experimental groups. Treatments started 48 h
after PBMC injection. (B) Media of the percentage change in tumor
volume for each of the experimental groups and for individual
animals. (C and D) Tumor weights at the end of the experiment.
t-test, *p<0.05, **p<0.01, ***p<0.001. ns,
non-significant.
[0165] FIG. 16. (A) Determination of tumor-infiltrating immune
cells. Tumors were excised and single cell suspensions were stained
with an antibody mixture containing: msCD45, huCD45 (A), huCD3 (B),
huCD8 (C) and huCD4 (D). Samples were analyzed by flow cytometry.
t-test, *p<0.05, **p<0.01, ***p<0.001. ns,
non-significant. (E) Percentage of huCD8 in FFPE tumor samples
determined by immunohistochemical analysis.
[0166] FIG. 17. Effect of p95HER2 TCB on the growth of xenografts
of cells expressing p95HER2. (A-C) MCF7 cells were stably
transduced with p95HER2 under the control of a
doxycycline-inducible promoter, and a non-targeting shRNA (sh-NT)
or a shRNA targeting p21 (sh-p21) under the control of an
independent doxycycline-inducible promoter. Cell lysates were
evaluated by Western blotting (A) and proliferation assays were
performed (B). Representative bright field images of the cells are
shown in (C). (D) NSG mice (n=6 per group) were injected with
10.sup.6 MCF7 Tet-On p95HER2 sh-p21 cells. When tumors reached
.about.200 mm.sup.3 (shadowed), human PBMCs from a healthy
volunteer were transferred by i.p. injection (10.sup.7
cells/mouse). Mice were treated with vehicle (control) or 1 mg/kg
of p95HER2 TCB (arrows). Tumor volumes were measured by caliper.
Graphs display averages; error bars correspond to 95% confidence
intervals. P values were calculated using the two-sided Student's t
test; *P<0.05, ** P<0.01. (E) Levels of human CD45.sup.+
after PBMCs injection. Leukocytes from mice analyzed in (D) were
obtained 15 days after PBMC injection, stained with anti-huCD45 and
quantified by flow cytometry. Box plots show the percentage
CD45.sup.+ cells in the mice analyzed in (D). Lower and higher
whiskers indicate 10.sup.th and 90.sup.th percentiles,
respectively; lower and higher edges of box indicate 25.sup.th and
75.sup.th percentiles, respectively; the inner line in the box
indicates 50.sup.th percentile. (F) Effect of p95HER2 TCB on tumor
weight. At the end of the experiment shown in (D), tumors were
removed and weighted. The results are expressed as averages; error
bars correspond to 95% confidence intervals. P values were
calculated using the two-sided Student's t test; *P<0.05.
[0167] FIG. 18. Effect of p95HER2 TCB on the growth of a
p95HER2-positive patient-derived xenograft (PDX). (A) Analysis of
the expression of p95HER2 by immunohistochemistry in the PDX used
for the study. (B) Effect of p95HER2 TCB on tumor growth. NSG mice
(n=6 per group) carrying the indicated PDX were monitored until
tumors reached .about.300 mm.sup.3 (shadowed). Then, human PBMCs
from a healthy volunteer were transferred by i.p. injection
(10.sup.7 cells/mouse). Mice were treated with vehicle (control) or
1 mg/kg of p95HER2 TCB (arrows). Tumor volumes were measured by
caliper. Graphs display averages; error bars correspond to 95%
confidence intervals. P values were calculated using the two-sided
Student's t test; *P<0.05. (C) Levels of human CD45.sup.+ after
PBMC injection. Leukocytes from mice analyzed in (B) were obtained
15 days after PBMC injection, stained with anti-huCD45 and
quantified by flow cytometry. Box plots show the percentage
CD45.sup.+ cells in the mice analyzed in (B). Lower and higher
whiskers indicate 10.sup.th and 90.sup.th percentiles,
respectively; lower and higher edges of box indicate 25.sup.th and
75.sup.th percentiles, respectively; the inner line in the box
indicates 50.sup.th percentile. (D) Effect of p95HER2 TCB on tumor
weight. At the end of the experiment shown in (B), tumors were
removed and weighted. The results are expressed as averages; error
bars correspond to 95% confidence intervals. P values were
calculated using the two-sided Student's t test; *P<0.05. (E)
Effect of p95HER2 TCB on T cell infiltration. At the end of the
experiment shown in (B), tumor samples corresponding to the
experiment shown in (B) were disaggregated to single cells, stained
with anti-human CD3, CD8 and CD4, and the number of positive cells
was quantified by flow cytometry. Box plots show the percentage of
the cells positive for the indicated marker. Lower and higher
whiskers indicate 10.sup.th and 90.sup.th percentiles,
respectively; lower and higher edges of box indicate 25.sup.th and
75.sup.th percentiles, respectively; the inner line in the box
indicates 50.sup.th percentile. P values were calculated using the
two-sided Student's t test; *P<0.05, **P<0.01. (F) Effect of
p95HER2 TCB on tumor cells. At the end of the experiment shown in
(B), sagittal cuts of tumors were stained with anti-human
cytokeratine antibodies and the % of positive cells was quantified.
The results are expressed as averages; error bars correspond to 95%
confidence intervals. P values were calculated using the two-sided
Student's t test; ***P<0.001. Representative stainings are shown
in (G).
[0168] FIG. 19. HER2 TCB and p95HER-TCB-induced T cell activation
and tumor cell lysis. (A,B) MCF10A cells and MCF7 cells were
incubated with increasing concentrations of HER2 TCB (A) or p95HER2
TCB (B) and with PBMCs in a 10:1 ratio. After 48 h supernatants
were collected and lysis was measured by LDH release. (C) PBMCs
from MCF10A-Vector in (A) and (B) were collected, stained for
huCD45/CD8/CD4/CD69/CD25 and analyzed by flow cytometry. Graph
represents the mean of three independent experiments and show the
percentage of CD8 or CD4 cells that are positive for the activation
markers CD25 or CD69.
[0169] FIG. 20. (A) Lysates from MCF10A cells transfected with wild
type HER2 or HER2 bearing a M611A mutation were analyzed by Western
blot with anti-HER2 antibodies. (B) The same cells as in (A) were
analyzed by flow cytometry with the indicated antibodies.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
[0170] Terms are used herein as generally used in the art, unless
otherwise defined in the following.
[0171] As used herein, the term "antigen binding molecule" refers
in its broadest sense to a molecule that specifically binds an
antigenic determinant. Examples of antigen binding molecules are
immunoglobulins and derivatives, e.g. fragments, thereof.
[0172] The term "bispecific" means that the antigen binding
molecule is able to specifically bind to at least two distinct
antigenic determinants. Typically, a bispecific antigen binding
molecule comprises two antigen binding sites, each of which is
specific for a different antigenic determinant. In certain
embodiments the bispecific antigen binding molecule is capable of
simultaneously binding two antigenic determinants, particularly two
antigenic determinants expressed on two distinct cells.
[0173] The term "valent" as used herein denotes the presence of a
specified number of antigen binding sites in an antigen binding
molecule. As such, the term "monovalent binding to an antigen"
denotes the presence of one (and not more than one) antigen binding
site specific for the antigen in the antigen binding molecule.
[0174] An "antigen binding site" refers to the site, i.e. one or
more amino acid residues, of an antigen binding molecule which
provides interaction with the antigen. For example, the antigen
binding site of an antibody comprises amino acid residues from the
complementarity determining regions (CDRs). A native immunoglobulin
molecule typically has two antigen binding sites, a Fab molecule
typically has a single antigen binding site.
[0175] As used herein, the term "antigen binding moiety" refers to
a polypeptide molecule that specifically binds to an antigenic
determinant. In one embodiment, an antigen binding moiety is able
to direct the entity to which it is attached (e.g. a second antigen
binding moiety) to a target site, for example to a specific type of
tumor cell or tumor stroma bearing the antigenic determinant. In
another embodiment an antigen binding moiety is able to activate
signaling through its target antigen, for example a T cell receptor
complex antigen. Antigen binding moieties include antibodies and
fragments thereof as further defined herein. Particular antigen
binding moieties include an antigen binding domain of an antibody,
comprising an antibody heavy chain variable region and an antibody
light chain variable region. In certain embodiments, the antigen
binding moieties may comprise antibody constant regions as further
defined herein and known in the art. Useful heavy chain constant
regions include any of the five isotypes: .alpha., .delta.,
.epsilon., .gamma., or .mu.. Useful light chain constant regions
include any of the two isotypes: .kappa. and .lamda..
[0176] As used herein, the term "antigenic determinant" is
synonymous with "antigen" and "epitope," and refers to a site (e.g.
a contiguous stretch of amino acids or a conformational
configuration made up of different regions of non-contiguous amino
acids) on a polypeptide macromolecule to which an antigen binding
moiety binds, forming an antigen binding moiety-antigen complex.
Useful antigenic determinants can be found, for example, on the
surfaces of tumor cells, on the surfaces of virus-infected cells,
on the surfaces of other diseased cells, on the surface of immune
cells, free in blood serum, and/or in the extracellular matrix
(ECM). The proteins referred to as antigens herein (e.g. CD3) can
be any native form of the proteins from any vertebrate source,
including mammals such as primates (e.g. humans) and rodents (e.g.
mice and rats), unless otherwise indicated. In a particular
embodiment the antigen is a human protein. Where reference is made
to a specific protein herein, the term encompasses the
"full-length", unprocessed protein as well as any form of the
protein that results from processing in the cell. The term also
encompasses naturally occurring variants of the protein, e.g.
splice variants or allelic variants. An exemplary human protein
useful as antigen is CD3, particularly the epsilon subunit of CD3
(see UniProt no. P07766 (version 130), NCBI RefSeq no. NP_000724.1,
SEQ ID NO: 1 for the human sequence; or UniProt no. Q95LI5 (version
49), NCBI GenBank no. BAB71849.1, SEQ ID NO: 2 for the cynomolgus
[Macaca fascicularis] sequence), or p95HER2 (see below). In certain
embodiments the T cell activating bispecific antigen binding
molecule of the invention binds to an epitope of CD3 or p95HER2
that is conserved among the CD3 or p95HER2 antigens from different
species. In particular embodiments, the T cell activating
bispecific antigen binding molecule of the invention binds to human
CD3 and human p95HER2.
[0177] The proto-oncogene HER2 (human epidermal growth factor
receptor 2) encodes a protein tyrosine kinase (p185HER2) that is
related to and somewhat homologous to the human epidermal growth
factor receptor (see Coussens, L. et al. Science 230:1132-1139
(1985); Yamamoto, T. et al., Nature 319:230-234 (1986); King, C. R.
et al., Science 229:974-976 (1985)). HER2 is also known in the
field as c-erbB-2, and sometimes by the name of the rat homolog,
neu. Amplification and/or overexpression of HER2 is associated with
multiple human malignancies and appears to be integrally involved
in progression of 25-30% of human breast and ovarian cancers
(Slamon, D. J. et al., Science 235:177-182 (1987), Slamon, D. J. et
al., Science 244:707-712 (1989)). Furthermore, the extent of
amplification is inversely correlated with the observed median
patient survival time (Slamon, supra, Science 1989).
[0178] The term "p95HER2" as used herein refers to a carboxy
terminal fragment (CTF) of the HER2 receptor protein, which is also
known as "611-CTF" or "100-115 kDa p95HER2". The p95HER2 fragment
is generated in the cell through initiation of translation of the
HER2 mRNA at codon position 611 of the full-length HER2 molecule
(Anido et al, EMBO J 25; 3234-44 (2006)). It has a molecular weight
of 100 to 115 kDa and is expressed at the cell membrane, where it
can form homodimers maintained by intermolecular disulfide bonds
(Pedersen et al., Mol Cell Biol 29, 3319-31 (2009)). An exemplary
sequence of human p95HER2 is given in SEQ ID NO: 30.
[0179] By "specific binding" is meant that the binding is selective
for the antigen and can be discriminated from unwanted or
non-specific interactions. The ability of an antigen binding moiety
to bind to a specific antigenic determinant can be measured either
through an enzyme-linked immunosorbent assay (ELISA) or other
techniques familiar to one of skill in the art, e.g. surface
plasmon resonance (SPR) technique (analyzed e.g. on a BIAcore
instrument) (Liljeblad et al., Glyco J 17, 323-329 (2000)), and
traditional binding assays (Heeley, Endocr Res 28, 217-229 (2002)).
In one embodiment, the extent of binding of an antigen binding
moiety to an unrelated protein is less than about 10% of the
binding of the antigen binding moiety to the antigen as measured,
e.g., by SPR. In certain embodiments, an antigen binding moiety
that binds to the antigen, or an antigen binding molecule
comprising that antigen binding moiety, has a dissociation constant
(K.sub.D) of .ltoreq.1 .mu.M, .ltoreq.100 nM, .ltoreq.10 nM,
.ltoreq.1 nM, .ltoreq.0.1 nM, .ltoreq.0.01 nM, or .ltoreq.0.001 nM
(e.g. 10.sup.-8M or less, e.g. from 10.sup.-8M to 10.sup.-13M,
e.g., from 10.sup.-9M to 10.sup.-13 M).
[0180] "Affinity" refers to the strength of the sum total of
non-covalent interactions between a single binding site of a
molecule (e.g., a receptor) and its binding partner (e.g., a
ligand). Unless indicated otherwise, as used herein, "binding
affinity" refers to intrinsic binding affinity which reflects a 1:1
interaction between members of a binding pair (e.g., an antigen
binding moiety and an antigen, or a receptor and its ligand). The
affinity of a molecule X for its partner Y can generally be
represented by the dissociation constant (K.sub.D), which is the
ratio of dissociation and association rate constants (k.sub.off and
k.sub.on, respectively). Thus, equivalent affinities may comprise
different rate constants, as long as the ratio of the rate
constants remains the same. Affinity can be measured by well
established methods known in the art, including those described
herein. A particular method for measuring affinity is Surface
Plasmon Resonance (SPR).
[0181] "Reduced binding", for example reduced binding to an Fc
receptor, refers to a decrease in affinity for the respective
interaction, as measured for example by SPR. For clarity the term
includes also reduction of the affinity to zero (or below the
detection limit of the analytic method), i.e. complete abolishment
of the interaction. Conversely, "increased binding" refers to an
increase in binding affinity for the respective interaction.
[0182] An "activating T cell antigen" as used herein refers to an
antigenic determinant expressed on the surface of a T lymphocyte,
particularly a cytotoxic T lymphocyte, which is capable of inducing
T cell activation upon interaction with an antigen binding
molecule. Specifically, interaction of an antigen binding molecule
with an activating T cell antigen may induce T cell activation by
triggering the signaling cascade of the T cell receptor complex. In
a particular embodiment the activating T cell antigen is CD3,
particularly the epsilon subunit of CD3 (see UniProt no. P07766
(version 130), NCBI RefSeq no. NP_000724.1, SEQ ID NO: 1 for the
human sequence; or UniProt no. Q95LI5 (version 49), NCBI GenBank
no. BAB71849.1, SEQ ID NO: 2 for the cynomolgus [Macaca
fascicularis] sequence).
[0183] "T cell activation" as used herein refers to one or more
cellular response of a T lymphocyte, particularly a cytotoxic T
lymphocyte, selected from: proliferation, differentiation, cytokine
secretion, cytotoxic effector molecule release, cytotoxic activity,
and expression of activation markers. The T cell activating
bispecific antigen binding molecules of the invention are capable
of inducing T cell activation. Suitable assays to measure T cell
activation are known in the art and described herein.
[0184] A "target cell antigen" as used herein refers to an
antigenic determinant presented on the surface of a target cell,
for example a cell in a tumor such as a cancer cell or a cell of
the tumor stroma. In a particular embodiment, the target cell
antigen is p95HER2, particularly human p95HER2.
[0185] As used herein, the terms "first", "second" or "third" with
respect to Fab molecules etc., are used for convenience of
distinguishing when there is more than one of each type of moiety.
Use of these terms is not intended to confer a specific order or
orientation of the T cell activating bispecific antigen binding
molecule unless explicitly so stated.
[0186] A "Fab molecule" refers to a protein consisting of the VH
and CH1 domain of the heavy chain (the "Fab heavy chain") and the
VL and CL domain of the light chain (the "Fab light chain") of an
immunoglobulin.
[0187] By "fused" is meant that the components (e.g. a Fab molecule
and an Fc domain subunit) are linked by peptide bonds, either
directly or via one or more peptide linkers.
[0188] As used herein, the term "single-chain" refers to a molecule
comprising amino acid monomers linearly linked by peptide bonds. In
certain embodiments, one of the antigen binding moieties is a
single-chain Fab molecule, i.e. a Fab molecule wherein the Fab
light chain and the Fab heavy chain are connected by a peptide
linker to form a single peptide chain. In a particular such
embodiment, the C-terminus of the Fab light chain is connected to
the N-terminus of the Fab heavy chain in the single-chain Fab
molecule.
[0189] By a "crossover" Fab molecule (also termed "Crossfab") is
meant a Fab molecule wherein the variable domains or the constant
domains of the Fab heavy and light chain are exchanged (i.e.
replaced by each other), i.e. the crossover Fab molecule comprises
a peptide chain composed of the light chain variable domain VL and
the heavy chain constant domain 1 CH1 (VL-CH1, in N- to C-terminal
direction), and a peptide chain composed of the heavy chain
variable domain VH and the light chain constant domain CL (VH-CL,
in N- to C-terminal direction). For clarity, in a crossover Fab
molecule wherein the variable domains of the Fab light chain and
the Fab heavy chain are exchanged, the peptide chain comprising the
heavy chain constant domain 1 CH1 is referred to herein as the
"heavy chain" of the (crossover) Fab molecule. Conversely, in a
crossover Fab molecule wherein the constant domains of the Fab
light chain and the Fab heavy chain are exchanged, the peptide
chain comprising the heavy chain variable domain VH is referred to
herein as the "heavy chain" of the (crossover) Fab molecule.
[0190] In contrast thereto, by a "conventional" Fab molecule is
meant a Fab molecule in its natural format, i.e. comprising a heavy
chain composed of the heavy chain variable and constant domains
(VH-CH1, in N- to C-terminal direction), and a light chain composed
of the light chain variable and constant domains (VL-CL, in N- to
C-terminal direction).
[0191] The term "immunoglobulin molecule" refers to a protein
having the structure of a naturally occurring antibody. For
example, immunoglobulins of the IgG class are heterotetrameric
glycoproteins of about 150,000 daltons, composed of two light
chains and two heavy chains that are disulfide-bonded. From N- to
C-terminus, each heavy chain has a variable domain (VH), also
called a variable heavy domain or a heavy chain variable region,
followed by three constant domains (CH1, CH2, and CH3), also called
a heavy chain constant region. Similarly, from N- to C-terminus,
each light chain has a variable domain (VL), also called a variable
light domain or a light chain variable region, followed by a
constant light (CL) domain, also called a light chain constant
region. The heavy chain of an immunoglobulin may be assigned to one
of five types, called .alpha. (IgA), .delta. (IgD), .epsilon.
(IgE), .gamma. (IgG), or .mu. (IgM), some of which may be further
divided into subtypes, e.g. .gamma..sub.1 (IgG.sub.1),
.gamma..sub.2 (IgG.sub.2), .gamma..sub.3 (IgG.sub.3), .gamma..sub.4
(IgG.sub.4), .alpha..sub.1 (IgA.sub.1) and .alpha..sub.2
(IgA.sub.2). The light chain of an immunoglobulin may be assigned
to one of two types, called kappa (.kappa.) and lambda (.lamda.),
based on the amino acid sequence of its constant domain. An
immunoglobulin essentially consists of two Fab molecules and an Fc
domain, linked via the immunoglobulin hinge region.
[0192] The term "antibody" herein is used in the broadest sense and
encompasses various antibody structures, including but not limited
to monoclonal antibodies, polyclonal antibodies, and antibody
fragments so long as they exhibit the desired antigen-binding
activity.
[0193] An "antibody fragment" refers to a molecule other than an
intact antibody that comprises a portion of an intact antibody that
binds the antigen to which the intact antibody binds. Examples of
antibody fragments include but are not limited to Fv, Fab, Fab',
Fab'-SH, F(ab')2, diabodies, linear antibodies, single-chain
antibody molecules (e.g. scFv), and single-domain antibodies. For a
review of certain antibody fragments, see Hudson et al., Nat Med 9,
129-134 (2003). For a review of scFv fragments, see e.g. Pluckthun,
in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg
and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994); see
also WO 93/16185; and U.S. Pat. Nos. 5,571,894 and 5,587,458. For
discussion of Fab and F(ab').sub.2 fragments comprising salvage
receptor binding epitope residues and having increased in vivo
half-life, see U.S. Pat. No. 5,869,046. Diabodies are antibody
fragments with two antigen-binding sites that may be bivalent or
bispecific. See, for example, EP 404,097; WO 1993/01161; Hudson et
al., Nat Med 9, 129-134 (2003); and Hollinger et al., Proc Natl
Acad Sci USA 90, 6444-6448 (1993). Triabodies and tetrabodies are
also described in Hudson et al., Nat Med 9, 129-134 (2003).
Single-domain antibodies are antibody fragments comprising all or a
portion of the heavy chain variable domain or all or a portion of
the light chain variable domain of an antibody. In certain
embodiments, a single-domain antibody is a human single-domain
antibody (Domantis, Inc., Waltham, Mass.; see e.g. U.S. Pat. No.
6,248,516 B1). Antibody fragments can be made by various
techniques, including but not limited to proteolytic digestion of
an intact antibody as well as production by recombinant host cells
(e.g. E. coli or phage), as described herein.
[0194] The term "antigen binding domain" refers to the part of an
antibody that comprises the area which specifically binds to and is
complementary to part or all of an antigen. An antigen binding
domain may be provided by, for example, one or more antibody
variable domains (also called antibody variable regions).
Particularly, an antigen binding domain comprises an antibody light
chain variable domain (VL) and an antibody heavy chain variable
domain (VH).
[0195] The term "variable region" or "variable domain" refers to
the domain of an antibody heavy or light chain that is involved in
binding the antibody to antigen. The variable domains of the heavy
chain and light chain (VH and VL, respectively) of a native
antibody generally have similar structures, with each domain
comprising four conserved framework regions (FRs) and three
hypervariable regions (HVRs). See, e.g., Kindt et al., Kuby
Immunology, 6.sup.th ed., W.H. Freeman and Co., page 91 (2007). A
single VH or VL domain may be sufficient to confer antigen-binding
specificity.
[0196] The term "hypervariable region" or "HVR", as used herein,
refers to each of the regions of an antibody variable domain which
are hypervariable in sequence and/or form structurally defined
loops ("hypervariable loops"). Generally, native four-chain
antibodies comprise six HVRs; three in the VH (H1, H2, H3), and
three in the VL (L1, L2, L3). HVRs generally comprise amino acid
residues from the hypervariable loops and/or from the
complementarity determining regions (CDRs), the latter being of
highest sequence variability and/or involved in antigen
recognition. With the exception of CDR1 in VH, CDRs generally
comprise the amino acid residues that form the hypervariable loops.
Hypervariable regions (HVRs) are also referred to as
"complementarity determining regions" (CDRs), and these terms are
used herein interchangeably in reference to portions of the
variable region that form the antigen binding regions. This
particular region has been described by Kabat et al., Sequences of
Proteins of Immunological Interest, 5th Ed. Public Health Service,
National Institutes of Health, Bethesda, Md. (1991) and by Chothia
et al., J Mol Biol 196:901-917 (1987), where the definitions
include overlapping or subsets of amino acid residues when compared
against each other. Nevertheless, application of either definition
to refer to a CDR of an antibody or variants thereof is intended to
be within the scope of the term as defined and used herein. The
appropriate amino acid residues which encompass the CDRs as defined
by each of the above cited references are set forth below in Table
A as a comparison. The exact residue numbers which encompass a
particular CDR will vary depending on the sequence and size of the
CDR. Those skilled in the art can routinely determine which
residues comprise a particular CDR given the variable region amino
acid sequence of the antibody. The CDR sequences given herein are
generally according to the Kabat definition.
TABLE-US-00001 TABLE A CDR Definitions.sup.1 CDR Kabat Chothia
AbM.sup.2 V.sub.H CDR1 31-35 26-32 26-35 V.sub.H CDR2 50-65 52-58
50-58 V.sub.H CDR3 95-102 95-102 95-102 V.sub.L CDR1 24-34 26-32
24-34 V.sub.L CDR2 50-56 50-52 50-56 V.sub.L CDR3 89-97 91-96 89-97
.sup.1Numbering of all CDR definitions in Table A is according to
the numbering conventions set forth by Kabat et al. (see below).
.sup.2"AbM" with a lowercase "b" as used in Table A refers to the
CDRs as defined by Oxford Molecular's "AbM" antibody modeling
software.
[0197] Kabat et al. also defined a numbering system for variable
region sequences that is applicable to any antibody. One of
ordinary skill in the art can unambiguously assign this system of
"Kabat numbering" to any variable region sequence, without reliance
on any experimental data beyond the sequence itself. As used herein
in connection with variable region sequences, "Kabat numbering"
refers to the numbering system set forth by Kabat et al., Sequences
of Proteins of Immunological Interest, 5th Ed. Public Health
Service, National Institutes of Health, Bethesda, Md. (1991).
Unless otherwise specified, references to the numbering of specific
amino acid residue positions in an antibody variable region are
according to the Kabat numbering system.
[0198] As used herein, the amino acid positions of all constant
regions and domains of the heavy and light chain are numbered
according to the Kabat numbering system described in Kabat, et al.,
Sequences of Proteins of Immunological Interest, 5th ed., Public
Health Service, National Institutes of Health, Bethesda, Md.
(1991), referred to as "numbering according to Kabat" or "Kabat
numbering" herein. Specifically the Kabat numbering system (see
pages 647-660 of Kabat, et al., Sequences of Proteins of
Immunological Interest, 5th ed., Public Health Service, National
Institutes of Health, Bethesda, Md. (1991)) is used for the light
chain constant domain CL of kappa and lambda isotype and the Kabat
EU index numbering system (see pages 661-723) is used for the heavy
chain constant domains (CH1, Hinge, CH2 and CH3), which is herein
further clarified by referring to "numbering according to Kabat EU
index" in this case.
[0199] The polypeptide sequences of the sequence listing are not
numbered according to the Kabat numbering system. However, it is
well within the ordinary skill of one in the art to convert the
numbering of the sequences of the Sequence Listing to Kabat
numbering.
[0200] "Framework" or "FR" refers to variable domain residues other
than hypervariable region (HVR) residues. The FR of a variable
domain generally consists of four FR domains: FR1, FR2, FR3, and
FR4. Accordingly, the HVR and FR sequences generally appear in the
following order in VH (or VL): FR1-H1 (L1)-FR2-H2(L2)-FR3-H3
(L3)-FR4.
[0201] A "humanized" antibody refers to a chimeric antibody
comprising amino acid residues from non-human HVRs and amino acid
residues from human FRs. In certain embodiments, a humanized
antibody will comprise substantially all of at least one, and
typically two, variable domains, in which all or substantially all
of the HVRs (e.g., CDRs) correspond to those of a non-human
antibody, and all or substantially all of the FRs correspond to
those of a human antibody. Such variable domains are referred to
herein as "humanized variable region". A humanized antibody
optionally may comprise at least a portion of an antibody constant
region derived from a human antibody. In some embodiments, some FR
residues in a humanized antibody are substituted with corresponding
residues from a non-human antibody (e.g., the antibody from which
the HVR residues are derived), e.g., to restore or improve antibody
specificity or affinity. A "humanized form" of an antibody, e.g., a
non-human antibody, refers to an antibody that has undergone
humanization. Other forms of "humanized antibodies" encompassed by
the present invention are those in which the constant region has
been additionally modified or changed from that of the original
antibody to generate the properties according to the invention,
especially in regard to C1q binding and/or Fc receptor (FcR)
binding.
[0202] The "class" of an antibody or immunoglobulin refers to the
type of constant domain or constant region possessed by its heavy
chain. There are five major classes of antibodies: IgA, IgD, IgE,
IgG, and IgM, and several of these may be further divided into
subclasses (isotypes), e.g., IgG.sub.1, IgG.sub.2, IgG.sub.3,
IgG.sub.4, IgA.sub.1, and IgA.sub.2. The heavy chain constant
domains that correspond to the different classes of immunoglobulins
are called .alpha., .delta., .epsilon., .gamma., and .mu.,
respectively.
[0203] The term "Fc domain" or "Fc region" herein is used to define
a C-terminal region of an immunoglobulin heavy chain that contains
at least a portion of the constant region. The term includes native
sequence Fc regions and variant Fc regions. Although the boundaries
of the Fc region of an IgG heavy chain might vary slightly, the
human IgG heavy chain Fc region is usually defined to extend from
Cys226, or from Pro230, to the carboxyl-terminus of the heavy
chain. However, antibodies produced by host cells may undergo
post-translational cleavage of one or more, particularly one or
two, amino acids from the C-terminus of the heavy chain. Therefore
an antibody produced by a host cell by expression of a specific
nucleic acid molecule encoding a full-length heavy chain may
include the full-length heavy chain, or it may include a cleaved
variant of the full-length heavy chain (also referred to herein as
a "cleaved variant heavy chain"). This may be the case where the
final two C-terminal amino acids of the heavy chain are glycine
(G446) and lysine (K447, numbering according to Kabat EU index).
Therefore, the C-terminal lysine (Lys447), or the C-terminal
glycine (Gly446) and lysine (K447), of the Fc region may or may not
be present. Amino acid sequences of heavy chains including Fc
domains (or a subunit of an Fc domain as defined herein) are
denoted herein without C-terminal glycine-lysine dipeptide if not
indicated otherwise. In one embodiment of the invention, a heavy
chain including a subunit of an Fc domain as specified herein,
comprised in a T cell activating bispecific antigen binding
molecule according to the invention, comprises an additional
C-terminal glycine-lysine dipeptide (G446 and K447, numbering
according to EU index of Kabat). In one embodiment of the
invention, a heavy chain including a subunit of an Fc domain as
specified herein, comprised in a T cell activating bispecific
antigen binding molecule according to the invention, comprises an
additional C-terminal glycine residue (G446, numbering according to
EU index of Kabat). Compositions of the invention, such as the
pharmaceutical compositions described herein, comprise a population
of T cell activating bispecific antigen binding molecules of the
invention. The population of T cell activating bispecific antigen
binding molecule may comprise molecules having a full-length heavy
chain and molecules having a cleaved variant heavy chain. The
population of T cell activating bispecific antigen binding
molecules may consist of a mixture of molecules having a
full-length heavy chain and molecules having a cleaved variant
heavy chain, wherein at least 50%, at least 60%, at least 70%, at
least 80% or at least 90% of the T cell activating bispecific
antigen binding molecules have a cleaved variant heavy chain. In
one embodiment of the invention a composition comprising a
population of T cell activating bispecific antigen binding
molecules of the invention comprises an T cell activating
bispecific antigen binding molecule comprising a heavy chain
including a subunit of an Fc domain as specified herein with an
additional C-terminal glycine-lysine dipeptide (G446 and K447,
numbering according to EU index of Kabat). In one embodiment of the
invention a composition comprising a population of T cell
activating bispecific antigen binding molecules of the invention
comprises an T cell activating bispecific antigen binding molecule
comprising a heavy chain including a subunit of an Fc domain as
specified herein with an additional C-terminal glycine residue
(G446, numbering according to EU index of Kabat). In one embodiment
of the invention such a composition comprises a population of T
cell activating bispecific antigen binding molecules comprised of
molecules comprising a heavy chain including a subunit of an Fc
domain as specified herein; molecules comprising a heavy chain
including a subunit of a Fc domain as specified herein with an
additional C-terminal glycine residue (G446, numbering according to
EU index of Kabat); and molecules comprising a heavy chain
including a subunit of an Fc domain as specified herein with an
additional C-terminal glycine-lysine dipeptide (G446 and K447,
numbering according to EU index of Kabat). Unless otherwise
specified herein, numbering of amino acid residues in the Fc region
or constant region is according to the EU numbering system, also
called the EU index, as described in Kabat et al., Sequences of
Proteins of Immunological Interest, 5th Ed. Public Health Service,
National Institutes of Health, Bethesda, Md., 1991 (see also
above). A "subunit" of an Fc domain as used herein refers to one of
the two polypeptides forming the dimeric Fc domain, i.e. a
polypeptide comprising C-terminal constant regions of an
immunoglobulin heavy chain, capable of stable self-association. For
example, a subunit of an IgG Fc domain comprises an IgG CH2 and an
IgG CH3 constant domain.
[0204] A "modification promoting the association of the first and
the second subunit of the Fc domain" is a manipulation of the
peptide backbone or the post-translational modifications of an Fc
domain subunit that reduces or prevents the association of a
polypeptide comprising the Fc domain subunit with an identical
polypeptide to form a homodimer. A modification promoting
association as used herein particularly includes separate
modifications made to each of the two Fc domain subunits desired to
associate (i.e. the first and the second subunit of the Fc domain),
wherein the modifications are complementary to each other so as to
promote association of the two Fc domain subunits. For example, a
modification promoting association may alter the structure or
charge of one or both of the Fc domain subunits so as to make their
association sterically or electrostatically favorable,
respectively. Thus, (hetero)dimerization occurs between a
polypeptide comprising the first Fc domain subunit and a
polypeptide comprising the second Fc domain subunit, which might be
non-identical in the sense that further components fused to each of
the subunits (e.g. antigen binding moieties) are not the same. In
some embodiments the modification promoting association comprises
an amino acid mutation in the Fc domain, specifically an amino acid
substitution. In a particular embodiment, the modification
promoting association comprises a separate amino acid mutation,
specifically an amino acid substitution, in each of the two
subunits of the Fc domain.
[0205] The term "effector functions" refers to those biological
activities attributable to the Fc region of an antibody, which vary
with the antibody isotype. Examples of antibody effector functions
include: C1q binding and complement dependent cytotoxicity (CDC),
Fc receptor binding, antibody-dependent cell-mediated cytotoxicity
(ADCC), antibody-dependent cellular phagocytosis (ADCP), cytokine
secretion, immune complex-mediated antigen uptake by antigen
presenting cells, down regulation of cell surface receptors (e.g. B
cell receptor), and B cell activation.
[0206] As used herein, the terms "engineer, engineered,
engineering", are considered to include any manipulation of the
peptide backbone or the post-translational modifications of a
naturally occurring or recombinant polypeptide or fragment thereof.
Engineering includes modifications of the amino acid sequence, of
the glycosylation pattern, or of the side chain group of individual
amino acids, as well as combinations of these approaches.
[0207] The term "amino acid mutation" as used herein is meant to
encompass amino acid substitutions, deletions, insertions, and
modifications. Any combination of substitution, deletion,
insertion, and modification can be made to arrive at the final
construct, provided that the final construct possesses the desired
characteristics, e.g., reduced binding to an Fc receptor, or
increased association with another peptide. Amino acid sequence
deletions and insertions include amino- and/or carboxy-terminal
deletions and insertions of amino acids. Particular amino acid
mutations are amino acid substitutions. For the purpose of altering
e.g. the binding characteristics of an Fc region, non-conservative
amino acid substitutions, i.e. replacing one amino acid with
another amino acid having different structural and/or chemical
properties, are particularly preferred. Amino acid substitutions
include replacement by non-naturally occurring amino acids or by
naturally occurring amino acid derivatives of the twenty standard
amino acids (e.g. 4-hydroxyproline, 3-methylhistidine, ornithine,
homoserine, 5-hydroxylysine). Amino acid mutations can be generated
using genetic or chemical methods well known in the art. Genetic
methods may include site-directed mutagenesis, PCR, gene synthesis
and the like. It is contemplated that methods of altering the side
chain group of an amino acid by methods other than genetic
engineering, such as chemical modification, may also be useful.
Various designations may be used herein to indicate the same amino
acid mutation. For example, a substitution from proline at position
329 of the Fc domain to glycine can be indicated as 329G, G329,
G329, P329G, or Pro329Gly.
[0208] As used herein, term "polypeptide" refers to a molecule
composed of monomers (amino acids) linearly linked by amide bonds
(also known as peptide bonds). The term "polypeptide" refers to any
chain of two or more amino acids, and does not refer to a specific
length of the product. Thus, peptides, dipeptides, tripeptides,
oligopeptides, "protein," "amino acid chain," or any other term
used to refer to a chain of two or more amino acids, are included
within the definition of "polypeptide," and the term "polypeptide"
may be used instead of, or interchangeably with any of these terms.
The term "polypeptide" is also intended to refer to the products of
post-expression modifications of the polypeptide, including without
limitation glycosylation, acetylation, phosphorylation, amidation,
derivatization by known protecting/blocking groups, proteolytic
cleavage, or modification by non-naturally occurring amino acids. A
polypeptide may be derived from a natural biological source or
produced by recombinant technology, but is not necessarily
translated from a designated nucleic acid sequence. It may be
generated in any manner, including by chemical synthesis. A
polypeptide of the invention may be of a size of about 3 or more, 5
or more, 10 or more, 20 or more, 25 or more, 50 or more, 75 or
more, 100 or more, 200 or more, 500 or more, 1,000 or more, or
2,000 or more amino acids. Polypeptides may have a defined
three-dimensional structure, although they do not necessarily have
such structure. Polypeptides with a defined three-dimensional
structure are referred to as folded, and polypeptides which do not
possess a defined three-dimensional structure, but rather can adopt
a large number of different conformations, and are referred to as
unfolded.
[0209] By an "isolated" polypeptide or a variant, or derivative
thereof is intended a polypeptide that is not in its natural
milieu. No particular level of purification is required. For
example, an isolated polypeptide can be removed from its native or
natural environment. Recombinantly produced polypeptides and
proteins expressed in host cells are considered isolated for the
purpose of the invention, as are native or recombinant polypeptides
which have been separated, fractionated, or partially or
substantially purified by any suitable technique.
[0210] "Percent (%) amino acid sequence identity" with respect to a
reference polypeptide sequence is defined as the percentage of
amino acid residues in a candidate sequence that are identical with
the amino acid residues in the reference polypeptide sequence,
after aligning the sequences and introducing gaps, if necessary, to
achieve the maximum percent sequence identity, and not considering
any conservative substitutions as part of the sequence identity.
Alignment for purposes of determining percent amino acid sequence
identity can be achieved in various ways that are within the skill
in the art, for instance, using publicly available computer
software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR)
software. Those skilled in the art can determine appropriate
parameters for aligning sequences, including any algorithms needed
to achieve maximal alignment over the full length of the sequences
being compared. For purposes herein, however, % amino acid sequence
identity values are generated using the sequence comparison
computer program ALIGN-2. The ALIGN-2 sequence comparison computer
program was authored by Genentech, Inc., and the source code has
been filed with user documentation in the U.S. Copyright Office,
Washington D.C., 20559, where it is registered under U.S. Copyright
Registration No. TXU510087. The ALIGN-2 program is publicly
available from Genentech, Inc., South San Francisco, Calif., or may
be compiled from the source code. The ALIGN-2 program should be
compiled for use on a UNIX operating system, including digital UNIX
V4.0D. All sequence comparison parameters are set by the ALIGN-2
program and do not vary. In situations where ALIGN-2 is employed
for amino acid sequence comparisons, the % amino acid sequence
identity of a given amino acid sequence A to, with, or against a
given amino acid sequence B (which can alternatively be phrased as
a given amino acid sequence A that has or comprises a certain %
amino acid sequence identity to, with, or against a given amino
acid sequence B) is calculated as follows:
100 times the fraction X/Y
where X is the number of amino acid residues scored as identical
matches by the sequence alignment program ALIGN-2 in that program's
alignment of A and B, and where Y is the total number of amino acid
residues in B. It will be appreciated that where the length of
amino acid sequence A is not equal to the length of amino acid
sequence B, the % amino acid sequence identity of A to B will not
equal the % amino acid sequence identity of B to A. Unless
specifically stated otherwise, all % amino acid sequence identity
values used herein are obtained as described in the immediately
preceding paragraph using the ALIGN-2 computer program.
[0211] The term "polynucleotide" refers to an isolated nucleic acid
molecule or construct, e.g. messenger RNA (mRNA), virally-derived
RNA, or plasmid DNA (pDNA). A polynucleotide may comprise a
conventional phosphodiester bond or a non-conventional bond (e.g.
an amide bond, such as found in peptide nucleic acids (PNA). The
term "nucleic acid molecule" refers to any one or more nucleic acid
segments, e.g. DNA or RNA fragments, present in a
polynucleotide.
[0212] By "isolated" nucleic acid molecule or polynucleotide is
intended a nucleic acid molecule, DNA or RNA, which has been
removed from its native environment. For example, a recombinant
polynucleotide encoding a polypeptide contained in a vector is
considered isolated for the purposes of the present invention.
Further examples of an isolated polynucleotide include recombinant
polynucleotides maintained in heterologous host cells or purified
(partially or substantially) polynucleotides in solution. An
isolated polynucleotide includes a polynucleotide molecule
contained in cells that ordinarily contain the polynucleotide
molecule, but the polynucleotide molecule is present
extrachromosomally or at a chromosomal location that is different
from its natural chromosomal location. Isolated RNA molecules
include in vivo or in vitro RNA transcripts of the present
invention, as well as positive and negative strand forms, and
double-stranded forms. Isolated polynucleotides or nucleic acids
according to the present invention further include such molecules
produced synthetically. In addition, a polynucleotide or a nucleic
acid may be or may include a regulatory element such as a promoter,
ribosome binding site, or a transcription terminator.
[0213] By a nucleic acid or polynucleotide having a nucleotide
sequence at least, for example, 95% "identical" to a reference
nucleotide sequence of the present invention, it is intended that
the nucleotide sequence of the polynucleotide is identical to the
reference sequence except that the polynucleotide sequence may
include up to five point mutations per each 100 nucleotides of the
reference nucleotide sequence. In other words, to obtain a
polynucleotide having a nucleotide sequence at least 95% identical
to a reference nucleotide sequence, up to 5% of the nucleotides in
the reference sequence may be deleted or substituted with another
nucleotide, or a number of nucleotides up to 5% of the total
nucleotides in the reference sequence may be inserted into the
reference sequence. These alterations of the reference sequence may
occur at the 5' or 3' terminal positions of the reference
nucleotide sequence or anywhere between those terminal positions,
interspersed either individually among residues in the reference
sequence or in one or more contiguous groups within the reference
sequence. As a practical matter, whether any particular
polynucleotide sequence is at least 80%, 85%, 90%, 95%, 96%, 97%,
98% or 99% identical to a nucleotide sequence of the present
invention can be determined conventionally using known computer
programs, such as the ones discussed above for polypeptides (e.g.
ALIGN-2).
[0214] "Isolated polynucleotide (or nucleic acid) encoding [e.g. a
T cell activating bispecific antigen binding molecule of the
invention]" refers to one or more polynucleotide molecules encoding
antibody heavy and light chains (or fragments thereof), including
such polynucleotide molecule(s) in a single vector or separate
vectors, and such nucleic acid molecule(s) present at one or more
locations in a host cell.
[0215] The term "expression cassette" refers to a polynucleotide
generated recombinantly or synthetically, with a series of
specified nucleic acid elements that permit transcription of a
particular nucleic acid in a target cell. The recombinant
expression cassette can be incorporated into a plasmid, chromosome,
mitochondrial DNA, plastid DNA, virus, or nucleic acid fragment.
Typically, the recombinant expression cassette portion of an
expression vector includes, among other sequences, a nucleic acid
sequence to be transcribed and a promoter. In certain embodiments,
the expression cassette comprises polynucleotide sequences that
encode bispecific antigen binding molecules of the invention or
fragments thereof.
[0216] The term "vector" or "expression vector" is synonymous with
"expression construct" and refers to a DNA molecule that is used to
introduce and direct the expression of a specific gene to which it
is operably associated in a cell. The term includes the vector as a
self-replicating nucleic acid structure as well as the vector
incorporated into the genome of a host cell into which it has been
introduced. The expression vector of the present invention
comprises an expression cassette. Expression vectors allow
transcription of large amounts of stable mRNA. Once the expression
vector is inside the cell, the ribonucleic acid molecule or protein
that is encoded by the gene is produced by the cellular
transcription and/or translation machinery. In one embodiment, the
expression vector of the invention comprises an expression cassette
that comprises polynucleotide sequences that encode bispecific
antigen binding molecules of the invention or fragments
thereof.
[0217] The terms "host cell", "host cell line," and "host cell
culture" are used interchangeably and refer to cells into which
exogenous nucleic acid has been introduced, including the progeny
of such cells. Host cells include "transformants" and "transformed
cells," which include the primary transformed cell and progeny
derived therefrom without regard to the number of passages. Progeny
may not be completely identical in nucleic acid content to a parent
cell, but may contain mutations. Mutant progeny that have the same
function or biological activity as screened or selected for in the
originally transformed cell are included herein. A host cell is any
type of cellular system that can be used to generate the bispecific
antigen binding molecules of the present invention. Host cells
include cultured cells, e.g. mammalian cultured cells, such as CHO
cells, HEK cells, BHK cells, NS0 cells, SP2/0 cells, YO myeloma
cells, P3X63 mouse myeloma cells, PER cells, PER.C6 cells or
hybridoma cells, yeast cells, insect cells, and plant cells, to
name only a few, but also cells comprised within a transgenic
animal, transgenic plant or cultured plant or animal tissue.
[0218] An "activating Fc receptor" is an Fc receptor that following
engagement by an Fc domain of an antibody elicits signaling events
that stimulate the receptor-bearing cell to perform effector
functions. Human activating Fc receptors include Fc.gamma.RIIIa
(CD16a), Fc.gamma.RI (CD64), Fc.gamma.RIIa (CD32), and Fc.alpha.RI
(CD89).
[0219] Antibody-dependent cell-mediated cytotoxicity (ADCC) is an
immune mechanism leading to the lysis of antibody-coated target
cells by immune effector cells. The target cells are cells to which
antibodies or derivatives thereof comprising an Fc region
specifically bind, generally via the protein part that is
N-terminal to the Fc region. As used herein, the term "reduced
ADCC" is defined as either a reduction in the number of target
cells that are lysed in a given time, at a given concentration of
antibody in the medium surrounding the target cells, by the
mechanism of ADCC defined above, and/or an increase in the
concentration of antibody in the medium surrounding the target
cells, required to achieve the lysis of a given number of target
cells in a given time, by the mechanism of ADCC. The reduction in
ADCC is relative to the ADCC mediated by the same antibody produced
by the same type of host cells, using the same standard production,
purification, formulation and storage methods (which are known to
those skilled in the art), but that has not been engineered. For
example the reduction in ADCC mediated by an antibody comprising in
its Fc domain an amino acid substitution that reduces ADCC, is
relative to the ADCC mediated by the same antibody without this
amino acid substitution in the Fc domain. Suitable assays to
measure ADCC are well known in the art (see e.g. PCT publication
no. WO 2006/082515 or PCT publication no. WO 2012/130831).
[0220] An "effective amount" of an agent refers to the amount that
is necessary to result in a physiological change in the cell or
tissue to which it is administered.
[0221] A "therapeutically effective amount" of an agent, e.g. a
pharmaceutical composition, refers to an amount effective, at
dosages and for periods of time necessary, to achieve the desired
therapeutic or prophylactic result. A therapeutically effective
amount of an agent for example eliminates, decreases, delays,
minimizes or prevents adverse effects of a disease.
[0222] An "individual" or "subject" is a mammal. Mammals include,
but are not limited to, domesticated animals (e.g. cows, sheep,
cats, dogs, and horses), primates (e.g. humans and non-human
primates such as monkeys), rabbits, and rodents (e.g. mice and
rats). Particularly, the individual or subject is a human.
[0223] The term "pharmaceutical composition" refers to a
preparation which is in such form as to permit the biological
activity of an active ingredient contained therein to be effective,
and which contains no additional components which are unacceptably
toxic to a subject to which the composition would be
administered.
[0224] A "pharmaceutically acceptable carrier" refers to an
ingredient in a pharmaceutical composition, other than an active
ingredient, which is nontoxic to a subject. A pharmaceutically
acceptable carrier includes, but is not limited to, a buffer,
excipient, stabilizer, or preservative. As used herein, "treatment"
(and grammatical variations thereof such as "treat" or "treating")
refers to clinical intervention in an attempt to alter the natural
course of a disease in the individual being treated, and can be
performed either for prophylaxis or during the course of clinical
pathology. Desirable effects of treatment include, but are not
limited to, preventing occurrence or recurrence of disease,
alleviation of symptoms, diminishment of any direct or indirect
pathological consequences of the disease, preventing metastasis,
decreasing the rate of disease progression, amelioration or
palliation of the disease state, and remission or improved
prognosis. In some embodiments, T cell activating bispecific
antigen binding molecules of the invention are used to delay
development of a disease or to slow the progression of a
disease.
[0225] The term "package insert" is used to refer to instructions
customarily included in commercial packages of therapeutic
products, that contain information about the indications, usage,
dosage, administration, combination therapy, contraindications
and/or warnings concerning the use of such therapeutic
products.
DETAILED DESCRIPTION OF THE EMBODIMENTS
[0226] The invention provides a T cell activating bispecific
antigen binding molecule with favorable properties for therapeutic
application, in particular with improved efficacy and safety (e.g.
with respect to selectivity towards tumor cells over normal cells
such as cardiomyocytes), and improved produceability (e.g. with
respect to purity, yield).
[0227] The inventors have discovered that surprisingly the T cell
activating antigen binding molecule of the invention is able to
induce killing of p95HER2+ tumor cells while sparing cardiomyocytes
that are characterized by expression of low levels of HER2. Such
low levels of HER2 on cardiomyocytes are believed to be prohibitive
for the use of highly potent T cell activating antigen binding
molecules, as HER2 targeted T cell activating bispecific antigen
binding molecules e.g. based on trastuzumab are able to kill
cardiomyocytes in vitro. In fact, current drugs targeting HER2 are
known to induce cardiotoxicity, likely because the expression of
HER2 in cardiomyocytes (Valachis et al., Int. J. Cancer (2013) 133,
2245-2252). Similarly, MCF10A cells, a human epithelial cell line
that is immortalized but not transformed, which express normal
levels of HER2 can be killed by a HER2-targeted T cell activating
bispecific antigen binding molecule but not by the T cell
activating bispecific antigen binding molecule of the present
invention. The T cell activating bispecific antigen binding
molecule of the invention may also be of use for the killing of
tumor cells that are positive for p95HER2, but have lost
extracellular HER2 expression and thus are resistant towards
conventional HER2 targeted therapies.
Charge Modifications
[0228] The T cell activating bispecific antigen binding molecules
of the invention may comprise amino acid substitutions in Fab
molecules comprised therein which are particularly efficient in
reducing mispairing of light chains with non-matching heavy chains
(Bence-Jones-type side products), which can occur in the production
of Fab-based bi-/multispecific antigen binding molecules with a
VH/VL exchange in one (or more, in case of molecules comprising
more than two antigen-binding Fab molecules) of their binding arms
(see also PCT publication no. WO 2015/150447, particularly the
examples therein, incorporated herein by reference in its
entirety).
[0229] Accordingly, in particular embodiments, the T cell
activating bispecific antigen binding molecule of the invention
comprises
[0230] (a) a first Fab molecule which specifically binds to a first
antigen
[0231] (b) a second Fab molecule which specifically binds to a
second antigen, and wherein the variable domains VL and VH of the
Fab light chain and the Fab heavy chain are replaced by each
other,
[0232] wherein the first antigen is an activating T cell antigen
and the second antigen is p95HER2, or the first antigen is p95HER2
and the second antigen is an activating T cell antigen; and
[0233] wherein [0234] i) in the constant domain CL of the first Fab
molecule under a) the amino acid at position 124 is substituted by
a positively charged amino acid (numbering according to Kabat), and
wherein in the constant domain CH1 of the first Fab molecule under
a) the amino acid at position 147 or the amino acid at position 213
is substituted by a negatively charged amino acid (numbering
according to Kabat EU index); or [0235] ii) in the constant domain
CL of the second Fab molecule under b) the amino acid at position
124 is substituted by a positively charged amino acid (numbering
according to Kabat), and wherein in the constant domain CH1 of the
second Fab molecule under b) the amino acid at position 147 or the
amino acid at position 213 is substituted by a negatively charged
amino acid (numbering according to Kabat EU index).
[0236] The T cell activating bispecific antigen binding molecule
does not comprise both modifications mentioned under i) and ii).
The constant domains CL and CH1 of the second Fab molecule are not
replaced by each other (i.e. remain unexchanged).
[0237] In one embodiment of the T cell activating bispecific
antigen binding molecule according to the invention, in the
constant domain CL of the first Fab molecule under a) the amino
acid at position 124 is substituted independently by lysine (K),
arginine (R) or histidine (H) (numbering according to Kabat) (in
one preferred embodiment independently by lysine (K) or arginine
(R)), and in the constant domain CH1 of the first Fab molecule
under a) the amino acid at position 147 or the amino acid at
position 213 is substituted independently by glutamic acid (E), or
aspartic acid (D) (numbering according to Kabat EU index).
[0238] In a further embodiment, in the constant domain CL of the
first Fab molecule under a) the amino acid at position 124 is
substituted independently by lysine (K), arginine (R) or histidine
(H) (numbering according to Kabat), and in the constant domain CH1
of the first Fab molecule under a) the amino acid at position 147
is substituted independently by glutamic acid (E), or aspartic acid
(D) (numbering according to Kabat EU index).
[0239] In a particular embodiment, in the constant domain CL of the
first Fab molecule under a) the amino acid at position 124 is
substituted independently by lysine (K), arginine (R) or histidine
(H) (numbering according to Kabat) (in one preferred embodiment
independently by lysine (K) or arginine (R)) and the amino acid at
position 123 is substituted independently by lysine (K), arginine
(R) or histidine (H) (numbering according to Kabat) (in one
preferred embodiment independently by lysine (K) or arginine (R)),
and in the constant domain CH1 of the first Fab molecule under a)
the amino acid at position 147 is substituted independently by
glutamic acid (E), or aspartic acid (D) (numbering according to
Kabat EU index) and the amino acid at position 213 is substituted
independently by glutamic acid (E), or aspartic acid (D) (numbering
according to Kabat EU index).
[0240] In a more particular embodiment, in the constant domain CL
of the first Fab molecule under a) the amino acid at position 124
is substituted by lysine (K) (numbering according to Kabat) and the
amino acid at position 123 is substituted by lysine (K) or arginine
(R) (numbering according to Kabat), and in the constant domain CH1
of the first Fab molecule under a) the amino acid at position 147
is substituted by glutamic acid (E) (numbering according to Kabat
EU index) and the amino acid at position 213 is substituted by
glutamic acid (E) (numbering according to Kabat EU index).
[0241] In an even more particular embodiment, in the constant
domain CL of the first Fab molecule under a) the amino acid at
position 124 is substituted by lysine (K) (numbering according to
Kabat) and the amino acid at position 123 is substituted by
arginine (R) (numbering according to Kabat), and in the constant
domain CH1 of the first Fab molecule under a) the amino acid at
position 147 is substituted by glutamic acid (E) (numbering
according to Kabat EU index) and the amino acid at position 213 is
substituted by glutamic acid (E) (numbering according to Kabat EU
index).
[0242] In particular embodiments, the constant domain CL of the
first Fab molecule under a) is of kappa isotype.
[0243] Alternatively, the amino acid substitutions according to the
above embodiments may be made in the constant domain CL and the
constant domain CH1 of the second Fab molecule under b) instead of
in the constant domain CL and the constant domain CH1 of the first
Fab molecule under a). In particular such embodiments, the constant
domain CL of the second Fab molecule under b) is of kappa
isotype.
[0244] The T cell activating bispecific antigen binding molecule
according to the invention may further comprise a third Fab
molecule which specifically binds to the first antigen. In
particular embodiments, said third Fab molecule is identical to the
first Fab molecule under a). In these embodiments, the amino acid
substitutions according to the above embodiments will be made in
the constant domain CL and the constant domain CH1 of each of the
first Fab molecule and the third Fab molecule. Alternatively, the
amino acid substitutions according to the above embodiments may be
made in the constant domain CL and the constant domain CH1 of the
second Fab molecule under b), but not in the constant domain CL and
the constant domain CH1 of the first Fab molecule and the third Fab
molecule. In particular embodiments, the T cell activating
bispecific antigen binding molecule according to the invention
further comprises an Fc domain composed of a first and a second
subunit capable of stable association.
T Cell Activating Bispecific Antigen Binding Molecule Formats
[0245] The components of the T cell activating bispecific antigen
binding molecule can be fused to each other in a variety of
configurations. Exemplary configurations are depicted in FIG.
1.
[0246] In particular embodiments, the antigen binding moieties
comprised in the T cell activating bispecific antigen binding
molecule are Fab molecules. In such embodiments, the first, second,
third etc. antigen binding moiety may be referred to herein as
first, second, third etc. Fab molecule, respectively. Furthermore,
in particular embodiments, the T cell activating bispecific antigen
binding molecule comprises an Fc domain composed of a first and a
second subunit capable of stable association.
[0247] In some embodiments, the second Fab molecule is fused at the
C-terminus of the Fab heavy chain to the N-terminus of the first or
the second subunit of the Fc domain.
[0248] In one such embodiment, the first Fab molecule is fused at
the C-terminus of the Fab heavy chain to the N-terminus of the Fab
heavy chain of the second Fab molecule. In a specific such
embodiment, the T cell activating bispecific antigen binding
molecule essentially consists of the first and the second Fab
molecule, the Fc domain composed of a first and a second subunit,
and optionally one or more peptide linkers, wherein the first Fab
molecule is fused at the C-terminus of the Fab heavy chain to the
N-terminus of the Fab heavy chain of the second Fab molecule, and
the second Fab molecule is fused at the C-terminus of the Fab heavy
chain to the N-terminus of the first or the second subunit of the
Fc domain. Such a configuration is schematically depicted in FIGS.
1G and 1K. Optionally, the Fab light chain of the first Fab
molecule and the Fab light chain of the second Fab molecule may
additionally be fused to each other.
[0249] In another such embodiment, the first Fab molecule is fused
at the C-terminus of the Fab heavy chain to the N-terminus of the
first or second subunit of the Fc domain. In a specific such
embodiment, the T cell activating bispecific antigen binding
molecule essentially consists of the first and the second Fab
molecule, the Fc domain composed of a first and a second subunit,
and optionally one or more peptide linkers, wherein the first and
the second Fab molecule are each fused at the C-terminus of the Fab
heavy chain to the N-terminus of one of the subunits of the Fc
domain. Such a configuration is schematically depicted in FIGS. 1A
and 1D. The first and the second Fab molecule may be fused to the
Fc domain directly or through a peptide linker. In a particular
embodiment the first and the second Fab molecule are each fused to
the Fc domain through an immunoglobulin hinge region. In a specific
embodiment, the immunoglobulin hinge region is a human IgG.sub.1
hinge region, particularly where the Fc domain is an IgG.sub.1 Fc
domain.
[0250] In other embodiments, the first Fab molecule is fused at the
C-terminus of the Fab heavy chain to the N-terminus of the first or
second subunit of the Fc domain.
[0251] In one such embodiment, the second Fab molecule is fused at
the C-terminus of the Fab heavy chain to the N-terminus of the Fab
heavy chain of the first Fab molecule. In a specific such
embodiment, the T cell activating bispecific antigen binding
molecule essentially consists of the first and the second Fab
molecule, the Fc domain composed of a first and a second subunit,
and optionally one or more peptide linkers, wherein the second Fab
molecule is fused at the C-terminus of the Fab heavy chain to the
N-terminus of the Fab heavy chain of the first Fab molecule, and
the first Fab molecule is fused at the C-terminus of the Fab heavy
chain to the N-terminus of the first or the second subunit of the
Fc domain. Such a configuration is schematically depicted in FIGS.
1H and 1L. Optionally, the Fab light chain of the first Fab
molecule and the Fab light chain of the second Fab molecule may
additionally be fused to each other.
[0252] The Fab molecules may be fused to the Fc domain or to each
other directly or through a peptide linker, comprising one or more
amino acids, typically about 2-20 amino acids. Peptide linkers are
known in the art and are described herein. Suitable,
non-immunogenic peptide linkers include, for example,
(G.sub.4S).sub.n, (SG.sub.4).sub.n, (G.sub.4S).sub.n or
G.sub.4(SG.sub.4).sub.n peptide linkers. "n" is generally an
integer from 1 to 10, typically from 2 to 4. In one embodiment said
peptide linker has a length of at least 5 amino acids, in one
embodiment a length of 5 to 100, in a further embodiment of 10 to
50 amino acids. In one embodiment said peptide linker is
(GxS).sub.n or (GxS).sub.nG.sub.m, with G=glycine, S=serine, and
(x=3, n=3, 4, 5 or 6, and m=0, 1, 2 or 3) or (x=4, n=2, 3, 4 or 5
and m=0, 1, 2 or 3), in one embodiment x=4 and n=2 or 3, in a
further embodiment x=4 and n=2. In one embodiment said peptide
linker is (G4S).sub.2. A particularly suitable peptide linker for
fusing the Fab light chains of the first and the second Fab
molecule to each other is (G.sub.4S).sub.2. An exemplary peptide
linker suitable for connecting the Fab heavy chains of the first
and the second Fab fragments comprises the sequence
(D)-(G.sub.4S).sub.2 (SEQ ID NOs 11 and 12). Another suitable such
linker comprises the sequence (G.sub.4S).sub.4. Additionally,
linkers may comprise (a portion of) an immunoglobulin hinge region.
Particularly where a Fab molecule is fused to the N-terminus of an
Fc domain subunit, it may be fused via an immunoglobulin hinge
region or a portion thereof, with or without an additional peptide
linker.
[0253] A T cell activating bispecific antigen binding molecule with
a single antigen binding moiety (such as a Fab molecule) capable of
specific binding to a target cell antigen (for example as shown in
FIG. 1A, D, G, H, K, L) is useful, particularly in cases where
internalization of the target cell antigen is to be expected
following binding of a high affinity antigen binding moiety. In
such cases, the presence of more than one antigen binding moiety
specific for the target cell antigen may enhance internalization of
the target cell antigen, thereby reducing its availability.
[0254] In many other cases, however, it will be advantageous to
have a T cell activating bispecific antigen binding molecule
comprising two or more antigen binding moieties (such as Fab
molecules) specific for a target cell antigen (see examples shown
in FIG. 1B, 1C, 1E, 1F, 1I, 1J. 1M or 1N), for example to optimize
targeting to the target site or to allow crosslinking of target
cell antigens.
[0255] Accordingly, in particular embodiments, the T cell
activating bispecific antigen binding molecule of the invention
further comprises a third Fab molecule which specifically binds to
the first antigen. The first antigen preferably is the target cell
antigen, i.e. p95HER2. In one embodiment, the third Fab molecule is
a conventional Fab molecule. In one embodiment, the third Fab
molecule is identical to the first Fab molecule (i.e. the first and
the third Fab molecule comprise the same heavy and light chain
amino acid sequences and have the same arrangement of domains (i.e.
conventional or crossover)). In a particular embodiment, the second
Fab molecule specifically binds to an activating T cell antigen,
particularly CD3, and the first and third Fab molecule specifically
bind to p95HER2.
[0256] In alternative embodiments, the T cell activating bispecific
antigen binding molecule of the invention further comprises a third
Fab molecule which specifically binds to the second antigen. In
these embodiments, the second antigen preferably is the target cell
antigen, i.e. p95HER2. In one such embodiment, the third Fab
molecule is a crossover Fab molecule (a Fab molecule wherein the
variable domains VH and VL or the constant domains CL and CH1 of
the Fab heavy and light chains are exchanged/replaced by each
other). In one such embodiment, the third Fab molecule is identical
to the second Fab molecule (i.e. the second and the third Fab
molecule comprise the same heavy and light chain amino acid
sequences and have the same arrangement of domains (i.e.
conventional or crossover)). In one such embodiment, the first Fab
molecule specifically binds to an activating T cell antigen,
particularly CD3, and the second and third Fab molecule
specifically bind to p95HER2.
[0257] In one embodiment, the third Fab molecule is fused at the
C-terminus of the Fab heavy chain to the N-terminus of the first or
second subunit of the Fc domain.
[0258] In a particular embodiment, the second and the third Fab
molecule are each fused at the C-terminus of the Fab heavy chain to
the N-terminus of one of the subunits of the Fc domain, and the
first Fab molecule is fused at the C-terminus of the Fab heavy
chain to the N-terminus of the Fab heavy chain of the second Fab
molecule. In a specific such embodiment, the T cell activating
bispecific antigen binding molecule essentially consists of the
first, the second and the third Fab molecule, the Fc domain
composed of a first and a second subunit, and optionally one or
more peptide linkers, wherein the first Fab molecule is fused at
the C-terminus of the Fab heavy chain to the N-terminus of the Fab
heavy chain of the second Fab molecule, and the second Fab molecule
is fused at the C-terminus of the Fab heavy chain to the N-terminus
of the first subunit of the Fc domain, and wherein the third Fab
molecule is fused at the C-terminus of the Fab heavy chain to the
N-terminus of the second subunit of the Fc domain. Such a
configuration is schematically depicted in FIGS. 1B and 1E
(particular embodiments, wherein the third Fab molecule is a
conventional Fab molecule and preferably identical to the first Fab
molecule), and FIGS. 1I and 1M (alternative embodiments, wherein
the third Fab molecule is a crossover Fab molecule and preferably
identical to the second Fab molecule). The second and the third Fab
molecule may be fused to the Fc domain directly or through a
peptide linker. In a particular embodiment the second and the third
Fab molecule are each fused to the Fc domain through an
immunoglobulin hinge region. In a specific embodiment, the
immunoglobulin hinge region is a human IgG.sub.1 hinge region,
particularly where the Fc domain is an IgG.sub.1 Fc domain.
Optionally, the Fab light chain of the first Fab molecule and the
Fab light chain of the second Fab molecule may additionally be
fused to each other.
[0259] In another embodiment, the first and the third Fab molecule
are each fused at the C-terminus of the Fab heavy chain to the
N-terminus of one of the subunits of the Fc domain, and the second
Fab molecule is fused at the C-terminus of the Fab heavy chain to
the N-terminus of the Fab heavy chain of the first Fab molecule. In
a specific such embodiment, the T cell activating bispecific
antigen binding molecule essentially consists of the first, the
second and the third Fab molecule, the Fc domain composed of a
first and a second subunit, and optionally one or more peptide
linkers, wherein the second Fab molecule is fused at the C-terminus
of the Fab heavy chain to the N-terminus of the Fab heavy chain of
the first Fab molecule, and the first Fab molecule is fused at the
C-terminus of the Fab heavy chain to the N-terminus of the first
subunit of the Fc domain, and wherein the third Fab molecule is
fused at the C-terminus of the Fab heavy chain to the N-terminus of
the second subunit of the Fc domain. Such a configuration is
schematically depicted in FIGS. 1C and 1F (particular embodiments,
wherein the third Fab molecule is a conventional Fab molecule and
preferably identical to the first Fab molecule) and in FIGS. 1J and
1N (alternative embodiments, wherein the third Fab molecule is a
crossover Fab molecule and preferably identical to the second Fab
molecule). The first and the third Fab molecule may be fused to the
Fc domain directly or through a peptide linker. In a particular
embodiment the first and the third Fab molecule are each fused to
the Fc domain through an immunoglobulin hinge region. In a specific
embodiment, the immunoglobulin hinge region is a human IgG.sub.1
hinge region, particularly where the Fc domain is an IgG.sub.1 Fc
domain. Optionally, the Fab light chain of the first Fab molecule
and the Fab light chain of the second Fab molecule may additionally
be fused to each other.
[0260] In configurations of the T cell activating bispecific
antigen binding molecule wherein a Fab molecule is fused at the
C-terminus of the Fab heavy chain to the N-terminus of each of the
subunits of the Fc domain through an immunoglobulin hinge regions,
the two Fab molecules, the hinge regions and the Fc domain
essentially form an immunoglobulin molecule. In a particular
embodiment the immunoglobulin molecule is an IgG class
immunoglobulin. In an even more particular embodiment the
immunoglobulin is an IgG.sub.1 subclass immunoglobulin. In another
embodiment the immunoglobulin is an IgG.sub.4 subclass
immunoglobulin. In a further particular embodiment the
immunoglobulin is a human immunoglobulin. In other embodiments the
immunoglobulin is a chimeric immunoglobulin or a humanized
immunoglobulin.
[0261] In some of the T cell activating bispecific antigen binding
molecule of the invention, the Fab light chain of the first Fab
molecule and the Fab light chain of the second Fab molecule are
fused to each other, optionally via a peptide linker. Depending on
the configuration of the first and the second Fab molecule, the Fab
light chain of the first Fab molecule may be fused at its
C-terminus to the N-terminus of the Fab light chain of the second
Fab molecule, or the Fab light chain of the second Fab molecule may
be fused at its C-terminus to the N-terminus of the Fab light chain
of the first Fab molecule. Fusion of the Fab light chains of the
first and the second Fab molecule further reduces mispairing of
unmatched Fab heavy and light chains, and also reduces the number
of plasmids needed for expression of some of the T cell activating
bispecific antigen binding molecules of the invention.
[0262] In certain embodiments the T cell activating bispecific
antigen binding molecule according to the invention comprises a
polypeptide wherein the Fab light chain variable region of the
second Fab molecule shares a carboxy-terminal peptide bond with the
Fab heavy chain constant region of the second Fab molecule (i.e.
the second Fab molecule comprises a crossover Fab heavy chain,
wherein the heavy chain variable region is replaced by a light
chain variable region), which in turn shares a carboxy-terminal
peptide bond with an Fc domain subunit
(VL.sub.(2)-CH1.sub.(2)-CH2-CH3(-CH4)), and a polypeptide wherein
the Fab heavy chain of the first Fab molecule shares a
carboxy-terminal peptide bond with an Fc domain subunit
(VH.sub.(1)-CH1.sub.(1)-CH2-CH3(-CH4)). In some embodiments the T
cell activating bispecific antigen binding molecule further
comprises a polypeptide wherein the Fab heavy chain variable region
of the second Fab molecule shares a carboxy-terminal peptide bond
with the Fab light chain constant region of the second Fab molecule
(VH.sub.(2)-CL.sub.(2)) and the Fab light chain polypeptide of the
first Fab molecule (VL.sub.(1)-CL.sub.(1). In certain embodiments
the polypeptides are covalently linked, e.g., by a disulfide
bond.
[0263] In certain embodiments the T cell activating bispecific
antigen binding molecule according to the invention comprises a
polypeptide wherein the Fab heavy chain variable region of the
second Fab molecule shares a carboxy-terminal peptide bond with the
Fab light chain constant region of the second Fab molecule (i.e.
the second Fab molecule comprises a crossover Fab heavy chain,
wherein the heavy chain constant region is replaced by a light
chain constant region), which in turn shares a carboxy-terminal
peptide bond with an Fc domain subunit
(VH.sub.(2)-CL.sub.(2)-CH2-CH3(-CH4)), and a polypeptide wherein
the Fab heavy chain of the first Fab molecule shares a
carboxy-terminal peptide bond with an Fc domain subunit
(VH.sub.(1)-CH1.sub.(1)-CH2-CH3(-CH4)). In some embodiments the T
cell activating bispecific antigen binding molecule further
comprises a polypeptide wherein the Fab light chain variable region
of the second Fab molecule shares a carboxy-terminal peptide bond
with the Fab heavy chain constant region of the second Fab molecule
(VL.sub.(2)-CH1.sub.(2)) and the Fab light chain polypeptide of the
first Fab molecule (VL.sub.(1)-CL.sub.(1). In certain embodiments
the polypeptides are covalently linked, e.g., by a disulfide
bond.
[0264] In some embodiments, the T cell activating bispecific
antigen binding molecule comprises a polypeptide wherein the Fab
light chain variable region of the second Fab molecule shares a
carboxy-terminal peptide bond with the Fab heavy chain constant
region of the second Fab molecule (i.e. the second Fab molecule
comprises a crossover Fab heavy chain, wherein the heavy chain
variable region is replaced by a light chain variable region),
which in turn shares a carboxy-terminal peptide bond with the Fab
heavy chain of the first Fab molecule, which in turn shares a
carboxy-terminal peptide bond with an Fc domain subunit
(VL.sub.(2)-CH1.sub.(2)-VH.sub.(1)-CH1.sub.(1)-CH2-CH3(-CH4)). In
other embodiments, the T cell activating bispecific antigen binding
molecule comprises a polypeptide wherein the Fab heavy chain of the
first Fab molecule shares a carboxy-terminal peptide bond with the
Fab light chain variable region of the second Fab molecule which in
turn shares a carboxy-terminal peptide bond with the Fab heavy
chain constant region of the second Fab molecule (i.e. the second
Fab molecule comprises a crossover Fab heavy chain, wherein the
heavy chain variable region is replaced by a light chain variable
region), which in turn shares a carboxy-terminal peptide bond with
an Fc domain subunit
(VH.sub.(1)-CH1.sub.(1)-VL.sub.(2)-CH1.sub.(2)-CH2-CH3 (-CH4)).
[0265] In some of these embodiments the T cell activating
bispecific antigen binding molecule further comprises a crossover
Fab light chain polypeptide of the second Fab molecule, wherein the
Fab heavy chain variable region of the second Fab molecule shares a
carboxy-terminal peptide bond with the Fab light chain constant
region of the second Fab molecule (VH.sub.(2)-CL.sub.(2)), and the
Fab light chain polypeptide of the first Fab molecule
(VL.sub.(1)-CL.sub.(1). In others of these embodiments the T cell
activating bispecific antigen binding molecule further comprises a
polypeptide wherein the Fab heavy chain variable region of the
second Fab molecule shares a carboxy-terminal peptide bond with the
Fab light chain constant region of the second Fab molecule which in
turn shares a carboxy-terminal peptide bond with the Fab light
chain polypeptide of the first Fab molecule
(VH.sub.(2)-CL.sub.(2)-VL.sub.(1)-CL.sub.(1), or a polypeptide
wherein the Fab light chain polypeptide of the first Fab molecule
shares a carboxy-terminal peptide bond with the Fab heavy chain
variable region of the second Fab molecule which in turn shares a
carboxy-terminal peptide bond with the Fab light chain constant
region of the second Fab molecule
(VL.sub.(1)-CL.sub.(1)-VH.sub.(2)-CL.sub.(2)), as appropriate.
[0266] The T cell activating bispecific antigen binding molecule
according to these embodiments may further comprise (i) an Fc
domain subunit polypeptide (CH2-CH3(-CH4)), or (ii) a polypeptide
wherein the Fab heavy chain of a third Fab molecule shares a
carboxy-terminal peptide bond with an Fc domain subunit
(VH.sub.(3)-CH1.sub.(3)-CH2-CH3(-CH4)) and the Fab light chain
polypeptide of a third Fab molecule (VL.sub.(3)-CL.sub.(3)). In
certain embodiments the polypeptides are covalently linked, e.g.,
by a disulfide bond.
[0267] In some embodiments, the T cell activating bispecific
antigen binding molecule comprises a polypeptide wherein the Fab
heavy chain variable region of the second Fab molecule shares a
carboxy-terminal peptide bond with the Fab light chain constant
region of the second Fab molecule (i.e. the second Fab molecule
comprises a crossover Fab heavy chain, wherein the heavy chain
constant region is replaced by a light chain constant region),
which in turn shares a carboxy-terminal peptide bond with the Fab
heavy chain of the first Fab molecule, which in turn shares a
carboxy-terminal peptide bond with an Fc domain subunit
(VH.sub.(2)-CL.sub.(2)-VH.sub.(1)-CH1.sub.(1)-CH2-CH3(-CH4)). In
other embodiments, the T cell activating bispecific antigen binding
molecule comprises a polypeptide wherein the Fab heavy chain of the
first Fab molecule shares a carboxy-terminal peptide bond with the
Fab heavy chain variable region of the second Fab molecule which in
turn shares a carboxy-terminal peptide bond with the Fab light
chain constant region of the second Fab molecule (i.e. the second
Fab molecule comprises a crossover Fab heavy chain, wherein the
heavy chain constant region is replaced by a light chain constant
region), which in turn shares a carboxy-terminal peptide bond with
an Fc domain subunit
(VH.sub.(1)-CH1.sub.(1)-VH.sub.(2)-CL.sub.(2)-CH2-CH3 (-CH4)).
[0268] In some of these embodiments the T cell activating
bispecific antigen binding molecule further comprises a crossover
Fab light chain polypeptide of the second Fab molecule, wherein the
Fab light chain variable region of the second Fab molecule shares a
carboxy-terminal peptide bond with the Fab heavy chain constant
region of the second Fab molecule (VL.sub.(2)-CH1.sub.(2)), and the
Fab light chain polypeptide of the first Fab molecule
(VL.sub.(1)-CL.sub.(1). In others of these embodiments the T cell
activating bispecific antigen binding molecule further comprises a
polypeptide wherein the Fab light chain variable region of the
second Fab molecule shares a carboxy-terminal peptide bond with the
Fab heavy chain constant region of the second Fab molecule which in
turn shares a carboxy-terminal peptide bond with the Fab light
chain polypeptide of the first Fab molecule
(VL.sub.(2)-CH1.sub.(2)-VL.sub.(1)-CL.sub.(1), or a polypeptide
wherein the Fab light chain polypeptide of the first Fab molecule
shares a carboxy-terminal peptide bond with the Fab heavy chain
variable region of the second Fab molecule which in turn shares a
carboxy-terminal peptide bond with the Fab light chain constant
region of the second Fab molecule
(VL.sub.(1)-CL.sub.(1)-VH.sub.(2)-CL.sub.(2)), as appropriate.
[0269] The T cell activating bispecific antigen binding molecule
according to these embodiments may further comprise (i) an Fc
domain subunit polypeptide (CH2-CH3(-CH4)), or (ii) a polypeptide
wherein the Fab heavy chain of a third Fab molecule shares a
carboxy-terminal peptide bond with an Fc domain subunit
(VH.sub.(3)-CH1.sub.(3)-CH2-CH3(-CH4)) and the Fab light chain
polypeptide of a third Fab molecule (VL.sub.(3)-CL.sub.(3)). In
certain embodiments the polypeptides are covalently linked, e.g.,
by a disulfide bond.
[0270] In some embodiments, the first Fab molecule is fused at the
C-terminus of the Fab heavy chain to the N-terminus of the Fab
heavy chain of the second Fab molecule. In certain such
embodiments, the T cell activating bispecific antigen binding
molecule does not comprise an Fc domain. In certain embodiments,
the T cell activating bispecific antigen binding molecule
essentially consists of the first and the second Fab molecule, and
optionally one or more peptide linkers, wherein the first Fab
molecule is fused at the C-terminus of the Fab heavy chain to the
N-terminus of the Fab heavy chain of the second Fab molecule. Such
a configuration is schematically depicted in FIGS. 1O and 1S.
[0271] In other embodiments, the second Fab molecule is fused at
the C-terminus of the Fab heavy chain to the N-terminus of the Fab
heavy chain of the first Fab molecule. In certain such embodiments,
the T cell activating bispecific antigen binding molecule does not
comprise an Fc domain. In certain embodiments, the T cell
activating bispecific antigen binding molecule essentially consists
of the first and the second Fab molecule, and optionally one or
more peptide linkers, wherein the second Fab molecule is fused at
the C-terminus of the Fab heavy chain to the N-terminus of the Fab
heavy chain of the first Fab molecule. Such a configuration is
schematically depicted in FIGS. 1P and 1T.
[0272] In some embodiments, the first Fab molecule is fused at the
C-terminus of the Fab heavy chain to the N-terminus of the Fab
heavy chain of the second Fab molecule, and the T cell activating
bispecific antigen binding molecule further comprises a third Fab
molecule, wherein said third Fab molecule is fused at the
C-terminus of the Fab heavy chain to the N-terminus of the Fab
heavy chain of the first Fab molecule. In particular such
embodiments, said third Fab molecule is a conventional Fab
molecule. In other such embodiments, said third Fab molecule is a
crossover Fab molecule as described herein, i.e. a Fab molecule
wherein the variable domains VH and VL or the constant domains CL
and CH1 of the Fab heavy and light chains are exchanged/replaced by
each other. In certain such embodiments, the T cell activating
bispecific antigen binding molecule essentially consists of the
first, the second and the third Fab molecule, and optionally one or
more peptide linkers, wherein the first Fab molecule is fused at
the C-terminus of the Fab heavy chain to the N-terminus of the Fab
heavy chain of the second Fab molecule, and the third Fab molecule
is fused at the C-terminus of the Fab heavy chain to the N-terminus
of the Fab heavy chain of the first Fab molecule. Such a
configuration is schematically depicted in FIGS. 1Q and 1U
(particular embodiments, wherein the third Fab molecule is a
conventional Fab molecule and preferably identical to the first Fab
molecule).
[0273] In some embodiments, the first Fab molecule is fused at the
C-terminus of the Fab heavy chain to the N-terminus of the Fab
heavy chain of the second Fab molecule, and the T cell activating
bispecific antigen binding molecule further comprises a third Fab
molecule, wherein said third Fab molecule is fused at the
N-terminus of the Fab heavy chain to the C-terminus of the Fab
heavy chain of the second Fab molecule. In particular such
embodiments, said third Fab molecule is a crossover Fab molecule as
described herein, i.e. a Fab molecule wherein the variable domains
VH and VL or the constant domains CH1 and CL of the Fab heavy and
light chains are exchanged/replaced by each other. In other such
embodiments, said third Fab molecule is a conventional Fab
molecule. In certain such embodiments, the T cell activating
bispecific antigen binding molecule essentially consists of the
first, the second and the third Fab molecule, and optionally one or
more peptide linkers, wherein the first Fab molecule is fused at
the C-terminus of the Fab heavy chain to the N-terminus of the Fab
heavy chain of the second Fab molecule, and the third Fab molecule
is fused at the N-terminus of the Fab heavy chain to the C-terminus
of the Fab heavy chain of the second Fab molecule. Such a
configuration is schematically depicted in FIGS. 1W and 1Y
(particular embodiments, wherein the third Fab molecule is a
crossover Fab molecule and preferably identical to the second Fab
molecule).
[0274] In some embodiments, the second Fab molecule is fused at the
C-terminus of the Fab heavy chain to the N-terminus of the Fab
heavy chain of the first Fab molecule, and the T cell activating
bispecific antigen binding molecule further comprises a third Fab
molecule, wherein said third Fab molecule is fused at the
N-terminus of the Fab heavy chain to the C-terminus of the Fab
heavy chain of the first Fab molecule. In particular such
embodiments, said third Fab molecule is a conventional Fab
molecule. In other such embodiments, said third Fab molecule is a
crossover Fab molecule as described herein, i.e. a Fab molecule
wherein the variable domains VH and VL or the constant domains CH1
and CL of the Fab heavy and light chains are exchanged/replaced by
each other. In certain such embodiments, the T cell activating
bispecific antigen binding molecule essentially consists of the
first, the second and the third Fab molecule, and optionally one or
more peptide linkers, wherein the second Fab molecule is fused at
the C-terminus of the Fab heavy chain to the N-terminus of the Fab
heavy chain of the first Fab molecule, and the third Fab molecule
is fused at the N-terminus of the Fab heavy chain to the C-terminus
of the Fab heavy chain of the first Fab molecule. Such a
configuration is schematically depicted in FIGS. 1R and 1V
(particular embodiments, wherein the third Fab molecule is a
conventional Fab molecule and preferably identical to the first Fab
molecule).
[0275] In some embodiments, the second Fab molecule is fused at the
C-terminus of the Fab heavy chain to the N-terminus of the Fab
heavy chain of the first Fab molecule, and the T cell activating
bispecific antigen binding molecule further comprises a third Fab
molecule, wherein said third Fab molecule is fused at the
C-terminus of the Fab heavy chain to the N-terminus of the Fab
heavy chain of the second Fab molecule. In particular such
embodiments, said third Fab molecule is a crossover Fab molecule as
described herein, i.e. a Fab molecule wherein the variable domains
VH and VL or the constant domains CH1 and CL of the Fab heavy and
light chains are exchanged/replaced by each other. In other such
embodiments, said third Fab molecule is a conventional Fab
molecule. In certain such embodiments, the T cell activating
bispecific antigen binding molecule essentially consists of the
first, the second and the third Fab molecule, and optionally one or
more peptide linkers, wherein the second Fab molecule is fused at
the C-terminus of the Fab heavy chain to the N-terminus of the Fab
heavy chain of the first Fab molecule, and the third Fab molecule
is fused at the C-terminus of the Fab heavy chain to the N-terminus
of the Fab heavy chain of the second Fab molecule. Such a
configuration is schematically depicted in FIGS. 1X and 1Z
(particular embodiments, wherein the third Fab molecule is a
crossover Fab molecule and preferably identical to the first Fab
molecule). In certain embodiments the T cell activating bispecific
antigen binding molecule according to the invention comprises a
polypeptide wherein the Fab heavy chain of the first Fab molecule
shares a carboxy-terminal peptide bond with the Fab light chain
variable region of the second Fab molecule, which in turn shares a
carboxy-terminal peptide bond with the Fab heavy chain constant
region of the second Fab molecule (i.e. the second Fab molecule
comprises a crossover Fab heavy chain, wherein the heavy chain
variable region is replaced by a light chain variable region)
(VH.sub.(1)-CH1.sub.(1)-VL.sub.(2)-CH1.sub.(2)). In some
embodiments the T cell activating bispecific antigen binding
molecule further comprises a polypeptide wherein the Fab heavy
chain variable region of the second Fab molecule shares a
carboxy-terminal peptide bond with the Fab light chain constant
region of the second Fab molecule (VH.sub.(2)-CL.sub.(2)) and the
Fab light chain polypeptide of the first Fab molecule
(VL.sub.(1)-CL.sub.(1). In certain embodiments the T cell
activating bispecific antigen binding molecule according to the
invention comprises a polypeptide wherein the Fab light chain
variable region of the second Fab molecule shares a
carboxy-terminal peptide bond with the Fab heavy chain constant
region of the second Fab molecule (i.e. the second Fab molecule
comprises a crossover Fab heavy chain, wherein the heavy chain
variable region is replaced by a light chain variable region),
which in turn shares a carboxy-terminal peptide bond with the Fab
heavy chain of the first Fab molecule
(VL.sub.(2)-CH1.sub.(2)-VH.sub.(1)-CH1.sub.(1). In some embodiments
the T cell activating bispecific antigen binding molecule further
comprises a polypeptide wherein the Fab heavy chain variable region
of the second Fab molecule shares a carboxy-terminal peptide bond
with the Fab light chain constant region of the second Fab molecule
(VH.sub.(2)-CL.sub.(2)) and the Fab light chain polypeptide of the
first Fab molecule (VL.sub.(1)-CL.sub.(1).
[0276] In certain embodiments the T cell activating bispecific
antigen binding molecule according to the invention comprises a
polypeptide wherein the Fab heavy chain variable region of the
second Fab molecule shares a carboxy-terminal peptide bond with the
Fab light chain constant region of the second Fab molecule (i.e.
the second Fab molecule comprises a crossover Fab heavy chain,
wherein the heavy chain constant region is replaced by a light
chain constant region), which in turn shares a carboxy-terminal
peptide bond with the Fab heavy chain of the first Fab molecule
(VH.sub.(2)-CL.sub.(2)-VH.sub.(1)-CH1.sub.(1)). In some embodiments
the T cell activating bispecific antigen binding molecule further
comprises a polypeptide wherein the Fab light chain variable region
of the second Fab molecule shares a carboxy-terminal peptide bond
with the Fab heavy chain constant region of the second Fab molecule
(VL.sub.(2)-CH1.sub.(2)) and the Fab light chain polypeptide of the
first Fab molecule (VL.sub.(1)-CL.sub.(1)).
[0277] In certain embodiments the T cell activating bispecific
antigen binding molecule according to the invention comprises a
polypeptide wherein the Fab heavy chain of a third Fab molecule
shares a carboxy-terminal peptide bond with the Fab heavy chain of
the first Fab molecule, which in turn shares a carboxy-terminal
peptide bond with the Fab light chain variable region of the second
Fab molecule, which in turn shares a carboxy-terminal peptide bond
with the Fab heavy chain constant region of the second Fab molecule
(i.e. the second Fab molecule comprises a crossover Fab heavy
chain, wherein the heavy chain variable region is replaced by a
light chain variable region)
(VH.sub.(3)-CH1.sub.(3)-VH.sub.(1)-CH1.sub.(1)-VL.sub.(2)-CH1.sub.(2)).
In some embodiments the T cell activating bispecific antigen
binding molecule further comprises a polypeptide wherein the Fab
heavy chain variable region of the second Fab molecule shares a
carboxy-terminal peptide bond with the Fab light chain constant
region of the second Fab molecule (VH.sub.(2)-CL.sub.(2)) and the
Fab light chain polypeptide of the first Fab molecule
(VL.sub.(1)-CL.sub.(1)). In some embodiments the T cell activating
bispecific antigen binding molecule further comprises the Fab light
chain polypeptide of a third Fab molecule
(VL.sub.(3)-CL.sub.(3)).
[0278] In certain embodiments the T cell activating bispecific
antigen binding molecule according to the invention comprises a
polypeptide wherein the Fab heavy chain of a third Fab molecule
shares a carboxy-terminal peptide bond with the Fab heavy chain of
the first Fab molecule, which in turn shares a carboxy-terminal
peptide bond with the Fab heavy chain variable region of the second
Fab molecule, which in turn shares a carboxy-terminal peptide bond
with the Fab light chain constant region of the second Fab molecule
(i.e. the second Fab molecule comprises a crossover Fab heavy
chain, wherein the heavy chain constant region is replaced by a
light chain constant region)
(VH.sub.(3)-CH1.sub.(3)-VH.sub.(1)-CH1.sub.(1)-VH.sub.(2)-CL.sub.(2)).
In some embodiments the T cell activating bispecific antigen
binding molecule further comprises a polypeptide wherein the Fab
light chain variable region of the second Fab molecule shares a
carboxy-terminal peptide bond with the Fab heavy chain constant
region of the second Fab molecule (VL.sub.(2)-CH1.sub.(2)) and the
Fab light chain polypeptide of the first Fab molecule
(VL.sub.(1)-CL.sub.(1). In some embodiments the T cell activating
bispecific antigen binding molecule further comprises the Fab light
chain polypeptide of a third Fab molecule
(VL.sub.(3)-CL.sub.(3)).
[0279] In certain embodiments the T cell activating bispecific
antigen binding molecule according to the invention comprises a
polypeptide wherein the Fab light chain variable region of the
second Fab molecule shares a carboxy-terminal peptide bond with the
Fab heavy chain constant region of the second Fab molecule (i.e.
the second Fab molecule comprises a crossover Fab heavy chain,
wherein the heavy chain variable region is replaced by a light
chain variable region), which in turn shares a carboxy-terminal
peptide bond with the Fab heavy chain of the first Fab molecule,
which in turn shares a carboxy-terminal peptide bond with the Fab
heavy chain of a third Fab molecule
(VL.sub.(2)-CH1.sub.(2)-VH.sub.(1)-CH1.sub.(1)-VH.sub.(3)-CH1.sub.(3)).
In some embodiments the T cell activating bispecific antigen
binding molecule further comprises a polypeptide wherein the Fab
heavy chain variable region of the second Fab molecule shares a
carboxy-terminal peptide bond with the Fab light chain constant
region of the second Fab molecule (VH.sub.(2)-CL.sub.(2)) and the
Fab light chain polypeptide of the first Fab molecule
(VL.sub.(1)-CL.sub.(1). In some embodiments the T cell activating
bispecific antigen binding molecule further comprises the Fab light
chain polypeptide of a third Fab molecule
(VL.sub.(3)-CL.sub.(3)).
[0280] In certain embodiments the T cell activating bispecific
antigen binding molecule according to the invention comprises a
polypeptide wherein the Fab heavy chain variable region of the
second Fab molecule shares a carboxy-terminal peptide bond with the
Fab light chain constant region of the second Fab molecule (i.e.
the second Fab molecule comprises a crossover Fab heavy chain,
wherein the heavy chain constant region is replaced by a light
chain constant region), which in turn shares a carboxy-terminal
peptide bond with the Fab heavy chain of the first Fab molecule,
which in turn shares a carboxy-terminal peptide bond with the Fab
heavy chain of a third Fab molecule
(VH.sub.(2)-CL.sub.(2)-VH.sub.(1)-CH1.sub.(1)-VH.sub.(3)-CH1.sub.(3)).
In some embodiments the T cell activating bispecific antigen
binding molecule further comprises a polypeptide wherein the Fab
light chain variable region of the second Fab molecule shares a
carboxy-terminal peptide bond with the Fab heavy chain constant
region of the second Fab molecule (VL.sub.(2)-CH1.sub.(2)) and the
Fab light chain polypeptide of the first Fab molecule
(VL.sub.(1)-CL.sub.(1). In some embodiments the T cell activating
bispecific antigen binding molecule further comprises the Fab light
chain polypeptide of a third Fab molecule
(VL.sub.(3)-CL.sub.(3)).
[0281] In certain embodiments the T cell activating bispecific
antigen binding molecule according to the invention comprises a
polypeptide wherein the Fab heavy chain of the first Fab molecule
shares a carboxy-terminal peptide bond with the Fab light chain
variable region of the second Fab molecule, which in turn shares a
carboxy-terminal peptide bond with the Fab heavy chain constant
region of the second Fab molecule (i.e. the second Fab molecule
comprises a crossover Fab heavy chain, wherein the heavy chain
variable region is replaced by a light chain variable region),
which in turn shares a carboxy-terminal peptide bond with the Fab
light chain variable region of a third Fab molecule, which in turn
shares a carboxy-terminal peptide bond with the Fab heavy chain
constant region of a third Fab molecule (i.e. the third Fab
molecule comprises a crossover Fab heavy chain, wherein the heavy
chain variable region is replaced by a light chain variable region)
(VH.sub.(1)-CH1.sub.(1)-VL.sub.(2)-CH1.sub.(2)-VL.sub.(3)-CH1.sub.(3)).
In some embodiments the T cell activating bispecific antigen
binding molecule further comprises a polypeptide wherein the Fab
heavy chain variable region of the second Fab molecule shares a
carboxy-terminal peptide bond with the Fab light chain constant
region of the second Fab molecule (VH.sub.(2)-CL.sub.(2)) and the
Fab light chain polypeptide of the first Fab molecule
(VL.sub.(1)-CL.sub.(1). In some embodiments the T cell activating
bispecific antigen binding molecule further comprises a polypeptide
wherein the Fab heavy chain variable region of a third Fab molecule
shares a carboxy-terminal peptide bond with the Fab light chain
constant region of a third Fab molecule
(VH.sub.(3)-CL.sub.(3)).
[0282] In certain embodiments the T cell activating bispecific
antigen binding molecule according to the invention comprises a
polypeptide wherein the Fab heavy chain of the first Fab molecule
shares a carboxy-terminal peptide bond with the Fab heavy chain
variable region of the second Fab molecule, which in turn shares a
carboxy-terminal peptide bond with the Fab light chain constant
region of the second Fab molecule (i.e. the second Fab molecule
comprises a crossover Fab heavy chain, wherein the heavy chain
constant region is replaced by a light chain constant region),
which in turn shares a carboxy-terminal peptide bond with the Fab
heavy chain variable region of a third Fab molecule, which in turn
shares a carboxy-terminal peptide bond with the Fab light chain
constant region of a third Fab molecule (i.e. the third Fab
molecule comprises a crossover Fab heavy chain, wherein the heavy
chain constant region is replaced by a light chain constant region)
(VH.sub.(1)-CH1.sub.(1)-VH.sub.(2)-CL.sub.(2)-VH.sub.(3)-CL.sub.(3)).
In some embodiments the T cell activating bispecific antigen
binding molecule further comprises a polypeptide wherein the Fab
light chain variable region of the second Fab molecule shares a
carboxy-terminal peptide bond with the Fab heavy chain constant
region of the second Fab molecule (VL.sub.(2)-CH1.sub.(2)) and the
Fab light chain polypeptide of the first Fab molecule
(VL.sub.(1)-CL.sub.(1). In some embodiments the T cell activating
bispecific antigen binding molecule further comprises a polypeptide
wherein the Fab light chain variable region of a third Fab molecule
shares a carboxy-terminal peptide bond with the Fab heavy chain
constant region of a third Fab molecule
(VL.sub.(3)-CH1.sub.(3)).
[0283] In certain embodiments the T cell activating bispecific
antigen binding molecule according to the invention comprises a
polypeptide wherein the Fab light chain variable region of a third
Fab molecule shares a carboxy-terminal peptide bond with the Fab
heavy chain constant region of a third Fab molecule (i.e. the third
Fab molecule comprises a crossover Fab heavy chain, wherein the
heavy chain variable region is replaced by a light chain variable
region), which in turn shares a carboxy-terminal peptide bond with
the Fab light chain variable region of the second Fab molecule,
which in turn shares a carboxy-terminal peptide bond with the Fab
heavy chain constant region of the second Fab molecule (i.e. the
second Fab molecule comprises a crossover Fab heavy chain, wherein
the heavy chain variable region is replaced by a light chain
variable region), which in turn shares a carboxy-terminal peptide
bond with the Fab heavy chain of the first Fab molecule
(VL.sub.(3)-CH1.sub.(3)-VL.sub.(2)-CH1.sub.(2)-VH.sub.(1)-CH1.sub.(1).
In some embodiments the T cell activating bispecific antigen
binding molecule further comprises a polypeptide wherein the Fab
heavy chain variable region of the second Fab molecule shares a
carboxy-terminal peptide bond with the Fab light chain constant
region of the second Fab molecule (VH.sub.(2)-CL.sub.(2)) and the
Fab light chain polypeptide of the first Fab molecule
(VL.sub.(1)-CL.sub.(1). In some embodiments the T cell activating
bispecific antigen binding molecule further comprises a polypeptide
wherein the Fab heavy chain variable region of a third Fab molecule
shares a carboxy-terminal peptide bond with the Fab light chain
constant region of a third Fab molecule (VH.sub.(3)-CL.sub.(3)). In
certain embodiments the T cell activating bispecific antigen
binding molecule according to the invention comprises a polypeptide
wherein the Fab heavy chain variable region of a third Fab molecule
shares a carboxy-terminal peptide bond with the Fab light chain
constant region of a third Fab molecule (i.e. the third Fab
molecule comprises a crossover Fab heavy chain, wherein the heavy
chain constant region is replaced by a light chain constant
region), which in turn shares a carboxy-terminal peptide bond with
the Fab heavy chain variable region of the second Fab molecule,
which in turn shares a carboxy-terminal peptide bond with the Fab
light chain constant region of the second Fab molecule (i.e. the
second Fab molecule comprises a crossover Fab heavy chain, wherein
the heavy chain constant region is replaced by a light chain
constant region), which in turn shares a carboxy-terminal peptide
bond with the Fab heavy chain of the first Fab molecule
(VH.sub.(3)-CL.sub.(3)-VH.sub.(2)-CL.sub.(2)-VH.sub.(1)-CH1.sub.(1).
In some embodiments the T cell activating bispecific antigen
binding molecule further comprises a polypeptide wherein the Fab
light chain variable region of the second Fab molecule shares a
carboxy-terminal peptide bond with the Fab heavy chain constant
region of the second Fab molecule (VL.sub.(2)-CH1.sub.(2)) and the
Fab light chain polypeptide of the first Fab molecule
(VL.sub.(1)-CL.sub.(1). In some embodiments the T cell activating
bispecific antigen binding molecule further comprises a polypeptide
wherein the Fab light chain variable region of a third Fab molecule
shares a carboxy-terminal peptide bond with the Fab heavy chain
constant region of a third Fab molecule
(VL.sub.(3)-CH1.sub.(3)).
[0284] According to any of the above embodiments, components of the
T cell activating bispecific antigen binding molecule (e.g. Fab
molecules, Fc domain) may be fused directly or through various
linkers, particularly peptide linkers comprising one or more amino
acids, typically about 2-20 amino acids, that are described herein
or are known in the art. Suitable, non-immunogenic peptide linkers
include, for example, (G.sub.4S).sub.n, (SG.sub.4).sub.n,
(G.sub.4S).sub.n or G.sub.4(SG.sub.4).sub.n peptide linkers,
wherein n is generally an integer from 1 to 10, typically from 2 to
4.
Fc Domain
[0285] The Fc domain of the T cell activating bispecific antigen
binding molecule consists of a pair of polypeptide chains
comprising heavy chain domains of an immunoglobulin molecule. For
example, the Fc domain of an immunoglobulin G (IgG) molecule is a
dimer, each subunit of which comprises the CH2 and CH3 IgG heavy
chain constant domains. The two subunits of the Fc domain are
capable of stable association with each other. In one embodiment
the T cell activating bispecific antigen binding molecule of the
invention comprises not more than one Fc domain.
[0286] In one embodiment according the invention the Fc domain of
the T cell activating bispecific antigen binding molecule is an IgG
Fc domain. In a particular embodiment the Fc domain is an IgG.sub.1
Fc domain. In another embodiment the Fc domain is an IgG.sub.4 Fc
domain. In a more specific embodiment, the Fc domain is an
IgG.sub.4 Fc domain comprising an amino acid substitution at
position S228 (Kabat EU index numbering), particularly the amino
acid substitution S228P. This amino acid substitution reduces in
vivo Fab arm exchange of IgG.sub.4 antibodies (see Stubenrauch et
al., Drug Metabolism and Disposition 38, 84-91 (2010)). In a
further particular embodiment the Fc domain is a human Fc domain.
In an even more particular embodiment, the Fc domain is a human
IgG.sub.1 Fc domain. An exemplary sequence of a human IgG.sub.1 Fc
region is given in SEQ ID NO: 13.
Fc Domain Modifications Promoting Heterodimerization
[0287] T cell activating bispecific antigen binding molecules
according to the invention comprise different antigen binding
moieties, which may be fused to one or the other of the two
subunits of the Fc domain, thus the two subunits of the Fc domain
are typically comprised in two non-identical polypeptide chains.
Recombinant co-expression of these polypeptides and subsequent
dimerization leads to several possible combinations of the two
polypeptides. To improve the yield and purity of T cell activating
bispecific antigen binding molecules in recombinant production, it
will thus be advantageous to introduce in the Fc domain of the T
cell activating bispecific antigen binding molecule a modification
promoting the association of the desired polypeptides.
[0288] Accordingly, in particular embodiments the Fc domain of the
T cell activating bispecific antigen binding molecule according to
the invention comprises a modification promoting the association of
the first and the second subunit of the Fc domain. The site of most
extensive protein-protein interaction between the two subunits of a
human IgG Fc domain is in the CH3 domain of the Fc domain. Thus, in
one embodiment said modification is in the CH3 domain of the Fc
domain.
[0289] There exist several approaches for modifications in the CH3
domain of the Fc domain in order to enforce heterodimerization,
which are well described e.g. in WO 96/27011, WO 98/050431, EP
1870459, WO 2007/110205, WO 2007/147901, WO 2009/089004, WO
2010/129304, WO 2011/90754, WO 2011/143545, WO 2012058768, WO
2013157954, WO 2013096291. Typically, in all such approaches the
CH3 domain of the first subunit of the Fc domain and the CH3 domain
of the second subunit of the Fc domain are both engineered in a
complementary manner so that each CH3 domain (or the heavy chain
comprising it) can no longer homodimerize with itself but is forced
to heterodimerize with the complementarily engineered other CH3
domain (so that the first and second CH3 domain heterodimerize and
no homdimers between the two first or the two second CH3 domains
are formed). These different approaches for improved heavy chain
heterodimerization are contemplated as different alternatives in
combination with the heavy-light chain modifications (VH and VL
exchange/replacement in one binding arm and the introduction of
substitutions of charged amino acids with opposite charges in the
CH1/CL interface) in the T cell activating bispecific antigen
binding molecule according to the invention which reduce light
chain mispairing and Bence Jones-type side products.
[0290] In a specific embodiment said modification promoting the
association of the first and the second subunit of the Fc domain is
a so-called "knob-into-hole" modification, comprising a "knob"
modification in one of the two subunits of the Fc domain and a
"hole" modification in the other one of the two subunits of the Fc
domain.
[0291] The knob-into-hole technology is described e.g. in U.S. Pat.
Nos. 5,731,168; 7,695,936; Ridgway et al., Prot Eng 9, 617-621
(1996) and Carter, J Immunol Meth 248, 7-15 (2001). Generally, the
method involves introducing a protuberance ("knob") at the
interface of a first polypeptide and a corresponding cavity
("hole") in the interface of a second polypeptide, such that the
protuberance can be positioned in the cavity so as to promote
heterodimer formation and hinder homodimer formation. Protuberances
are constructed by replacing small amino acid side chains from the
interface of the first polypeptide with larger side chains (e.g.
tyrosine or tryptophan). Compensatory cavities of identical or
similar size to the protuberances are created in the interface of
the second polypeptide by replacing large amino acid side chains
with smaller ones (e.g. alanine or threonine).
[0292] Accordingly, in a particular embodiment, in the CH3 domain
of the first subunit of the Fc domain of the T cell activating
bispecific antigen binding molecule an amino acid residue is
replaced with an amino acid residue having a larger side chain
volume, thereby generating a protuberance within the CH3 domain of
the first subunit which is positionable in a cavity within the CH3
domain of the second subunit, and in the CH3 domain of the second
subunit of the Fc domain an amino acid residue is replaced with an
amino acid residue having a smaller side chain volume, thereby
generating a cavity within the CH3 domain of the second subunit
within which the protuberance within the CH3 domain of the first
subunit is positionable.
[0293] Preferably said amino acid residue having a larger side
chain volume is selected from the group consisting of arginine (R),
phenylalanine (F), tyrosine (Y), and tryptophan (W).
[0294] Preferably said amino acid residue having a smaller side
chain volume is selected from the group consisting of alanine (A),
serine (S), threonine (T), and valine (V).
[0295] The protuberance and cavity can be made by altering the
nucleic acid encoding the polypeptides, e.g. by site-specific
mutagenesis, or by peptide synthesis.
[0296] In a specific embodiment, in (the CH3 domain of) the first
subunit of the Fc domain (the "knobs" subunit) the threonine
residue at position 366 is replaced with a tryptophan residue
(T366W), and in (the CH3 domain of) the second subunit of the Fc
domain (the "hole" subunit) the tyrosine residue at position 407 is
replaced with a valine residue (Y407V). In one embodiment, in the
second subunit of the Fc domain additionally the threonine residue
at position 366 is replaced with a serine residue (T366S) and the
leucine residue at position 368 is replaced with an alanine residue
(L368A) (numberings according to Kabat EU index).
[0297] In yet a further embodiment, in the first subunit of the Fc
domain additionally the serine residue at position 354 is replaced
with a cysteine residue (S354C) or the glutamic acid residue at
position 356 is replaced with a cysteine residue (E356C)
(particularly the serine residue at position 354 is replaced with a
cysteine residue), and in the second subunit of the Fc domain
additionally the tyrosine residue at position 349 is replaced by a
cysteine residue (Y349C) (numberings according to Kabat EU index).
Introduction of these two cysteine residues results in formation of
a disulfide bridge between the two subunits of the Fc domain,
further stabilizing the dimer (Carter, J Immunol Methods 248, 7-15
(2001)).
[0298] In a particular embodiment, the first subunit of the Fc
domain comprises the amino acid substitutions S354C and T366W, and
the second subunit of the Fc domain comprises the amino acid
substitutions Y349C, T366S, L368A and Y407V (numbering according to
Kabat EU index).
[0299] In a particular embodiment the Fab molecule which
specifically binds an activating T cell antigen is fused
(optionally via a Fab molecule which specifically binds to a target
cell antigen) to the first subunit of the Fc domain (comprising the
"knob" modification). Without wishing to be bound by theory, fusion
of the Fab molecule which specifically binds an activating T cell
antigen to the knob-containing subunit of the Fc domain will
(further) minimize the generation of antigen binding molecules
comprising two Fab molecules which bind to an activating T cell
antigen (steric clash of two knob-containing polypeptides).
[0300] Other techniques of CH3-modification for enforcing the
heterodimerization are contemplated as alternatives according to
the invention and are described e.g. in WO 96/27011, WO 98/050431,
EP 1870459, WO 2007/110205, WO 2007/147901, WO 2009/089004, WO
2010/129304, WO 2011/90754, WO 2011/143545, WO 2012/058768, WO
2013/157954, WO 2013/096291.
[0301] In one embodiment the heterodimerization approach described
in EP 1870459 A1, is used alternatively. This approach is based on
the introduction of charged amino acids with opposite charges at
specific amino acid positions in the CH3/CH3 domain interface
between the two subunits of the Fc domain. One preferred embodiment
for the T cell activating bispecific antigen binding molecule of
the invention are amino acid mutations R409D; K370E in one of the
two CH3 domains (of the Fc domain) and amino acid mutations D399K;
E357K in the other one of the CH3 domains of the Fc domain
(numbering according to Kabat EU index).
[0302] In another embodiment the T cell activating bispecific
antigen binding molecule of the invention comprises amino acid
mutation T366W in the CH3 domain of the first subunit of the Fc
domain and amino acid mutations T366S, L368A, Y407V in the CH3
domain of the second subunit of the Fc domain, and additionally
amino acid mutations R409D; K370E in the CH3 domain of the first
subunit of the Fc domain and amino acid mutations D399K; E357K in
the CH3 domain of the second subunit of the Fc domain (numberings
according to Kabat EU index).
[0303] In another embodiment the T cell activating bispecific
antigen binding molecule of the invention comprises amino acid
mutations S354C, T366W in the CH3 domain of the first subunit of
the Fc domain and amino acid mutations Y349C, T366S, L368A, Y407V
in the CH3 domain of the second subunit of the Fc domain, or said T
cell activating bispecific antigen binding molecule comprises amino
acid mutations Y349C, T366W in the CH3 domain of the first subunit
of the Fc domain and amino acid mutations S354C, T366S, L368A,
Y407V in the CH3 domains of the second subunit of the Fc domain and
additionally amino acid mutations R409D; K370E in the CH3 domain of
the first subunit of the Fc domain and amino acid mutations D399K;
E357K in the CH3 domain of the second subunit of the Fc domain (all
numberings according to Kabat EU index).
[0304] In one embodiment the heterodimerization approach described
in WO 2013/157953 is used alternatively. In one embodiment a first
CH3 domain comprises amino acid mutation T366K and a second CH3
domain comprises amino acid mutation L351D (numberings according to
Kabat EU index). In a further embodiment the first CH3 domain
comprises further amino acid mutation L351K. In a further
embodiment the second CH3 domain comprises further an amino acid
mutation selected from Y349E, Y349D and L368E (preferably L368E)
(numberings according to Kabat EU index).
[0305] In one embodiment the heterodimerization approach described
in WO 2012/058768 is used alternatively. In one embodiment a first
CH3 domain comprises amino acid mutations L351Y, Y407A and a second
CH3 domain comprises amino acid mutations T366A, K409F. In a
further embodiment the second CH3 domain comprises a further amino
acid mutation at position T411, D399, 5400, F405, N390, or K392,
e.g. selected from a) T411N, T411R, T411Q, T411K, T411D, T411E or
T411W, b) D399R, D399W, D399Y or D399K, c) S400E, S400D, S400R, or
S400K, d) F4051, F405M, F405T, F405S, F405V or F405W, e) N390R,
N390K or N390D, f) K392V, K392M, K392R, K392L, K392F or K392E
(numberings according to Kabat EU index). In a further embodiment a
first CH3 domain comprises amino acid mutations L351Y, Y407A and a
second CH3 domain comprises amino acid mutations T366V, K409F. In a
further embodiment a first CH3 domain comprises amino acid mutation
Y407A and a second CH3 domain comprises amino acid mutations T366A,
K409F. In a further embodiment the second CH3 domain further
comprises amino acid mutations K392E, T411E, D399R and S400R
(numberings according to Kabat EU index).
[0306] In one embodiment the heterodimerization approach described
in WO 2011/143545 is used alternatively, e.g. with the amino acid
modification at a position selected from the group consisting of
368 and 409 (numbering according to Kabat EU index).
[0307] In one embodiment the heterodimerization approach described
in WO 2011/090762, which also uses the knobs-into-holes technology
described above, is used alternatively. In one embodiment a first
CH3 domain comprises amino acid mutation T366W and a second CH3
domain comprises amino acid mutation Y407A. In one embodiment a
first CH3 domain comprises amino acid mutation T366Y and a second
CH3 domain comprises amino acid mutation Y407T (numberings
according to Kabat EU index).
[0308] In one embodiment the T cell activating bispecific antigen
binding molecule or its Fc domain is of IgG.sub.2 subclass and the
heterodimerization approach described in WO 2010/129304 is used
alternatively.
[0309] In an alternative embodiment a modification promoting
association of the first and the second subunit of the Fc domain
comprises a modification mediating electrostatic steering effects,
e.g. as described in PCT publication no. WO 2009/089004. Generally,
this method involves replacement of one or more amino acid residues
at the interface of the two Fc domain subunits by charged amino
acid residues so that homodimer formation becomes electrostatically
unfavorable but heterodimerization electrostatically favorable. In
one such embodiment a first CH3 domain comprises amino acid
substitution of K392 or N392 with a negatively charged amino acid
(e.g. glutamic acid (E), or aspartic acid (D), preferably K392D or
N392D) and a second CH3 domain comprises amino acid substitution of
D399, E356, D356, or E357 with a positively charged amino acid
(e.g. lysine (K) or arginine (R), preferably D399K, E356K, D356K,
or E357K, and more preferably D399K and E356K). In a further
embodiment the first CH3 domain further comprises amino acid
substitution of K409 or R409 with a negatively charged amino acid
(e.g. glutamic acid (E), or aspartic acid (D), preferably K409D or
R409D). In a further embodiment the first CH3 domain further or
alternatively comprises amino acid substitution of K439 and/or K370
with a negatively charged amino acid (e.g. glutamic acid (E), or
aspartic acid (D)) (all numberings according to Kabat EU
index).
[0310] In yet a further embodiment the heterodimerization approach
described in WO 2007/147901 is used alternatively. In one
embodiment a first CH3 domain comprises amino acid mutations K253E,
D282K, and K322D and a second CH3 domain comprises amino acid
mutations D239K, E240K, and K292D (numberings according to Kabat EU
index).
[0311] In still another embodiment the heterodimerization approach
described in WO 2007/110205 can be used alternatively.
[0312] In one embodiment, the first subunit of the Fc domain
comprises amino acid substitutions K392D and K409D, and the second
subunit of the Fc domain comprises amino acid substitutions D356K
and D399K (numbering according to Kabat EU index).
Fc Domain Modifications Reducing Fc Receptor Binding and/or
Effector Function
[0313] The Fc domain confers to the T cell activating bispecific
antigen binding molecule favorable pharmacokinetic properties,
including a long serum half-life which contributes to good
accumulation in the target tissue and a favorable tissue-blood
distribution ratio. At the same time it may, however, lead to
undesirable targeting of the T cell activating bispecific antigen
binding molecule to cells expressing Fc receptors rather than to
the preferred antigen-bearing cells. Moreover, the co-activation of
Fc receptor signaling pathways may lead to cytokine release which,
in combination with the T cell activating properties and the long
half-life of the antigen binding molecule, results in excessive
activation of cytokine receptors and severe side effects upon
systemic administration. Activation of (Fc receptor-bearing) immune
cells other than T cells may even reduce efficacy of the T cell
activating bispecific antigen binding molecule due to the potential
destruction of T cells e.g. by NK cells.
[0314] Accordingly, in particular embodiments, the Fc domain of the
T cell activating bispecific antigen binding molecule according to
the invention exhibits reduced binding affinity to an Fc receptor
and/or reduced effector function, as compared to a native IgG.sub.1
Fc domain. In one such embodiment the Fc domain (or the T cell
activating bispecific antigen binding molecule comprising said Fc
domain) exhibits less than 50%, preferably less than 20%, more
preferably less than 10% and most preferably less than 5% of the
binding affinity to an Fc receptor, as compared to a native
IgG.sub.1 Fc domain (or a T cell activating bispecific antigen
binding molecule comprising a native IgG.sub.1 Fc domain), and/or
less than 50%, preferably less than 20%, more preferably less than
10% and most preferably less than 5% of the effector function, as
compared to a native IgG.sub.1 Fc domain (or a T cell activating
bispecific antigen binding molecule comprising a native IgG.sub.1
Fc domain). In one embodiment, the Fc domain (or the T cell
activating bispecific antigen binding molecule comprising said Fc
domain) does not substantially bind to an Fc receptor and/or induce
effector function. In a particular embodiment the Fc receptor is an
Fey receptor. In one embodiment the Fc receptor is a human Fc
receptor. In one embodiment the Fc receptor is an activating Fc
receptor. In a specific embodiment the Fc receptor is an activating
human Fey receptor, more specifically human Fc.gamma.RIIIa,
Fc.gamma.RI or Fc.gamma.RIIa, most specifically human
Fc.gamma.RIIIa. In one embodiment the effector function is one or
more selected from the group of CDC, ADCC, ADCP, and cytokine
secretion. In a particular embodiment the effector function is
ADCC. In one embodiment the Fc domain exhibits substantially
similar binding affinity to neonatal Fc receptor (FcRn), as
compared to a native IgG.sub.1 Fc domain domain. Substantially
similar binding to FcRn is achieved when the Fc domain (or the T
cell activating bispecific antigen binding molecule comprising said
Fc domain) exhibits greater than about 70%, particularly greater
than about 80%, more particularly greater than about 90% of the
binding affinity of a native IgG.sub.1 Fc domain (or the T cell
activating bispecific antigen binding molecule comprising a native
IgG.sub.1 Fc domain) to FcRn.
[0315] In certain embodiments the Fc domain is engineered to have
reduced binding affinity to an Fc receptor and/or reduced effector
function, as compared to a non-engineered Fc domain. In particular
embodiments, the Fc domain of the T cell activating bispecific
antigen binding molecule comprises one or more amino acid mutation
that reduces the binding affinity of the Fc domain to an Fc
receptor and/or effector function. Typically, the same one or more
amino acid mutation is present in each of the two subunits of the
Fc domain. In one embodiment the amino acid mutation reduces the
binding affinity of the Fc domain to an Fc receptor. In one
embodiment the amino acid mutation reduces the binding affinity of
the Fc domain to an Fc receptor by at least 2-fold, at least
5-fold, or at least 10-fold. In embodiments where there is more
than one amino acid mutation that reduces the binding affinity of
the Fc domain to the Fc receptor, the combination of these amino
acid mutations may reduce the binding affinity of the Fc domain to
an Fc receptor by at least 10-fold, at least 20-fold, or even at
least 50-fold. In one embodiment the T cell activating bispecific
antigen binding molecule comprising an engineered Fc domain
exhibits less than 20%, particularly less than 10%, more
particularly less than 5% of the binding affinity to an Fc receptor
as compared to a T cell activating bispecific antigen binding
molecule comprising a non-engineered Fc domain. In a particular
embodiment the Fc receptor is an Fey receptor. In some embodiments
the Fc receptor is a human Fc receptor. In some embodiments the Fc
receptor is an activating Fc receptor. In a specific embodiment the
Fc receptor is an activating human Fc.gamma. receptor, more
specifically human Fc.gamma.RIIIa, Fc.gamma.RI or Fc.gamma.RIIa,
most specifically human Fc.gamma.RIIIa. Preferably, binding to each
of these receptors is reduced. In some embodiments binding affinity
to a complement component, specifically binding affinity to C1q, is
also reduced. In one embodiment binding affinity to neonatal Fc
receptor (FcRn) is not reduced. Substantially similar binding to
FcRn, i.e. preservation of the binding affinity of the Fc domain to
said receptor, is achieved when the Fc domain (or the T cell
activating bispecific antigen binding molecule comprising said Fc
domain) exhibits greater than about 70% of the binding affinity of
a non-engineered form of the Fc domain (or the T cell activating
bispecific antigen binding molecule comprising said non-engineered
form of the Fc domain) to FcRn. The Fc domain, or T cell activating
bispecific antigen binding molecules of the invention comprising
said Fc domain, may exhibit greater than about 80% and even greater
than about 90% of such affinity. In certain embodiments the Fc
domain of the T cell activating bispecific antigen binding molecule
is engineered to have reduced effector function, as compared to a
non-engineered Fc domain. The reduced effector function can
include, but is not limited to, one or more of the following:
reduced complement dependent cytotoxicity (CDC), reduced
antibody-dependent cell-mediated cytotoxicity (ADCC), reduced
antibody-dependent cellular phagocytosis (ADCP), reduced cytokine
secretion, reduced immune complex-mediated antigen uptake by
antigen-presenting cells, reduced binding to NK cells, reduced
binding to macrophages, reduced binding to monocytes, reduced
binding to polymorphonuclear cells, reduced direct signaling
inducing apoptosis, reduced crosslinking of target-bound
antibodies, reduced dendritic cell maturation, or reduced T cell
priming. In one embodiment the reduced effector function is one or
more selected from the group of reduced CDC, reduced ADCC, reduced
ADCP, and reduced cytokine secretion. In a particular embodiment
the reduced effector function is reduced ADCC. In one embodiment
the reduced ADCC is less than 20% of the ADCC induced by a
non-engineered Fc domain (or a T cell activating bispecific antigen
binding molecule comprising a non-engineered Fc domain).
[0316] In one embodiment the amino acid mutation that reduces the
binding affinity of the Fc domain to an Fc receptor and/or effector
function is an amino acid substitution. In one embodiment the Fc
domain comprises an amino acid substitution at a position selected
from the group of E233, L234, L235, N297, P331 and P329 (numberings
according to Kabat EU index). In a more specific embodiment the Fc
domain comprises an amino acid substitution at a position selected
from the group of L234, L235 and P329 (numberings according to
Kabat EU index). In some embodiments the Fc domain comprises the
amino acid substitutions L234A and L235A (numberings according to
Kabat EU index). In one such embodiment, the Fc domain is an
IgG.sub.1 Fc domain, particularly a human IgG.sub.1 Fc domain. In
one embodiment the Fc domain comprises an amino acid substitution
at position P329. In a more specific embodiment the amino acid
substitution is P329A or P329G, particularly P329G (numberings
according to Kabat EU index). In one embodiment the Fc domain
comprises an amino acid substitution at position P329 and a further
amino acid substitution at a position selected from E233, L234,
L235, N297 and P331 (numberings according to Kabat EU index). In a
more specific embodiment the further amino acid substitution is
E233P, L234A, L235A, L235E, N297A, N297D or P331S. In particular
embodiments the Fc domain comprises amino acid substitutions at
positions P329, L234 and L235 (numberings according to Kabat EU
index). In more particular embodiments the Fc domain comprises the
amino acid mutations L234A, L235A and P329G ("P329G LALA", "PGLALA"
or "LALAPG"). Specifically, in particular embodiments, each subunit
of the Fc domain comprises the amino acid substitutions L234A,
L235A and P329G (Kabat EU index numbering), i.e. in each of the
first and the second subunit of the Fc domain the leucine residue
at position 234 is replaced with an alanine residue (L234A), the
leucine residue at position 235 is replaced with an alanine residue
(L235A) and the proline residue at position 329 is replaced by a
glycine residue (P329G) (numbering according to Kabat EU index). In
one such embodiment, the Fc domain is an IgG.sub.1 Fc domain,
particularly a human IgG.sub.1 Fc domain. The "P329G LALA"
combination of amino acid substitutions almost completely abolishes
Fc.gamma. receptor (as well as complement) binding of a human
IgG.sub.1 Fc domain, as described in PCT publication no. WO
2012/130831, incorporated herein by reference in its entirety. WO
2012/130831 also describes methods of preparing such mutant Fc
domains and methods for determining its properties such as Fc
receptor binding or effector functions.
[0317] IgG.sub.4 antibodies exhibit reduced binding affinity to Fc
receptors and reduced effector functions as compared to IgG.sub.1
antibodies. Hence, in some embodiments the Fc domain of the T cell
activating bispecific antigen binding molecules of the invention is
an IgG.sub.4 Fc domain, particularly a human IgG.sub.4 Fc domain.
In one embodiment the IgG.sub.4 Fc domain comprises amino acid
substitutions at position S228, specifically the amino acid
substitution S228P (numberings according to Kabat EU index). To
further reduce its binding affinity to an Fc receptor and/or its
effector function, in one embodiment the IgG.sub.4 Fc domain
comprises an amino acid substitution at position L235, specifically
the amino acid substitution L235E (numberings according to Kabat EU
index). In another embodiment, the IgG.sub.4 Fc domain comprises an
amino acid substitution at position P329, specifically the amino
acid substitution P329G (numberings according to Kabat EU index).
In a particular embodiment, the IgG.sub.4 Fc domain comprises amino
acid substitutions at positions 5228, L235 and P329, specifically
amino acid substitutions S228P, L235E and P329G (numberings
according to Kabat EU index). Such IgG.sub.4 Fc domain mutants and
their Fc.gamma. receptor binding properties are described in PCT
publication no. WO 2012/130831, incorporated herein by reference in
its entirety.
[0318] In a particular embodiment the Fc domain exhibiting reduced
binding affinity to an Fc receptor and/or reduced effector
function, as compared to a native IgG.sub.1 Fc domain, is a human
IgG.sub.1 Fc domain comprising the amino acid substitutions L234A,
L235A and optionally P329G, or a human IgG.sub.4 Fc domain
comprising the amino acid substitutions S228P, L235E and optionally
P329G (numberings according to Kabat EU index).
[0319] In certain embodiments N-glycosylation of the Fc domain has
been eliminated. In one such embodiment the Fc domain comprises an
amino acid mutation at position N297, particularly an amino acid
substitution replacing asparagine by alanine (N297A) or aspartic
acid (N297D) (numberings according to Kabat EU index).
[0320] In addition to the Fc domains described hereinabove and in
PCT publication no. WO 2012/130831, Fc domains with reduced Fc
receptor binding and/or effector function also include those with
substitution of one or more of Fc domain residues 238, 265, 269,
270, 297, 327 and 329 (U.S. Pat. No. 6,737,056) (numberings
according to Kabat EU index). Such Fc mutants include Fc mutants
with substitutions at two or more of amino acid positions 265, 269,
270, 297 and 327, including the so-called "DANA" Fc mutant with
substitution of residues 265 and 297 to alanine (U.S. Pat. No.
7,332,581).
[0321] Mutant Fc domains can be prepared by amino acid deletion,
substitution, insertion or modification using genetic or chemical
methods well known in the art. Genetic methods may include
site-specific mutagenesis of the encoding DNA sequence, PCR, gene
synthesis, and the like. The correct nucleotide changes can be
verified for example by sequencing.
[0322] Binding to Fc receptors can be easily determined e.g. by
ELISA, or by Surface Plasmon Resonance (SPR) using standard
instrumentation such as a BIAcore instrument (GE Healthcare), and
Fc receptors such as may be obtained by recombinant expression.
Alternatively, binding affinity of Fc domains or cell activating
bispecific antigen binding molecules comprising an Fc domain for Fc
receptors may be evaluated using cell lines known to express
particular Fc receptors, such as human NK cells expressing
Fc.gamma.IIIa receptor.
[0323] Effector function of an Fc domain, or a T cell activating
bispecific antigen binding molecule comprising an Fc domain, can be
measured by methods known in the art. Examples of in vitro assays
to assess ADCC activity of a molecule of interest are described in
U.S. Pat. No. 5,500,362; Hellstrom et al. Proc Natl Acad Sci USA
83, 7059-7063 (1986) and Hellstrom et al., Proc Natl Acad Sci USA
82, 1499-1502 (1985); U.S. Pat. No. 5,821,337; Bruggemann et al., J
Exp Med 166, 1351-1361 (1987). Alternatively, non-radioactive
assays methods may be employed (see, for example, ACTI.TM.
non-radioactive cytotoxicity assay for flow cytometry
(CellTechnology, Inc. Mountain View, Calif.); and CytoTox 96.RTM.
non-radioactive cytotoxicity assay (Promega, Madison, Wis.)).
Useful effector cells for such assays include peripheral blood
mononuclear cells (PBMC) and Natural Killer (NK) cells.
Alternatively, or additionally, ADCC activity of the molecule of
interest may be assessed in vivo, e.g. in a animal model such as
that disclosed in Clynes et al., Proc Natl Acad Sci USA 95, 652-656
(1998).
[0324] In some embodiments, binding of the Fc domain to a
complement component, specifically to C1q, is reduced. Accordingly,
in some embodiments wherein the Fc domain is engineered to have
reduced effector function, said reduced effector function includes
reduced CDC. C1q binding assays may be carried out to determine
whether the Fc domain, or the T cell activating bispecific antigen
binding molecule comprising the Fc domain, is able to bind C1q and
hence has CDC activity. See e.g., C1q and C3c binding ELISA in WO
2006/029879 and WO 2005/100402. To assess complement activation, a
CDC assay may be performed (see, for example, Gazzano-Santoro et
al., J Immunol Methods 202, 163 (1996); Cragg et al., Blood 101,
1045-1052 (2003); and Cragg and Glennie, Blood 103, 2738-2743
(2004)).
Antigen Binding Moieties
[0325] The antigen binding molecule of the invention is bispecific,
i.e. it comprises at least two antigen binding moieties capable of
specific binding to two distinct antigenic determinants. According
to particular embodiments of the invention, the antigen binding
moieties are Fab molecules (i.e. antigen binding domains composed
of a heavy and a light chain, each comprising a variable and a
constant domain). In one embodiment said Fab molecules are human.
In another embodiment said Fab molecules are humanized. In yet
another embodiment said Fab molecules comprise human heavy and
light chain constant domains.
[0326] Preferably, at least one of the antigen binding moieties is
a crossover Fab molecule. Such modification reduces mispairing of
heavy and light chains from different Fab molecules, thereby
improving the yield and purity of the T cell activating bispecific
antigen binding molecule of the invention in recombinant
production. In a particular crossover Fab molecule useful for the T
cell activating bispecific antigen binding molecule of the
invention, the variable domains of the Fab light chain and the Fab
heavy chain (VL and VH, respectively) are exchanged. Even with this
domain exchange, however, the preparation of the T cell activating
bispecific antigen binding molecule may comprise certain side
products due to a so-called Bence Jones-type interaction between
mispaired heavy and light chains (see Schaefer et al, PNAS, 108
(2011) 11187-11191). To further reduce mispairing of heavy and
light chains from different Fab molecules and thus increase the
purity and yield of the desired T cell activating bispecific
antigen binding molecule, according to the present invention
charged amino acids with opposite charges may be introduced at
specific amino acid positions in the CH1 and CL domains of either
the Fab molecule(s) specifically binding to a target cell antigen,
or the Fab molecule specifically binding to an activating T cell
antigen. Charge modifications are made either in the conventional
Fab molecule(s) comprised in the T cell activating bispecific
antigen binding molecule (such as shown e.g. in FIGS. 1 A-C, G-J),
or in the VH/VL crossover Fab molecule(s) comprised in the T cell
activating bispecific antigen binding molecule (such as shown e.g.
in FIG. 1 D-F, K-N) (but not in both). In particular embodiments,
the charge modifications are made in the conventional Fab
molecule(s) comprised in the T cell activating bispecific antigen
binding molecule (which in particular embodiments specifically
bind(s) to the target cell antigen).
[0327] In a particular embodiment according to the invention, the T
cell activating bispecific antigen binding molecule is capable of
simultaneous binding to a target cell antigen, particularly a tumor
cell antigen, and an activating T cell antigen, particularly CD3.
In one embodiment, the T cell activating bispecific antigen binding
molecule is capable of crosslinking a T cell and a target cell by
simultaneous binding to a target cell antigen and an activating T
cell antigen. In an even more particular embodiment, such
simultaneous binding results in lysis of the target cell,
particularly a tumor cell. In one embodiment, such simultaneous
binding results in activation of the T cell. In other embodiments,
such simultaneous binding results in a cellular response of a T
lymphocyte, particularly a cytotoxic T lymphocyte, selected from
the group of: proliferation, differentiation, cytokine secretion,
cytotoxic effector molecule release, cytotoxic activity, and
expression of activation markers. In one embodiment, binding of the
T cell activating bispecific antigen binding molecule to the
activating T cell antigen, particularly CD3, without simultaneous
binding to the target cell antigen does not result in T cell
activation.
[0328] In one embodiment, the T cell activating bispecific antigen
binding molecule is capable of re-directing cytotoxic activity of a
T cell to a target cell. In a particular embodiment, said
re-direction is independent of MHC-mediated peptide antigen
presentation by the target cell and and/or specificity of the T
cell.
[0329] Particularly, a T cell according to any of the embodiments
of the invention is a cytotoxic T cell. In some embodiments the T
cell is a CD4.sup.+ or a CD8.sup.+ T cell, particularly a CD8.sup.+
T cell.
Activating T Cell Antigen Binding Moiety
[0330] The T cell activating bispecific antigen binding molecule of
the invention comprises at least one antigen binding moiety,
particularly a Fab molecule, which specifically binds to an
activating T cell antigen (also referred to herein as an
"activating T cell antigen binding moiety, or activating T cell
antigen binding Fab molecule"). In a particular embodiment, the T
cell activating bispecific antigen binding molecule comprises not
more than one antigen binding moiety capable of specific binding to
an activating T cell antigen. In one embodiment the T cell
activating bispecific antigen binding molecule provides monovalent
binding to the activating T cell antigen.
[0331] In particular embodiments, the antigen binding moiety which
specifically binds an activating T cell antigen is a crossover Fab
molecule as described herein, i.e. a Fab molecule wherein the
variable domains VH and VL or the constant domains CH1 and CL of
the Fab heavy and light chains are exchanged/replaced by each
other. In such embodiments, the antigen binding moiety(ies) which
specifically binds a target cell antigen is preferably a
conventional Fab molecule. In embodiments where there is more than
one antigen binding moiety, particularly Fab molecule, which
specifically binds to a target cell antigen comprised in the T cell
activating bispecific antigen binding molecule, the antigen binding
moiety which specifically binds to an activating T cell antigen
preferably is a crossover Fab molecule and the antigen binding
moieties which specifically bind to a target cell antigen are
conventional Fab molecules.
[0332] In alternative embodiments, the antigen binding moiety which
specifically binds an activating T cell antigen is a conventional
Fab molecule. In such embodiments, the antigen binding moiety(ies)
which specifically binds a target cell antigen is a crossover Fab
molecule as described herein, i.e. a Fab molecule wherein the
variable domains VH and VL or the constant domains CH1 and CL of
the Fab heavy and light chains are exchanged/replaced by each
other.
[0333] In a particular embodiment the activating T cell antigen is
CD3, particularly human CD3 (SEQ ID NO: 1) or cynomolgus CD3 (SEQ
ID NO: 2), most particularly human CD3. In a particular embodiment
the activating T cell antigen binding moiety is cross-reactive for
(i.e. specifically binds to) human and cynomolgus CD3. In some
embodiments, the activating T cell antigen is the epsilon subunit
of CD3 (CD3 epsilon).
[0334] In some embodiments, the activating T cell antigen binding
moiety specifically binds to CD3, particularly CD3 epsilon, and
comprises at least one heavy chain complementarity determining
region (CDR) selected from the group consisting of SEQ ID NO: 4,
SEQ ID NO: 5 and SEQ ID NO: 6 and at least one light chain CDR
selected from the group of SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:
10.
[0335] In one embodiment the CD3 binding antigen binding moiety,
particularly Fab molecule, comprises a heavy chain variable region
comprising the heavy chain CDR1 of SEQ ID NO: 4, the heavy chain
CDR2 of SEQ ID NO: 5, the heavy chain CDR3 of SEQ ID NO: 6, and a
light chain variable region comprising the light chain CDR1 of SEQ
ID NO: 8, the light chain CDR2 of SEQ ID NO: 9, and the light chain
CDR3 of SEQ ID NO: 10.
[0336] In one embodiment the CD3 binding antigen binding moiety,
particularly Fab molecule, comprises a heavy chain variable region
sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100%
identical to SEQ ID NO: 3 and a light chain variable region
sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100%
identical to SEQ ID NO: 7.
[0337] In one embodiment the CD3 binding antigen binding moiety,
particularly Fab molecule, comprises a heavy chain variable region
comprising the amino acid sequence of SEQ ID NO: 3 and a light
chain variable region comprising the amino acid sequence of SEQ ID
NO: 7.
[0338] In one embodiment the CD3 binding antigen binding moiety,
particularly Fab molecule, comprises the heavy chain variable
region sequence of SEQ ID NO: 3 and the light chain variable region
sequence of SEQ ID NO: 7.
Target Cell Antigen Binding Moiety
[0339] The T cell activating bispecific antigen binding molecule of
the invention comprises at least one antigen binding moiety,
particularly a Fab molecule, which specifically binds to p95HER2
(target cell antigen). In certain embodiments, the T cell
activating bispecific antigen binding molecule comprises two
antigen binding moieties, particularly Fab molecules, which
specifically bind to p95HER2. In a particular such embodiment, each
of these antigen binding moieties specifically binds to the same
antigenic determinant. In an even more particular embodiment, all
of these antigen binding moieties are identical, i.e. they comprise
the same amino acid sequences including the same amino acid
substitutions in the CH1 and CL domain as described herein (if
any). In one embodiment, the T cell activating bispecific antigen
binding molecule comprises an immunoglobulin molecule which
specifically binds to p95HER2. In one embodiment the T cell
activating bispecific antigen binding molecule comprises not more
than two antigen binding moieties, particularly Fab molecules,
which specifically bind to p95HER2.
[0340] In particular embodiments, the antigen binding moiety(ies)
which specifically bind to p95HER2 is/are a conventional Fab
molecule. In such embodiments, the antigen binding moiety(ies)
which specifically binds an activating T cell antigen is a
crossover Fab molecule as described herein, i.e. a Fab molecule
wherein the variable domains VH and VL or the constant domains CH1
and CL of the Fab heavy and light chains are exchanged/replaced by
each other.
[0341] In alternative embodiments, the antigen binding moiety(ies)
which specifically bind to p95HER2 is/are a crossover Fab molecule
as described herein, i.e. a Fab molecule wherein the variable
domains VH and VL or the constant domains CH1 and CL of the Fab
heavy and light chains are exchanged/replaced by each other. In
such embodiments, the antigen binding moiety(ies) which
specifically binds an activating T cell antigen is a conventional
Fab molecule.
[0342] The p95HER2 binding moiety is able to direct the T cell
activating bispecific antigen binding molecule to a target site,
for example to a specific type of tumor cell that expresses
p95HER2.
[0343] In one embodiment, the antigen binding moiety, particularly
Fab molecule, which specifically binds to p95HER2 comprises a heavy
chain variable region comprising the heavy chain complementarity
determining region (CDR) 1 of SEQ ID NO: 14, the heavy chain CDR 2
of SEQ ID NO: 15, and the heavy chain CDR 3 of SEQ ID NO: 16, and a
light chain variable region comprising the light chain CDR 1 of SEQ
ID NO: 17, the light chain CDR 2 of SEQ ID NO: 18 and the light
chain CDR 3 of SEQ ID NO: 19. In a further embodiment, the antigen
binding moiety, particularly Fab molecule, which specifically binds
to p95HER2 comprises a heavy chain variable region that is at least
95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO:
20, and a light chain variable region that is at least 95%, 96%,
97%, 98%, or 99% identical to the sequence of SEQ ID NO: 21. In
still a further embodiment, the antigen binding moiety,
particularly Fab molecule, which specifically binds to p95HER2
comprises the heavy chain variable region sequence of SEQ ID NO:
20, and the light chain variable region sequence of SEQ ID NO: 21.
In another embodiment, the p95HER2 antigen binding moiety comprises
a humanized version of the heavy chain variable region sequence of
SEQ ID NO: 20 and a humanized version of the light chain variable
region sequence of SEQ ID NO: 21. In one embodiment, the p95HER2
antigen binding moiety comprises the heavy chain CDR1 of SEQ ID NO:
14, the heavy chain CDR2 of SEQ ID NO: 15, the heavy chain CDR3 of
SEQ ID NO: 16, the light chain CDR1 of SEQ ID NO: 17, the light
chain CDR2 of SEQ ID NO: 18, the light chain CDR3 of SEQ ID NO: 19,
and human heavy and light chain variable region framework
sequences.
[0344] In a particular embodiment, the T cell activating bispecific
antigen binding molecule comprises a polypeptide that is at least
95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO:
22, a polypeptide that is at least 95%, 96%, 97%, 98%, or 99%
identical to the sequence of SEQ ID NO: 23, a polypeptide that is
at least 95%, 96%, 97%, 98%, or 99% identical to the sequence of
SEQ ID NO: 24, and a polypeptide that is at least 95%, 96%, 97%,
98%, or 99% identical to the sequence of SEQ ID NO: 25. In a
further particular embodiment, the T cell activating bispecific
antigen binding molecule comprises a polypeptide sequence of SEQ ID
NO: 22, a polypeptide sequence of SEQ ID NO: 23, a polypeptide
sequence of SEQ ID NO: 24 and a polypeptide sequence of SEQ ID NO:
25. In another embodiment, the T cell activating bispecific antigen
binding molecule comprises a polypeptide that is at least 95%, 96%,
97%, 98%, or 99% identical to the sequence of SEQ ID NO: 26, a
polypeptide that is at least 95%, 96%, 97%, 98%, or 99% identical
to the sequence of SEQ ID NO: 27, a polypeptide that is at least
95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO:
28, and a polypeptide that is at least 95%, 96%, 97%, 98%, or 99%
identical to the sequence of SEQ ID NO: 29. In a further
embodiment, the T cell activating bispecific antigen binding
molecule comprises a polypeptide sequence of SEQ ID NO: 26, a
polypeptide sequence of SEQ ID NO: 27, a polypeptide sequence of
SEQ ID NO: 28 and a polypeptide sequence of SEQ ID NO: 29.
Polynucleotides
[0345] The invention further provides isolated polynucleotides
encoding a T cell activating bispecific antigen binding molecule as
described herein or a fragment thereof. In some embodiments, said
fragment is an antigen binding fragment.
[0346] The polynucleotides encoding T cell activating bispecific
antigen binding molecules of the invention may be expressed as a
single polynucleotide that encodes the entire T cell activating
bispecific antigen binding molecule or as multiple (e.g., two or
more) polynucleotides that are co-expressed. Polypeptides encoded
by polynucleotides that are co-expressed may associate through,
e.g., disulfide bonds or other means to form a functional T cell
activating bispecific antigen binding molecule. For example, the
light chain portion of a Fab molecule may be encoded by a separate
polynucleotide from the portion of the T cell activating bispecific
antigen binding molecule comprising the heavy chain portion of the
Fab molecule, an Fc domain subunit and optionally (part of) another
Fab molecule. When co-expressed, the heavy chain polypeptides will
associate with the light chain polypeptides to form the Fab
molecule. In another example, the portion of the T cell activating
bispecific antigen binding molecule comprising one of the two Fc
domain subunits and optionally (part of) one or more Fab molecules
could be encoded by a separate polynucleotide from the portion of
the T cell activating bispecific antigen binding molecule
comprising the the other of the two Fc domain subunits and
optionally (part of) a Fab molecule. When co-expressed, the Fc
domain subunits will associate to form the Fc domain.
[0347] In some embodiments, the isolated polynucleotide encodes the
entire T cell activating bispecific antigen binding molecule
according to the invention as described herein. In other
embodiments, the isolated polynucleotide encodes a polypeptide
comprised in the T cell activating bispecific antigen binding
molecule according to the invention as described herein.
[0348] In certain embodiments the polynucleotide or nucleic acid is
DNA. In other embodiments, a polynucleotide of the present
invention is RNA, for example, in the form of messenger RNA (mRNA).
RNA of the present invention may be single stranded or double
stranded.
Recombinant Methods
[0349] T cell activating bispecific antigen binding molecules of
the invention may be obtained, for example, by solid-state peptide
synthesis (e.g. Merrifield solid phase synthesis) or recombinant
production. For recombinant production one or more polynucleotide
encoding the T cell activating bispecific antigen binding molecule
(fragment), e.g., as described above, is isolated and inserted into
one or more vectors for further cloning and/or expression in a host
cell. Such polynucleotide may be readily isolated and sequenced
using conventional procedures. In one embodiment a vector,
preferably an expression vector, comprising one or more of the
polynucleotides of the invention is provided. Methods which are
well known to those skilled in the art can be used to construct
expression vectors containing the coding sequence of a T cell
activating bispecific antigen binding molecule (fragment) along
with appropriate transcriptional/translational control signals.
These methods include in vitro recombinant DNA techniques,
synthetic techniques and in vivo recombination/genetic
recombination. See, for example, the techniques described in
Maniatis et al., MOLECULAR CLONING: A LABORATORY MANUAL, Cold
Spring Harbor Laboratory, N.Y. (1989); and Ausubel et al., CURRENT
PROTOCOLS IN MOLECULAR BIOLOGY, Greene Publishing Associates and
Wiley Interscience, N.Y (1989). The expression vector can be part
of a plasmid, virus, or may be a nucleic acid fragment. The
expression vector includes an expression cassette into which the
polynucleotide encoding the T cell activating bispecific antigen
binding molecule (fragment) (i.e. the coding region) is cloned in
operable association with a promoter and/or other transcription or
translation control elements. As used herein, a "coding region" is
a portion of nucleic acid which consists of codons translated into
amino acids. Although a "stop codon" (TAG, TGA, or TAA) is not
translated into an amino acid, it may be considered to be part of a
coding region, if present, but any flanking sequences, for example
promoters, ribosome binding sites, transcriptional terminators,
introns, 5' and 3' untranslated regions, and the like, are not part
of a coding region. Two or more coding regions can be present in a
single polynucleotide construct, e.g. on a single vector, or in
separate polynucleotide constructs, e.g. on separate (different)
vectors. Furthermore, any vector may contain a single coding
region, or may comprise two or more coding regions, e.g. a vector
of the present invention may encode one or more polypeptides, which
are post- or co-translationally separated into the final proteins
via proteolytic cleavage. In addition, a vector, polynucleotide, or
nucleic acid of the invention may encode heterologous coding
regions, either fused or unfused to a polynucleotide encoding the T
cell activating bispecific antigen binding molecule (fragment) of
the invention, or variant or derivative thereof. Heterologous
coding regions include without limitation specialized elements or
motifs, such as a secretory signal peptide or a heterologous
functional domain. An operable association is when a coding region
for a gene product, e.g. a polypeptide, is associated with one or
more regulatory sequences in such a way as to place expression of
the gene product under the influence or control of the regulatory
sequence(s). Two DNA fragments (such as a polypeptide coding region
and a promoter associated therewith) are "operably associated" if
induction of promoter function results in the transcription of mRNA
encoding the desired gene product and if the nature of the linkage
between the two DNA fragments does not interfere with the ability
of the expression regulatory sequences to direct the expression of
the gene product or interfere with the ability of the DNA template
to be transcribed. Thus, a promoter region would be operably
associated with a nucleic acid encoding a polypeptide if the
promoter was capable of effecting transcription of that nucleic
acid. The promoter may be a cell-specific promoter that directs
substantial transcription of the DNA only in predetermined cells.
Other transcription control elements, besides a promoter, for
example enhancers, operators, repressors, and transcription
termination signals, can be operably associated with the
polynucleotide to direct cell-specific transcription. Suitable
promoters and other transcription control regions are disclosed
herein. A variety of transcription control regions are known to
those skilled in the art. These include, without limitation,
transcription control regions, which function in vertebrate cells,
such as, but not limited to, promoter and enhancer segments from
cytomegaloviruses (e.g. the immediate early promoter, in
conjunction with intron-A), simian virus 40 (e.g. the early
promoter), and retroviruses (such as, e.g. Rous sarcoma virus).
Other transcription control regions include those derived from
vertebrate genes such as actin, heat shock protein, bovine growth
hormone and rabbit a-globin, as well as other sequences capable of
controlling gene expression in eukaryotic cells. Additional
suitable transcription control regions include tissue-specific
promoters and enhancers as well as inducible promoters (e.g.
promoters inducible tetracyclins). Similarly, a variety of
translation control elements are known to those of ordinary skill
in the art. These include, but are not limited to ribosome binding
sites, translation initiation and termination codons, and elements
derived from viral systems (particularly an internal ribosome entry
site, or IRES, also referred to as a CITE sequence). The expression
cassette may also include other features such as an origin of
replication, and/or chromosome integration elements such as
retroviral long terminal repeats (LTRs), or adeno-associated viral
(AAV) inverted terminal repeats (ITRs).
[0350] Polynucleotide and nucleic acid coding regions of the
present invention may be associated with additional coding regions
which encode secretory or signal peptides, which direct the
secretion of a polypeptide encoded by a polynucleotide of the
present invention. For example, if secretion of the T cell
activating bispecific antigen binding molecule is desired, DNA
encoding a signal sequence may be placed upstream of the nucleic
acid encoding a T cell activating bispecific antigen binding
molecule of the invention or a fragment thereof. According to the
signal hypothesis, proteins secreted by mammalian cells have a
signal peptide or secretory leader sequence which is cleaved from
the mature protein once export of the growing protein chain across
the rough endoplasmic reticulum has been initiated. Those of
ordinary skill in the art are aware that polypeptides secreted by
vertebrate cells generally have a signal peptide fused to the
N-terminus of the polypeptide, which is cleaved from the translated
polypeptide to produce a secreted or "mature" form of the
polypeptide. In certain embodiments, the native signal peptide,
e.g. an immunoglobulin heavy chain or light chain signal peptide is
used, or a functional derivative of that sequence that retains the
ability to direct the secretion of the polypeptide that is operably
associated with it. Alternatively, a heterologous mammalian signal
peptide, or a functional derivative thereof, may be used. For
example, the wild-type leader sequence may be substituted with the
leader sequence of human tissue plasminogen activator (TPA) or
mouse .beta.-glucuronidase.
[0351] DNA encoding a short protein sequence that could be used to
facilitate later purification (e.g. a histidine tag) or assist in
labeling the T cell activating bispecific antigen binding molecule
may be included within or at the ends of the T cell activating
bispecific antigen binding molecule (fragment) encoding
polynucleotide.
[0352] In a further embodiment, a host cell comprising one or more
polynucleotides of the invention is provided. In certain
embodiments a host cell comprising one or more vectors of the
invention is provided. The polynucleotides and vectors may
incorporate any of the features, singly or in combination,
described herein in relation to polynucleotides and vectors,
respectively. In one such embodiment a host cell comprises (e.g.
has been transformed or transfected with) one or more vector
comprising one or more polynucleotide that encodes (part of) a T
cell activating bispecific antigen binding molecule of the
invention. As used herein, the term "host cell" refers to any kind
of cellular system which can be engineered to generate the T cell
activating bispecific antigen binding molecules of the invention or
fragments thereof. Host cells suitable for replicating and for
supporting expression of T cell activating bispecific antigen
binding molecules are well known in the art. Such cells may be
transfected or transduced as appropriate with the particular
expression vector and large quantities of vector containing cells
can be grown for seeding large scale fermenters to obtain
sufficient quantities of the T cell activating bispecific antigen
binding molecule for clinical applications. Suitable host cells
include prokaryotic microorganisms, such as E. coli, or various
eukaryotic cells, such as Chinese hamster ovary cells (CHO), insect
cells, or the like. For example, polypeptides may be produced in
bacteria in particular when glycosylation is not needed. After
expression, the polypeptide may be isolated from the bacterial cell
paste in a soluble fraction and can be further purified. In
addition to prokaryotes, eukaryotic microbes such as filamentous
fungi or yeast are suitable cloning or expression hosts for
polypeptide-encoding vectors, including fungi and yeast strains
whose glycosylation pathways have been "humanized", resulting in
the production of a polypeptide with a partially or fully human
glycosylation pattern. See Gerngross, Nat Biotech 22, 1409-1414
(2004), and Li et al., Nat Biotech 24, 210-215 (2006). Suitable
host cells for the expression of (glycosylated) polypeptides are
also derived from multicellular organisms (invertebrates and
vertebrates). Examples of invertebrate cells include plant and
insect cells. Numerous baculoviral strains have been identified
which may be used in conjunction with insect cells, particularly
for transfection of Spodoptera frugiperda cells. Plant cell
cultures can also be utilized as hosts. See e.g. U.S. Pat. Nos.
5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429
(describing PLANTIBODIES.TM. technology for producing antibodies in
transgenic plants). Vertebrate cells may also be used as hosts. For
example, mammalian cell lines that are adapted to grow in
suspension may be useful. Other examples of useful mammalian host
cell lines are monkey kidney CV1 line transformed by SV40 (COS-7);
human embryonic kidney line (293 or 293T cells as described, e.g.,
in Graham et al., J Gen Virol 36, 59 (1977)), baby hamster kidney
cells (BHK), mouse sertoli cells (TM4 cells as described, e.g., in
Mather, Biol Reprod 23, 243-251 (1980)), monkey kidney cells (CV1),
African green monkey kidney cells (VERO-76), human cervical
carcinoma cells (HELA), canine kidney cells (MDCK), buffalo rat
liver cells (BRL 3A), human lung cells (W138), human liver cells
(Hep G2), mouse mammary tumor cells (MMT 060562), TRI cells (as
described, e.g., in Mather et al., Annals N.Y. Acad Sci 383, 44-68
(1982)), MRC 5 cells, and FS4 cells. Other useful mammalian host
cell lines include Chinese hamster ovary (CHO) cells, including
dhfr.sup.- CHO cells (Urlaub et al., Proc Natl Acad Sci USA 77,
4216 (1980)); and myeloma cell lines such as YO, NS0, P3X63 and
Sp2/0. For a review of certain mammalian host cell lines suitable
for protein production, see, e.g., Yazaki and Wu, Methods in
Molecular Biology, Vol. 248 (B.K.C. Lo, ed., Humana Press, Totowa,
N.J.), pp. 255-268 (2003). Host cells include cultured cells, e.g.,
mammalian cultured cells, yeast cells, insect cells, bacterial
cells and plant cells, to name only a few, but also cells comprised
within a transgenic animal, transgenic plant or cultured plant or
animal tissue. In one embodiment, the host cell is a eukaryotic
cell, preferably a mammalian cell, such as a Chinese Hamster Ovary
(CHO) cell, a human embryonic kidney (HEK) cell or a lymphoid cell
(e.g., Y0, NS0, Sp20 cell).
[0353] Standard technologies are known in the art to express
foreign genes in these systems. Cells expressing a polypeptide
comprising either the heavy or the light chain of an antigen
binding domain such as an antibody, may be engineered so as to also
express the other of the antibody chains such that the expressed
product is an antibody that has both a heavy and a light chain.
[0354] In one embodiment, a method of producing a T cell activating
bispecific antigen binding molecule according to the invention is
provided, wherein the method comprises culturing a host cell
comprising a polynucleotide encoding the T cell activating
bispecific antigen binding molecule, as provided herein, under
conditions suitable for expression of the T cell activating
bispecific antigen binding molecule, and optionally recovering the
T cell activating bispecific antigen binding molecule from the host
cell (or host cell culture medium).
[0355] The components of the T cell activating bispecific antigen
binding molecule may be genetically fused to each other. T cell
activating bispecific antigen binding molecule can be designed such
that its components are fused directly to each other or indirectly
through a linker sequence. The composition and length of the linker
may be determined in accordance with methods well known in the art
and may be tested for efficacy. Examples of linker sequences
between different components of T cell activating bispecific
antigen binding molecules are found in the sequences provided
herein. Additional sequences may also be included to incorporate a
cleavage site to separate the individual components of the fusion
if desired, for example an endopeptidase recognition sequence.
[0356] In certain embodiments the one or more antigen binding
moieties of the T cell activating bispecific antigen binding
molecules comprise at least an antibody variable region capable of
binding an antigenic determinant. Variable regions can form part of
and be derived from naturally or non-naturally occurring antibodies
and fragments thereof. Methods to produce polyclonal antibodies and
monoclonal antibodies are well known in the art (see e.g. Harlow
and Lane, "Antibodies, a laboratory manual", Cold Spring Harbor
Laboratory, 1988). Non-naturally occurring antibodies can be
constructed using solid phase-peptide synthesis, can be produced
recombinantly (e.g. as described in U.S. Pat. No. 4,186,567) or can
be obtained, for example, by screening combinatorial libraries
comprising variable heavy chains and variable light chains (see
e.g. U.S. Pat. No. 5,969,108 to McCafferty).
[0357] Any animal species of antibody, antibody fragment, antigen
binding domain or variable region may be used in the T cell
activating bispecific antigen binding molecules of the invention.
Non-limiting antibodies, antibody fragments, antigen binding
domains or variable regions useful in the present invention can be
of murine, primate, or human origin. If the T cell activating
bispecific antigen binding molecule is intended for human use, a
chimeric form of antibody may be used wherein the constant regions
of the antibody are from a human. A humanized or fully human form
of the antibody can also be prepared in accordance with methods
well known in the art (see e.g. U.S. Pat. No. 5,565,332 to Winter).
Humanization may be achieved by various methods including, but not
limited to (a) grafting the non-human (e.g., donor antibody) CDRs
onto human (e.g. recipient antibody) framework and constant regions
with or without retention of critical framework residues (e.g.
those that are important for retaining good antigen binding
affinity or antibody functions), (b) grafting only the non-human
specificity-determining regions (SDRs or a-CDRs; the residues
critical for the antibody-antigen interaction) onto human framework
and constant regions, or (c) transplanting the entire non-human
variable domains, but "cloaking" them with a human-like section by
replacement of surface residues. Humanized antibodies and methods
of making them are reviewed, e.g., in Almagro and Fransson, Front
Biosci 13, 1619-1633 (2008), and are further described, e.g., in
Riechmann et al., Nature 332, 323-329 (1988); Queen et al., Proc
Natl Acad Sci USA 86, 10029-10033 (1989); U.S. Pat. Nos. 5,821,337,
7,527,791, 6,982,321, and 7,087,409; Jones et al., Nature 321,
522-525 (1986); Morrison et al., Proc Natl Acad Sci 81, 6851-6855
(1984); Morrison and Oi, Adv Immunol 44, 65-92 (1988); Verhoeyen et
al., Science 239, 1534-1536 (1988); Padlan, Molec Immun 31(3),
169-217 (1994); Kashmiri et al., Methods 36, 25-34 (2005)
(describing SDR (a-CDR) grafting); Padlan, Mol Immunol 28, 489-498
(1991) (describing "resurfacing"); Dall'Acqua et al., Methods 36,
43-60 (2005) (describing "FR shuffling"); and Osbourn et al.,
Methods 36, 61-68 (2005) and Klimka et al., Br J Cancer 83, 252-260
(2000) (describing the "guided selection" approach to FR
shuffling). Human antibodies and human variable regions can be
produced using various techniques known in the art. Human
antibodies are described generally in van Dijk and van de Winkel,
Curr Opin Pharmacol 5, 368-74 (2001) and Lonberg, Curr Opin Immunol
20, 450-459 (2008). Human variable regions can form part of and be
derived from human monoclonal antibodies made by the hybridoma
method (see e.g. Monoclonal Antibody Production Techniques and
Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987)).
Human antibodies and human variable regions may also be prepared by
administering an immunogen to a transgenic animal that has been
modified to produce intact human antibodies or intact antibodies
with human variable regions in response to antigenic challenge (see
e.g. Lonberg, Nat Biotech 23, 1117-1125 (2005). Human antibodies
and human variable regions may also be generated by isolating Fv
clone variable region sequences selected from human-derived phage
display libraries (see e.g., Hoogenboom et al. in Methods in
Molecular Biology 178, 1-37 (O'Brien et al., ed., Human Press,
Totowa, N.J., 2001); and McCafferty et al., Nature 348, 552-554;
Clackson et al., Nature 352, 624-628 (1991)). Phage typically
display antibody fragments, either as single-chain Fv (scFv)
fragments or as Fab fragments.
[0358] In certain embodiments, the antigen binding moieties useful
in the present invention are engineered to have enhanced binding
affinity according to, for example, the methods disclosed in U.S.
Pat. Appl. Publ. No. 2004/0132066, the entire contents of which are
hereby incorporated by reference. The ability of the T cell
activating bispecific antigen binding molecule of the invention to
bind to a specific antigenic determinant can be measured either
through an enzyme-linked immunosorbent assay (ELISA) or other
techniques familiar to one of skill in the art, e.g. surface
plasmon resonance technique (analyzed on a BIACORE T100 system)
(Liljeblad, et al., Glyco J 17, 323-329 (2000)), and traditional
binding assays (Heeley, Endocr Res 28, 217-229 (2002)). Competition
assays may be used to identify an antibody, antibody fragment,
antigen binding domain or variable domain that competes with a
reference antibody for binding to a particular antigen, e.g. an
antibody that competes with the V9 antibody for binding to CD3. In
certain embodiments, such a competing antibody binds to the same
epitope (e.g. a linear or a conformational epitope) that is bound
by the reference antibody. Detailed exemplary methods for mapping
an epitope to which an antibody binds are provided in Morris (1996)
"Epitope Mapping Protocols," in Methods in Molecular Biology vol.
66 (Humana Press, Totowa, N.J.). In an exemplary competition assay,
immobilized antigen (e.g. CD3) is incubated in a solution
comprising a first labeled antibody that binds to the antigen (e.g.
V9 antibody, described in U.S. Pat. No. 6,054,297) and a second
unlabeled antibody that is being tested for its ability to compete
with the first antibody for binding to the antigen. The second
antibody may be present in a hybridoma supernatant. As a control,
immobilized antigen is incubated in a solution comprising the first
labeled antibody but not the second unlabeled antibody. After
incubation under conditions permissive for binding of the first
antibody to the antigen, excess unbound antibody is removed, and
the amount of label associated with immobilized antigen is
measured. If the amount of label associated with immobilized
antigen is substantially reduced in the test sample relative to the
control sample, then that indicates that the second antibody is
competing with the first antibody for binding to the antigen. See
Harlow and Lane (1988) Antibodies: A Laboratory Manual ch.14 (Cold
Spring Harbor Laboratory, Cold Spring Harbor, N.Y.).
[0359] T cell activating bispecific antigen binding molecules
prepared as described herein may be purified by art-known
techniques such as high performance liquid chromatography, ion
exchange chromatography, gel electrophoresis, affinity
chromatography, size exclusion chromatography, and the like. The
actual conditions used to purify a particular protein will depend,
in part, on factors such as net charge, hydrophobicity,
hydrophilicity etc., and will be apparent to those having skill in
the art. For affinity chromatography purification an antibody,
ligand, receptor or antigen can be used to which the T cell
activating bispecific antigen binding molecule binds. For example,
for affinity chromatography purification of T cell activating
bispecific antigen binding molecules of the invention, a matrix
with protein A or protein G may be used. Sequential Protein A or G
affinity chromatography and size exclusion chromatography can be
used to isolate a T cell activating bispecific antigen binding
molecule essentially as described in the Examples. The purity of
the T cell activating bispecific antigen binding molecule can be
determined by any of a variety of well known analytical methods
including gel electrophoresis, high pressure liquid chromatography,
and the like. For example, the heavy chain fusion proteins
expressed as described in the Examples were shown to be intact and
properly assembled as demonstrated by reducing SDS-PAGE (see e.g.
FIG. 4). Three bands were resolved at approximately Mr 25,000, Mr
50,000 and Mr 75,000, corresponding to the predicted molecular
weights of the T cell activating bispecific antigen binding
molecule light chain, heavy chain and heavy chain/light chain
fusion protein.
Assays
[0360] T cell activating bispecific antigen binding molecules
provided herein may be identified, screened for, or characterized
for their physical/chemical properties and/or biological activities
by various assays known in the art.
Affinity Assays
[0361] The affinity of the T cell activating bispecific antigen
binding molecule for an Fc receptor or a target antigen can be
determined for example by surface plasmon resonance (SPR), using
standard instrumentation such as a BIAcore instrument (GE
Healthcare), and receptors or target proteins such as may be
obtained by recombinant expression. Alternatively, binding of T
cell activating bispecific antigen binding molecules for different
receptors or target antigens may be evaluated using cell lines
expressing the particular receptor or target antigen, for example
by flow cytometry (FACS). A specific illustrative and exemplary
embodiment for measuring binding affinity is described in the
following.
[0362] According to one embodiment, K.sub.D is measured by surface
plasmon resonance using a BIACORE.RTM. T100 machine (GE Healthcare)
at 25.degree. C.
[0363] To analyze the interaction between the Fc-portion and Fc
receptors, His-tagged recombinant Fc-receptor is captured by an
anti-Penta His antibody (Qiagen) immobilized on CM5 chips and the
bispecific constructs are used as analytes. Briefly,
carboxymethylated dextran biosensor chips (CM5, GE Healthcare) are
activated with N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide
hydrochloride (EDC) and N-hydroxysuccinimide (NHS) according to the
supplier's instructions. Anti Penta-His antibody is diluted with 10
mM sodium acetate, pH 5.0, to 40 .mu.g/ml before injection at a
flow rate of 5 .mu.l/min to achieve approximately 6500 response
units (RU) of coupled protein. Following the injection of the
ligand, 1 M ethanolamine is injected to block unreacted groups.
Subsequently the Fc-receptor is captured for 60 s at 4 or 10 nM.
For kinetic measurements, four-fold serial dilutions of the
bispecific antigen binding molecule (range between 500 nM and 4000
nM) are injected in HBS-EP (GE Healthcare, 10 mM HEPES, 150 mM
NaCl, 3 mM EDTA, 0.05% Surfactant P20, pH 7.4) at 25.degree. C. at
a flow rate of 30 .mu.l/min for 120 s.
[0364] To determine the affinity to the target antigen, bispecific
antigen binding molecules are captured by an anti human Fab
specific antibody (GE Healthcare) that is immobilized on an
activated CM5-sensor chip surface as described for the anti
Penta-His antibody. The final amount of coupled protein is
approximately 12000 RU. The bispecific antigen binding molecules
are captured for 90 s at 300 nM. The target antigens are passed
through the flow cells for 180 s at a concentration range from 250
to 1000 nM with a flowrate of 30 .mu.l/min. The dissociation is
monitored for 180 s.
[0365] Bulk refractive index differences are corrected for by
subtracting the response obtained on reference flow cell. The
steady state response was used to derive the dissociation constant
K.sub.D by non-linear curve fitting of the Langmuir binding
isotherm. Association rates (k.sub.on) and dissociation rates
(k.sub.off) are calculated using a simple one-to-one Langmuir
binding model (BIACORE.RTM. T100 Evaluation Software version 1.1.1)
by simultaneously fitting the association and dissociation
sensorgrams. The equilibrium dissociation constant (K.sub.D) is
calculated as the ratio k.sub.off/k.sub.on. See, e.g., Chen et al.,
J Mol Biol 293, 865-881 (1999).
Activity Assays
[0366] Biological activity of the T cell activating bispecific
antigen binding molecules of the invention can be measured by
various assays as described in the Examples. Biological activities
may for example include the induction of proliferation of T cells,
the induction of signaling in T cells, the induction of expression
of activation markers in T cells, the induction of cytokine
secretion by T cells, the induction of lysis of target cells such
as tumor cells, and the induction of tumor regression and/or the
improvement of survival.
Compositions, Formulations, and Routes of Administration
[0367] In a further aspect, the invention provides pharmaceutical
compositions comprising any of the T cell activating bispecific
antigen binding molecules provided herein, e.g., for use in any of
the below therapeutic methods. In one embodiment, a pharmaceutical
composition comprises any of the T cell activating bispecific
antigen binding molecules provided herein and a pharmaceutically
acceptable carrier. In another embodiment, a pharmaceutical
composition comprises any of the T cell activating bispecific
antigen binding molecules provided herein and at least one
additional therapeutic agent, e.g., as described below.
[0368] Further provided is a method of producing a T cell
activating bispecific antigen binding molecule of the invention in
a form suitable for administration in vivo, the method comprising
(a) obtaining a T cell activating bispecific antigen binding
molecule according to the invention, and (b) formulating the T cell
activating bispecific antigen binding molecule with at least one
pharmaceutically acceptable carrier, whereby a preparation of T
cell activating bispecific antigen binding molecule is formulated
for administration in vivo.
[0369] Pharmaceutical compositions of the present invention
comprise a therapeutically effective amount of one or more T cell
activating bispecific antigen binding molecule dissolved or
dispersed in a pharmaceutically acceptable carrier. The phrases
"pharmaceutical or pharmacologically acceptable" refers to
molecular entities and compositions that are generally non-toxic to
recipients at the dosages and concentrations employed, i.e. do not
produce an adverse, allergic or other untoward reaction when
administered to an animal, such as, for example, a human, as
appropriate. The preparation of a pharmaceutical composition that
contains at least one T cell activating bispecific antigen binding
molecule and optionally an additional active ingredient will be
known to those of skill in the art in light of the present
disclosure, as exemplified by Remington's Pharmaceutical Sciences,
18th Ed. Mack Printing Company, 1990, incorporated herein by
reference. Moreover, for animal (e.g., human) administration, it
will be understood that preparations should meet sterility,
pyrogenicity, general safety and purity standards as required by
FDA Office of Biological Standards or corresponding authorities in
other countries. Preferred compositions are lyophilized
formulations or aqueous solutions. As used herein,
"pharmaceutically acceptable carrier" includes any and all
solvents, buffers, dispersion media, coatings, surfactants,
antioxidants, preservatives (e.g. antibacterial agents, antifungal
agents), isotonic agents, absorption delaying agents, salts,
preservatives, antioxidants, proteins, drugs, drug stabilizers,
polymers, gels, binders, excipients, disintegration agents,
lubricants, sweetening agents, flavoring agents, dyes, such like
materials and combinations thereof, as would be known to one of
ordinary skill in the art (see, for example, Remington's
Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp.
1289-1329, incorporated herein by reference). Except insofar as any
conventional carrier is incompatible with the active ingredient,
its use in the therapeutic or pharmaceutical compositions is
contemplated.
[0370] The composition may comprise different types of carriers
depending on whether it is to be administered in solid, liquid or
aerosol form, and whether it need to be sterile for such routes of
administration as injection. T cell activating bispecific antigen
binding molecules of the present invention (and any additional
therapeutic agent) can be administered intravenously,
intradermally, intraarterially, intraperitoneally, intralesionally,
intracranially, intraarticularly, intraprostatically, intrasplenic
ally, intrarenally, intrapleurally, intratracheally, intranasally,
intravitreally, intravaginally, intrarectally, intratumorally,
intramuscularly, intraperitoneally, subcutaneously,
subconjunctivally, intravesicularlly, mucosally,
intrapericardially, intraumbilically, intraocularally, orally,
topically, locally, by inhalation (e.g. aerosol inhalation),
injection, infusion, continuous infusion, localized perfusion
bathing target cells directly, via a catheter, via a lavage, in
cremes, in lipid compositions (e.g. liposomes), or by other method
or any combination of the forgoing as would be known to one of
ordinary skill in the art (see, for example, Remington's
Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990,
incorporated herein by reference). Parenteral administration, in
particular intravenous injection, is most commonly used for
administering polypeptide molecules such as the T cell activating
bispecific antigen binding molecules of the invention.
[0371] Parenteral compositions include those designed for
administration by injection, e.g. subcutaneous, intradermal,
intralesional, intravenous, intraarterial intramuscular,
intrathecal or intraperitoneal injection. For injection, the T cell
activating bispecific antigen binding molecules of the invention
may be formulated in aqueous solutions, preferably in
physiologically compatible buffers such as Hanks' solution,
Ringer's solution, or physiological saline buffer. The solution may
contain formulatory agents such as suspending, stabilizing and/or
dispersing agents. Alternatively, the T cell activating bispecific
antigen binding molecules may be in powder form for constitution
with a suitable vehicle, e.g., sterile pyrogen-free water, before
use. Sterile injectable solutions are prepared by incorporating the
T cell activating bispecific antigen binding molecules of the
invention in the required amount in the appropriate solvent with
various of the other ingredients enumerated below, as required.
Sterility may be readily accomplished, e.g., by filtration through
sterile filtration membranes. Generally, dispersions are prepared
by incorporating the various sterilized active ingredients into a
sterile vehicle which contains the basic dispersion medium and/or
the other ingredients. In the case of sterile powders for the
preparation of sterile injectable solutions, suspensions or
emulsion, the preferred methods of preparation are vacuum-drying or
freeze-drying techniques which yield a powder of the active
ingredient plus any additional desired ingredient from a previously
sterile-filtered liquid medium thereof. The liquid medium should be
suitably buffered if necessary and the liquid diluent first
rendered isotonic prior to injection with sufficient saline or
glucose. The composition must be stable under the conditions of
manufacture and storage, and preserved against the contaminating
action of microorganisms, such as bacteria and fungi. It will be
appreciated that endotoxin contamination should be kept minimally
at a safe level, for example, less that 0.5 ng/mg protein. Suitable
pharmaceutically acceptable carriers include, but are not limited
to: buffers such as phosphate, citrate, and other organic acids;
antioxidants including ascorbic acid and methionine; preservatives
(such as octadecyldimethylbenzyl ammonium chloride; hexamethonium
chloride; benzalkonium chloride; benzethonium chloride; phenol,
butyl or benzyl alcohol; alkyl parabens such as methyl or propyl
paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and
m-cresol); low molecular weight (less than about 10 residues)
polypeptides; proteins, such as serum albumin, gelatin, or
immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone;
amino acids such as glycine, glutamine, asparagine, histidine,
arginine, or lysine; monosaccharides, disaccharides, and other
carbohydrates including glucose, mannose, or dextrins; chelating
agents such as EDTA; sugars such as sucrose, mannitol, trehalose or
sorbitol; salt-forming counter-ions such as sodium; metal complexes
(e.g. Zn-protein complexes); and/or non-ionic surfactants such as
polyethylene glycol (PEG). Aqueous injection suspensions may
contain compounds which increase the viscosity of the suspension,
such as sodium carboxymethyl cellulose, sorbitol, dextran, or the
like. Optionally, the suspension may also contain suitable
stabilizers or agents which increase the solubility of the
compounds to allow for the preparation of highly concentrated
solutions. Additionally, suspensions of the active compounds may be
prepared as appropriate oily injection suspensions. Suitable
lipophilic solvents or vehicles include fatty oils such as sesame
oil, or synthetic fatty acid esters, such as ethyl cleats or
triglycerides, or liposomes.
[0372] Active ingredients may be entrapped in microcapsules
prepared, for example, by coacervation techniques or by interfacial
polymerization, for example, hydroxymethylcellulose or
gelatin-microcapsules and poly-(methylmethacylate) microcapsules,
respectively, in colloidal drug delivery systems (for example,
liposomes, albumin microspheres, microemulsions, nano-particles and
nanocapsules) or in macroemulsions. Such techniques are disclosed
in Remington's Pharmaceutical Sciences (18th Ed. Mack Printing
Company, 1990). Sustained-release preparations may be prepared.
Suitable examples of sustained-release preparations include
semipermeable matrices of solid hydrophobic polymers containing the
polypeptide, which matrices are in the form of shaped articles,
e.g. films, or microcapsules. In particular embodiments, prolonged
absorption of an injectable composition can be brought about by the
use in the compositions of agents delaying absorption, such as, for
example, aluminum monostearate, gelatin or combinations
thereof.
[0373] In addition to the compositions described previously, the T
cell activating bispecific antigen binding molecules may also be
formulated as a depot preparation. Such long acting formulations
may be administered by implantation (for example subcutaneously or
intramuscularly) or by intramuscular injection. Thus, for example,
the T cell activating bispecific antigen binding molecules may be
formulated with suitable polymeric or hydrophobic materials (for
example as an emulsion in an acceptable oil) or ion exchange
resins, or as sparingly soluble derivatives, for example, as a
sparingly soluble salt.
[0374] Pharmaceutical compositions comprising the T cell activating
bispecific antigen binding molecules of the invention may be
manufactured by means of conventional mixing, dissolving,
emulsifying, encapsulating, entrapping or lyophilizing processes.
Pharmaceutical compositions may be formulated in conventional
manner using one or more physiologically acceptable carriers,
diluents, excipients or auxiliaries which facilitate processing of
the proteins into preparations that can be used pharmaceutically.
Proper formulation is dependent upon the route of administration
chosen.
[0375] The T cell activating bispecific antigen binding molecules
may be formulated into a composition in a free acid or base,
neutral or salt form. Pharmaceutically acceptable salts are salts
that substantially retain the biological activity of the free acid
or base. These include the acid addition salts, e.g., those formed
with the free amino groups of a proteinaceous composition, or which
are formed with inorganic acids such as for example, hydrochloric
or phosphoric acids, or such organic acids as acetic, oxalic,
tartaric or mandelic acid. Salts formed with the free carboxyl
groups can also be derived from inorganic bases such as for
example, sodium, potassium, ammonium, calcium or ferric hydroxides;
or such organic bases as isopropylamine, trimethylamine, histidine
or procaine. Pharmaceutical salts tend to be more soluble in
aqueous and other protic solvents than are the corresponding free
base forms.
Therapeutic Methods and Compositions
[0376] Any of the T cell activating bispecific antigen binding
molecules provided herein may be used in therapeutic methods. T
cell activating bispecific antigen binding molecules of the
invention may be used as immunotherapeutic agents, for example in
the treatment of cancers.
[0377] For use in therapeutic methods, T cell activating bispecific
antigen binding molecules of the invention would be formulated,
dosed, and administered in a fashion consistent with good medical
practice. Factors for consideration in this context include the
particular disorder being treated, the particular mammal being
treated, the clinical condition of the individual patient, the
cause of the disorder, the site of delivery of the agent, the
method of administration, the scheduling of administration, and
other factors known to medical practitioners.
[0378] In one aspect, T cell activating bispecific antigen binding
molecules of the invention for use as a medicament are provided. In
further aspects, T cell activating bispecific antigen binding
molecules of the invention for use in treating a disease are
provided. In certain embodiments, T cell activating bispecific
antigen binding molecules of the invention for use in a method of
treatment are provided. In one embodiment, the invention provides a
T cell activating bispecific antigen binding molecule as described
herein for use in the treatment of a disease in an individual in
need thereof. In certain embodiments, the invention provides a T
cell activating bispecific antigen binding molecule for use in a
method of treating an individual having a disease comprising
administering to the individual a therapeutically effective amount
of the T cell activating bispecific antigen binding molecule. In
certain embodiments the disease to be treated is a proliferative
disorder. In a particular embodiment the disease is cancer. In
certain embodiments the method further comprises administering to
the individual a therapeutically effective amount of at least one
additional therapeutic agent, e.g., an anti-cancer agent if the
disease to be treated is cancer. In further embodiments, the
invention provides a T cell activating bispecific antigen binding
molecule as described herein for use in inducing lysis of a target
cell, particularly a tumor cell. In certain embodiments, the
invention provides a T cell activating bispecific antigen binding
molecule for use in a method of inducing lysis of a target cell,
particularly a tumor cell, in an individual comprising
administering to the individual an effective amount of the T cell
activating bispecific antigen binding molecule to induce lysis of a
target cell. An "individual" according to any of the above
embodiments is a mammal, preferably a human.
[0379] In a further aspect, the invention provides for the use of a
T cell activating bispecific antigen binding molecule of the
invention in the manufacture or preparation of a medicament. In one
embodiment the medicament is for the treatment of a disease in an
individual in need thereof. In a further embodiment, the medicament
is for use in a method of treating a disease comprising
administering to an individual having the disease a therapeutically
effective amount of the medicament. In certain embodiments the
disease to be treated is a proliferative disorder. In a particular
embodiment the disease is cancer. In one embodiment, the method
further comprises administering to the individual a therapeutically
effective amount of at least one additional therapeutic agent,
e.g., an anti-cancer agent if the disease to be treated is cancer.
In a further embodiment, the medicament is for inducing lysis of a
target cell, particularly a tumor cell. In still a further
embodiment, the medicament is for use in a method of inducing lysis
of a target cell, particularly a tumor cell, in an individual
comprising administering to the individual an effective amount of
the medicament to induce lysis of a target cell. An "individual"
according to any of the above embodiments may be a mammal,
preferably a human.
[0380] In a further aspect, the invention provides a method for
treating a disease. In one embodiment, the method comprises
administering to an individual having such disease a
therapeutically effective amount of a T cell activating bispecific
antigen binding molecule of the invention. In one embodiment a
composition is administered to said individual, comprising the T
cell activating bispecific antigen binding molecule of the
invention in a pharmaceutically acceptable form. In certain
embodiments the disease to be treated is a proliferative disorder.
In a particular embodiment the disease is cancer. In certain
embodiments the method further comprises administering to the
individual a therapeutically effective amount of at least one
additional therapeutic agent, e.g., an anti-cancer agent if the
disease to be treated is cancer. An "individual" according to any
of the above embodiments may be a mammal, preferably a human.
[0381] In a further aspect, the invention provides a method for
inducing lysis of a target cell, particularly a tumor cell. In one
embodiment the method comprises contacting a target cell with a T
cell activating bispecific antigen binding molecule of the
invention in the presence of a T cell, particularly a cytotoxic T
cell. In a further aspect, a method for inducing lysis of a target
cell, particularly a tumor cell, in an individual is provided. In
one such embodiment, the method comprises administering to the
individual an effective amount of a T cell activating bispecific
antigen binding molecule to induce lysis of a target cell. In one
embodiment, an "individual" is a human.
[0382] In certain embodiments the disease to be treated is a
proliferative disorder, particularly cancer. Non-limiting examples
of cancers include bladder cancer, brain cancer, head and neck
cancer, pancreatic cancer, lung cancer, breast cancer, ovarian
cancer, uterine cancer, cervical cancer, endometrial cancer,
esophageal cancer, colon cancer, colorectal cancer, rectal cancer,
gastric cancer, prostate cancer, blood cancer, skin cancer,
squamous cell carcinoma, bone cancer, and kidney cancer. Other cell
proliferation disorders that can be treated using a T cell
activating bispecific antigen binding molecule of the present
invention include, but are not limited to neoplasms located in the:
abdomen, bone, breast, digestive system, liver, pancreas,
peritoneum, endocrine glands (adrenal, parathyroid, pituitary,
testicles, ovary, thymus, thyroid), eye, head and neck, nervous
system (central and peripheral), lymphatic system, pelvic, skin,
soft tissue, spleen, thoracic region, and urogenital system. Also
included are pre-cancerous conditions or lesions and cancer
metastases. In certain embodiments the cancer is chosen from the
group consisting of renal cell cancer, skin cancer, lung cancer,
colorectal cancer, breast cancer, brain cancer, head and neck
cancer, gastric cancer, pancreatic cancer, ovarian cancer. In one
embodiment, the cancer is a solid tumor. In one embodiment, the
cancer is a HER2-positive cancer (i.e. a cancer expressing HER2).
In a particular embodiment, the cancer is breast cancer,
particularly HER2-positive breast cancer. In another embodiment,
the cancer is gastric cancer, particularly HER2-positive gastric
cancer. In still another embodiment, the cancer is colorectal
cancer, particularly HER2-positive colorectal cancer. A skilled
artisan readily recognizes that in many cases the T cell activating
bispecific antigen binding molecule may not provide a cure but may
only provide partial benefit. In some embodiments, a physiological
change having some benefit is also considered therapeutically
beneficial. Thus, in some embodiments, an amount of T cell
activating bispecific antigen binding molecule that provides a
physiological change is considered an "effective amount" or a
"therapeutically effective amount". The subject, patient, or
individual in need of treatment is typically a mammal, more
specifically a human.
[0383] In some embodiments, an effective amount of a T cell
activating bispecific antigen binding molecule of the invention is
administered to a cell. In other embodiments, a therapeutically
effective amount of a T cell activating bispecific antigen binding
molecule of the invention is administered to an individual for the
treatment of disease.
[0384] For the prevention or treatment of disease, the appropriate
dosage of a T cell activating bispecific antigen binding molecule
of the invention (when used alone or in combination with one or
more other additional therapeutic agents) will depend on the type
of disease to be treated, the route of administration, the body
weight of the patient, the type of T cell activating bispecific
antigen binding molecule, the severity and course of the disease,
whether the T cell activating bispecific antigen binding molecule
is administered for preventive or therapeutic purposes, previous or
concurrent therapeutic interventions, the patient's clinical
history and response to the T cell activating bispecific antigen
binding molecule, and the discretion of the attending physician.
The practitioner responsible for administration will, in any event,
determine the concentration of active ingredient(s) in a
composition and appropriate dose(s) for the individual subject.
Various dosing schedules including but not limited to single or
multiple administrations over various time-points, bolus
administration, and pulse infusion are contemplated herein.
[0385] The T cell activating bispecific antigen binding molecule is
suitably administered to the patient at one time or over a series
of treatments. Depending on the type and severity of the disease,
about 1 .mu.g/kg to 15 mg/kg (e.g. 0.1 mg/kg-10 mg/kg) of T cell
activating bispecific antigen binding molecule can be an initial
candidate dosage for administration to the patient, whether, for
example, by one or more separate administrations, or by continuous
infusion. One typical daily dosage might range from about 1
.mu.g/kg to 100 mg/kg or more, depending on the factors mentioned
above. For repeated administrations over several days or longer,
depending on the condition, the treatment would generally be
sustained until a desired suppression of disease symptoms occurs.
One exemplary dosage of the T cell activating bispecific antigen
binding molecule would be in the range from about 0.005 mg/kg to
about 10 mg/kg. In other non-limiting examples, a dose may also
comprise from about 1 microgram/kg body weight, about 5
microgram/kg body weight, about 10 microgram/kg body weight, about
50 microgram/kg body weight, about 100 microgram/kg body weight,
about 200 microgram/kg body weight, about 350 microgram/kg body
weight, about 500 microgram/kg body weight, about 1 milligram/kg
body weight, about 5 milligram/kg body weight, about 10
milligram/kg body weight, about 50 milligram/kg body weight, about
100 milligram/kg body weight, about 200 milligram/kg body weight,
about 350 milligram/kg body weight, about 500 milligram/kg body
weight, to about 1000 mg/kg body weight or more per administration,
and any range derivable therein. In non-limiting examples of a
derivable range from the numbers listed herein, a range of about 5
mg/kg body weight to about 100 mg/kg body weight, about 5
microgram/kg body weight to about 500 milligram/kg body weight,
etc., can be administered, based on the numbers described above.
Thus, one or more doses of about 0.5 mg/kg, 2.0 mg/kg, 5.0 mg/kg or
10 mg/kg (or any combination thereof) may be administered to the
patient. Such doses may be administered intermittently, e.g. every
week or every three weeks (e.g. such that the patient receives from
about two to about twenty, or e.g. about six doses of the T cell
activating bispecific antigen binding molecule). An initial higher
loading dose, followed by one or more lower doses may be
administered. However, other dosage regimens may be useful. The
progress of this therapy is easily monitored by conventional
techniques and assays.
[0386] The T cell activating bispecific antigen binding molecules
of the invention will generally be used in an amount effective to
achieve the intended purpose. For use to treat or prevent a disease
condition, the T cell activating bispecific antigen binding
molecules of the invention, or pharmaceutical compositions thereof,
are administered or applied in a therapeutically effective amount.
Determination of a therapeutically effective amount is well within
the capabilities of those skilled in the art, especially in light
of the detailed disclosure provided herein.
[0387] For systemic administration, a therapeutically effective
dose can be estimated initially from in vitro assays, such as cell
culture assays. A dose can then be formulated in animal models to
achieve a circulating concentration range that includes the
IC.sub.50 as determined in cell culture. Such information can be
used to more accurately determine useful doses in humans.
[0388] Initial dosages can also be estimated from in vivo data,
e.g., animal models, using techniques that are well known in the
art. One having ordinary skill in the art could readily optimize
administration to humans based on animal data.
[0389] Dosage amount and interval may be adjusted individually to
provide plasma levels of the T cell activating bispecific antigen
binding molecules which are sufficient to maintain therapeutic
effect. Usual patient dosages for administration by injection range
from about 0.1 to 50 mg/kg/day, typically from about 0.5 to 1
mg/kg/day. Therapeutically effective plasma levels may be achieved
by administering multiple doses each day. Levels in plasma may be
measured, for example, by HPLC.
[0390] In cases of local administration or selective uptake, the
effective local concentration of the T cell activating bispecific
antigen binding molecules may not be related to plasma
concentration. One having skill in the art will be able to optimize
therapeutically effective local dosages without undue
experimentation.
[0391] A therapeutically effective dose of the T cell activating
bispecific antigen binding molecules described herein will
generally provide therapeutic benefit without causing substantial
toxicity. Toxicity and therapeutic efficacy of a T cell activating
bispecific antigen binding molecule can be determined by standard
pharmaceutical procedures in cell culture or experimental animals.
Cell culture assays and animal studies can be used to determine the
LD.sub.50 (the dose lethal to 50% of a population) and the
ED.sub.50 (the dose therapeutically effective in 50% of a
population). The dose ratio between toxic and therapeutic effects
is the therapeutic index, which can be expressed as the ratio
LD.sub.50/ED.sub.50. T cell activating bispecific antigen binding
molecules that exhibit large therapeutic indices are preferred. In
one embodiment, the T cell activating bispecific antigen binding
molecule according to the present invention exhibits a high
therapeutic index. The data obtained from cell culture assays and
animal studies can be used in formulating a range of dosages
suitable for use in humans. The dosage lies preferably within a
range of circulating concentrations that include the ED.sub.50 with
little or no toxicity. The dosage may vary within this range
depending upon a variety of factors, e.g., the dosage form
employed, the route of administration utilized, the condition of
the subject, and the like. The exact formulation, route of
administration and dosage can be chosen by the individual physician
in view of the patient's condition (see, e.g., Fingl et al., 1975,
in: The Pharmacological Basis of Therapeutics, Ch. 1, p. 1,
incorporated herein by reference in its entirety).
[0392] The attending physician for patients treated with T cell
activating bispecific antigen binding molecules of the invention
would know how and when to terminate, interrupt, or adjust
administration due to toxicity, organ dysfunction, and the like.
Conversely, the attending physician would also know to adjust
treatment to higher levels if the clinical response were not
adequate (precluding toxicity). The magnitude of an administered
dose in the management of the disorder of interest will vary with
the severity of the condition to be treated, with the route of
administration, and the like. The severity of the condition may,
for example, be evaluated, in part, by standard prognostic
evaluation methods. Further, the dose and perhaps dose frequency
will also vary according to the age, body weight, and response of
the individual patient.
Other Agents and Treatments
[0393] The T cell activating bispecific antigen binding molecules
of the invention may be administered in combination with one or
more other agents in therapy. For instance, a T cell activating
bispecific antigen binding molecule of the invention may be
co-administered with at least one additional therapeutic agent. The
term "therapeutic agent" encompasses any agent administered to
treat a symptom or disease in an individual in need of such
treatment. Such additional therapeutic agent may comprise any
active ingredients suitable for the particular indication being
treated, preferably those with complementary activities that do not
adversely affect each other. In certain embodiments, an additional
therapeutic agent is an immunomodulatory agent, a cytostatic agent,
an inhibitor of cell adhesion, a cytotoxic agent, an activator of
cell apoptosis, or an agent that increases the sensitivity of cells
to apoptotic inducers. In a particular embodiment, the additional
therapeutic agent is an anti-cancer agent, for example a
microtubule disruptor, an antimetabolite, a topoisomerase
inhibitor, a DNA intercalator, an alkylating agent, a hormonal
therapy, a kinase inhibitor, a receptor antagonist, an activator of
tumor cell apoptosis, or an antiangiogenic agent.
[0394] Such other agents are suitably present in combination in
amounts that are effective for the purpose intended. The effective
amount of such other agents depends on the amount of T cell
activating bispecific antigen binding molecule used, the type of
disorder or treatment, and other factors discussed above. The T
cell activating bispecific antigen binding molecules are generally
used in the same dosages and with administration routes as
described herein, or about from 1 to 99% of the dosages described
herein, or in any dosage and by any route that is
empirically/clinically determined to be appropriate.
[0395] Such combination therapies noted above encompass combined
administration (where two or more therapeutic agents are included
in the same or separate compositions), and separate administration,
in which case, administration of the T cell activating bispecific
antigen binding molecule of the invention can occur prior to,
simultaneously, and/or following, administration of the additional
therapeutic agent and/or adjuvant. T cell activating bispecific
antigen binding molecules of the invention can also be used in
combination with radiation therapy.
Articles of Manufacture
[0396] In another aspect of the invention, an article of
manufacture containing materials useful for the treatment,
prevention and/or diagnosis of the disorders described above is
provided. The article of manufacture comprises a container and a
label or package insert on or associated with the container.
Suitable containers include, for example, bottles, vials, syringes,
IV solution bags, etc. The containers may be formed from a variety
of materials such as glass or plastic. The container holds a
composition which is by itself or combined with another composition
effective for treating, preventing and/or diagnosing the condition
and may have a sterile access port (for example the container may
be an intravenous solution bag or a vial having a stopper
pierceable by a hypodermic injection needle). At least one active
agent in the composition is a T cell activating bispecific antigen
binding molecule of the invention. The label or package insert
indicates that the composition is used for treating the condition
of choice. Moreover, the article of manufacture may comprise (a) a
first container with a composition contained therein, wherein the
composition comprises a T cell activating bispecific antigen
binding molecule of the invention; and (b) a second container with
a composition contained therein, wherein the composition comprises
a further cytotoxic or otherwise therapeutic agent. The article of
manufacture in this embodiment of the invention may further
comprise a package insert indicating that the compositions can be
used to treat a particular condition. Alternatively, or
additionally, the article of manufacture may further comprise a
second (or third) container comprising a
pharmaceutically-acceptable buffer, such as bacteriostatic water
for injection (BWFI), phosphate-buffered saline, Ringer's solution
and dextrose solution. It may further include other materials
desirable from a commercial and user standpoint, including other
buffers, diluents, filters, needles, and syringes.
EXAMPLES
[0397] The following are examples of methods and compositions of
the invention. It is understood that various other embodiments may
be practiced, given the general description provided above.
General Methods
Recombinant DNA Techniques
[0398] Standard methods were used to manipulate DNA as described in
Sambrook et al., Molecular cloning: A laboratory manual; Cold
Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989. The
molecular biological reagents were used according to the
manufacturers' instructions. General information regarding the
nucleotide sequences of human immunoglobulins light and heavy
chains is given in: Kabat, E. A. et al., (1991) Sequences of
Proteins of Immunological Interest, 5.sup.th ed., NIH Publication
No. 91-3242.
DNA Sequencing
[0399] DNA sequences were determined by double strand
sequencing.
Gene Synthesis
[0400] Desired gene segments where required were either generated
by PCR using appropriate templates or were synthesized by Geneart
AG (Regensburg, Germany) from synthetic oligonucleotides and PCR
products by automated gene synthesis. In cases where no exact gene
sequence was available, oligonucleotide primers were designed based
on sequences from closest homologues and the genes were isolated by
RT-PCR from RNA originating from the appropriate tissue. The gene
segments flanked by singular restriction endonuclease cleavage
sites were cloned into standard cloning/sequencing vectors. The
plasmid DNA was purified from transformed bacteria and
concentration determined by UV spectroscopy. The DNA sequence of
the subcloned gene fragments was confirmed by DNA sequencing. Gene
segments were designed with suitable restriction sites to allow
sub-cloning into the respective expression vectors. All constructs
were designed with a 5'-end DNA sequence coding for a leader
peptide which targets proteins for secretion in eukaryotic
cells.
Example 1
Preparation of Anti-p95HER2/Anti-CD3 T Cell Bispecific (TCB)
Molecules
[0401] The following molecules were prepared in this example;
schematic illustrations thereof are shown in FIG. 2: [0402] A. "2+1
IgG CrossFab, inverted" with charge modifications (VH/VL exchange
in CD3 binder, charge modification in p95HER2 binder) (FIG. 2A, SEQ
ID NOs 22-25). [0403] B. "2+1 IgG CrossFab, inverted" without
charge modifications (CH1/CL exchange in CD3 binder) (FIG. 2B, SEQ
ID NOs 26-29).
[0404] The DNA sequences encoding the variable heavy and light
chain regions of the CD3 and p95HER2 binders were subcloned in
frame with the respective constant regions which are pre-inserted
into the respective recipient mammalian expression vector. Protein
expression is driven by an MPSV promoter. Polyadenylation is driven
by a synthetic polyA signal sequence located at the 3' end of the
CDS. In addition each vector contains an EBV OriP sequence for
autosomal replication.
[0405] For production of the molecules, CHO-K1 cells growing in
suspension were co-transfected with the respective expression
vectors using eviFect (Evitria) as transfection reagent. The cells
were transfected with the corresponding expression vectors in a
1:2:1:1 ratio (A: "vector heavy chain (VH-CH1-VL-CH1-CH2-CH3)":
"vector light chain (VL-CL)": "vector heavy chain
(VH-CH1-CH2-CH3)": "vector light chain (VH-CL)"; B: "vector heavy
chain (VH-CH1-VH-CL-CH2-CH3)": "vector light chain (VL-CL)":
"vector heavy chain (VH-CH1-CH2-CH3)": "vector light chain
(VL-CH)").
[0406] For transfection, CHO-K1 cells were cultivated in suspension
serum free in eviMake culture medium (Evitria). After 7 days at
37.degree. C. in an incubator with a 5% CO.sub.2 atmosphere,
supernatant was collected for purification by centrifugation,
sterile filtered (0.22 .mu.m filter) and kept at 4.degree. C.
[0407] The titer of the molecules in the culture medium was
determined by Protein A-HPLC (Table 2). Calculation of the titer is
based on a two-step process and includes binding of Fc-containing
molecules to Protein A at pH 8.0 and release in a step elution at
pH 2.5. Both buffers used for the analysis contained Tris (10 mM),
glycine (50 mM), and NaCl (100 mM) and were adjusted to the
respective pHs (8 and 2.5). The column body was an Upchurch
2.times.20 mm pre-column with an internal volume of .about.63 .mu.l
packed with POROS 20A. After initial calibration, 100 .mu.l of each
sample was injected with a flow rate of 0.5 ml/min. After 0.67
minutes the sample was eluted with a pH step to pH 2.5.
Quantitation was done by determination of 280 nm absorbance and
calculation using a standard curve with a concentration range of
human IgG.sub.1 from 16 to 166 mg/l.
[0408] The secreted proteins were purified from cell culture
supernatants by affinity chromatography using Protein A affinity
chromatography, followed by a size exclusion chromatographic
step.
[0409] For affinity chromatography supernatant was loaded on a
HiTrap ProteinA HP column (CV=5 mL, GE Healthcare) equilibrated
with 25 ml 20 mM sodium phosphate, 20 mM sodium citrate, pH 7.5.
Unbound protein was removed by washing with at least 10 column
volumes 20 mM sodium phosphate, 20 mM sodium citrate, pH 7.5, and
target protein was eluted in 6 column volumes 20 mM sodium citrate,
100 mM sodium chloride, 100 mM glycine, pH 3.0. Protein solution
was neutralized by adding 1/10 of 0.5 M sodium phosphate, pH 8.0.
For in-process analytics after Protein A chromatography, the purity
and molecular weight of the molecules in the single fractions were
analyzed by SDS-PAGE in the absence of a reducing agent and
staining with Coomassie (InstantBlue.TM., Expedeon). The
NuPAGE.RTM. Pre-Cast gel system (4-12% Bis-Tris, Invitrogen) was
used according to the manufacturer's instruction. Selected
fractions of target protein were concentrated and filtrated prior
to loading on a HiLoad Superdex 200 column (GE Healthcare)
equilibrated with 20 mM histidine, 140 mM sodium chloride, 0.01%
Tween-20, pH 6.0 (for molecule A) or 20 mM histidine, 140 mM sodium
chloride, pH 6.0 (for molecule B).
[0410] The protein concentration of purified protein samples was
determined by measuring the optical density (OD) at 280 nm, using
the molar extinction coefficient calculated on the basis of the
amino acid sequence.
[0411] The aggregate content of the molecules was analyzed using a
TSKgel G3000 SW XL analytical size-exclusion column (Tosoh) in 25
mM K.sub.2HPO.sub.4, 125 mM NaCl, 200 mM L-arginine
monohydrocloride, 0.02% (w/v) NaN.sub.3, pH 6.7 running buffer at
25.degree. C.
[0412] Purity and molecular weight of molecules after the final
purification step were analyzed by CE-SDS analyses in the presence
and absence of a reducing agent. The Caliper LabChip GXII system
(Caliper lifescience) was used according to the manufacturer's
instruction (FIG. 3 and Table 2).
[0413] Mass spectrometry analysis of the molecules was performed on
an Agilent LC-MS system (Agilent Technologies, Santa Clara, Calif.,
USA). The chromatography system (Agilent 1260 Infinity) was coupled
on an Agilent 6224 TOF LC/MS ESI device. About 5 .mu.g of sample
were injected on a NUCLEOGEL RP1000-8, 250 mm.times.4.6 mm column
(MACHEREY-NAGEL GmbH & Co. KG, Duren, Germany) at a flow rate
of 1 ml/min at 40.degree. C. The mobile phase was as follows A: 5%
acetonitrile, 0.05% formic acid, and B: 95% acetonitrile, 0.05%
formic acid. To apply an elution gradient, 15% B was raised to 60%
B within 10 min, then to 100% B in 2.5 min. The mass spectrometer
was measuring in high resolution mode 4 GHz positive, and recorded
a range from 500 to 3200 m/z. The m/z spectra were deconvoluted
manually with the MassAnalyzer 2.4.1 from Roche (Hoffman-La Roche,
Ltd).
[0414] Molecules A and B were produced and purified essentially
following the same method. The final recovery was highest for
molecule B (13%, see Table 1), but the LC-MS analysis of light
chain mispairing revealed that only 10-20% of that molecule was
correctly assembled. The quality of the molecule A was clearly
better, with around 95% of correctly assembled molecule in the
LC-MS analysis.
[0415] The non-reduced CE-SDS profile was also better for molecule
A with less side products than in molecule B (Table 2, FIG. 3) and
the final quality was very good with 99% monomer content (Table 1).
The SDS-PAGE of the fractions after the Protein A purification
showed also little side products for molecule A (FIG. 4, this
analysis is not available for molecule B).
TABLE-US-00002 TABLE 1 Summary of production and purification of
anti-p95HER2/ anti-CD3 TCB molecules with and without charge
modifications. Analytical SEC Titer Recovery Yield
(HMW/Monomer/LMW) Molecule [mg/l] [%] [mg/l] [%] A 14 7.8 1.07
0.5/99.5/0 B 30 13 3.85 0.6/99.4/0
TABLE-US-00003 TABLE 2 CE-SDS analyses (non-reduced) of
anti-p95HER2/ anti-CD3 TCB molecules with and without charge
modifications. Molecule Peak # Size [kDa] Purity [%] A 1 205 96 2
214 4 B 1 173 10 2 190 11 3 204 75 4 215 4
[0416] Molecule A prepared in this Example will be referred to as
p95HER2 TCB in the following.
Example 2
Expression Levels of p95HER2 on Different Target Cells and Binding
of p95HER2 TCB to p95HER2 Positive Target Cells
[0417] The expression of p95HER2 on p95HER2 transfected MCF10A
(MCF10A_p95Her2) and HCC-1954 was determined by flow cytometry
using the anti-p95HER2 IgG clone 32H2 (Parra-Palau et al., Cancer
Res 70, 8537-46 (2010)). The expression of p95HER2 or HER2 of
different target cells (MCF10A transfected to express either
p95HER2, HER2, both or an empty vector) was determined by Western
Blot using an anti-HER2 antibody. The binding of p95HER2 TCB to
MCF10A transfected to express either p95HER2, HER2 or both or an
empty vector was tested by flow cytometry.
[0418] For Western Blot analysis, Protein extracts were obtained
from lysed MCF10A transfectants. Samples were mixed with loading
buffer containing DTT (250 mM Tris-HCl pH 6.8, 10% SDS, 30%
glycerol, 0.5 mM 1.4-dithiothreitol DTT (Roche, #10780984001), 0.2%
bromophenol blue) and incubated at 99.degree. C. for 5 min before
resolving proteins by SDS-polyacrylamide gel electrophoresis (PAGE)
and transferring them to nitrocellulose membranes. Proteins were
detected by autoradiography upon addition of Immobilon western
chemiluminescent HRP substrate (#WBKLS0500, Millipore). HER2
(c-erbB-2) (CB11) (mouse monoclonal, 1:1000), (#MU134-UCE,
BioGenex) was used as primary antibody. Secondary antibody: ECL
Mouse IgG, HRP-linked whole Ab (1:4000) (Amersham GE Healthcare,
#NA931). For analysis of p95HER2 TCB binding by flow cytometry
MCF10A transfectants were harvested with StemPro Accutase
(Invitrogen, #A11105-01) and incubated with p95HER2 TCB for one
hour before staining with an anti-human Alexa488 secondary antibody
for 30 min. Samples were acquired in a FACSCalibur flow cytometer
(BD Biosciences). The expression levels on MCF10A_p95HER2 and
HCC-1954 were determined by staining of the cells with anti-p95HER2
clone 32H2 for 30 min at 4.degree. C. followed by staining with
FITC-conjugated goat anti-mouse IgG (AbD Serotec) for 30 min at
4.degree. C. The fluorescence was measured using a BD FACS
CantoII.
[0419] Western blot of MCF10A transfectants verified the expression
of p95HER2, HER2 or the combination (FIG. 5A). Cells shown in FIG.
5A were incubated with 2 .mu.g/ml of p95HER2 TCB and analyzed by
flow cytometry (FIG. 5B). There was significant binding of p95HER2
TCB to p95HER2 and p95HER2-HER2 expressing MCF10A detectable,
whereas there was no binding to MCF10A-Vector cells. FIG. 5C shows
the comparison of p95HER2 expression levels on MCF10A_p95Her2 and
HCC-1954 cells analyzed by flow cytometry. MCF10A_p95Her2 expressed
approximately 5.times. higher p95HER2 on the cell surface compared
to the HER2 overexpressing mammary gland derived cell line HCC-1954
(ATCC, CRL-2238).
Example 3
Lysis of MCF10A Transfectants and HCC-1954 and Subsequent T Cell
Activation Mediated by p95HER2 TCB
[0420] The lysis of target cells and subsequent T cell activation
mediated by p95HER2 TCB was assessed using MCF10A_p95Her2,
MCF10A_Her2, MCF10A_p95Her2-Her2 and MCF10A_Vector as well as
HCC-1954. Human PBMCs were used as effectors and tumor lysis was
detected at 46-48 h of incubation with p95HER2 TCB or an untargeted
control TCB. Briefly, target cells were harvested with either
StemPro Accutase or Trypsin/EDTA, washed and seeded into
flat-bottom 96-well plates. Cells were left to adhere overnight.
Peripheral blood mononuclear cells (PBMCs) were prepared by
Histopaque density centrifugation of enriched lymphocyte
preparations (buffy coats) or fresh heparinized blood obtained from
healthy human donors. Fresh blood was diluted with sterile PBS and
layered over Histopaque gradient or Ficoll-Paque. After
centrifugation (450.times.g or 400.times.g, 30 minutes, room
temperature, w/o break), the plasma above the PBMC-containing
interphase was discarded and PBMCs transferred in a new falcon tube
subsequently filled with PBS. The mixture was centrifuged
(400.times.g for 5 min or 350.times.g for 10 min at room
temperature, with break), the supernatant was discarded and the
PBMC pellet washed twice with sterile PBS. The resulting PBMC
population was counted and stored in RPMI1640 medium containing 10%
FCS and 1% L-alanyl-L-glutamine (Biochrom, K0302) at 37.degree. C.,
5% CO.sub.2 in cell incubator until further use (no longer than 24
h). For the tumor lysis assay, the p95HER2 TCB or control TCB were
added at the indicated concentrations (range of 1 pM-100 nM in
triplicates). PBMCs were added to target cells at final E:T ratio
of 10:1. Tumor cell lysis was assessed after 46-48 h of incubation
at 37.degree. C., 5% CO.sub.2 by quantification of LDH released
into cell supernatants by apoptotic/necrotic cells (LDH detection
kit, Roche Applied Science, #11 644 793 001 or CytoTox 96
Non-Radioactive Cytotoxicity Assay, Promega, #G1780). Maximal lysis
of the target cells (=100%) was achieved by incubation of target
cells with 1% Triton X-100. Minimal lysis (=0%) refers to target
cells co-incubated with effector cells without bispecific
construct. For the assessment of T cell activation occurring upon
tumor cell lysis, PBMCs were transferred to a round-bottom 96-well
plate, centrifuged at 400.times.g for 4 min and washed with PBS
containing 0.1% BSA. Surface staining for CD8 (APCCy7 anti-human
CD8, Biolegend #301016), CD4 (FITC anti-human CD4, Biolegend
#300506), CD69 (BV421 anti-human CD69, Biolegend #310930) and CD25
(PECy7 anti-human CD25, Biolegend #302612) was performed according
to the suppliers' indications. Cells were washed twice with 150
.mu.l/well PBS containing 0.1% BSA and fixed using 2% PFA. Samples
were analyzed using a BD FACS CantoII.
[0421] Determination of lysis of MCF10A cells stably expressing
Vector, p95HER2, HER2 or the combination after 48 hours incubation
with PBMCs and increasing concentrations of p95HER2 TCB antibody
showed no lysis of the p95HER2 negative control cell line
MCF10A_Vector and only very minor lysis of MCF10A_Her2 cells (FIG.
6). In contrast to that, there was significant lysis of
MCF10A_p95Her2 and MCF10A_p95Her2-Her target cells by p95HER2 TCB
detectable. These results show that p95HER2 TCB induces
target-specific tumor cell lysis.
[0422] Lysis of MCF10A_p95Her2 (FIG. 7A) and HCC-1954 (FIG. 7C)
after incubation for 46 hours with PBMCs (effector: target 10:1)
and increasing concentrations of p95HER2 TCB showed significant
lysis of MCF10A_p95Her2 target cells (EC50 370 pM, maximal release
70%). There was no lysis induced by the untargeted control TCB. For
HCC-1954 cells which express 5.times.lower p95HER2 than
MCF10A_p95Her2, TCB showed some tumor cell lysis (up to 40%) at
high p95HER2 TCB concentrations (25-100 nM). The EC50 could not be
determined. Again, there was no lysis by the untargeted TCB
detectable. Furthermore, there was no lysis of the negative control
cell line MCF10A_Vector (FIG. 7B). These results suggest that the
efficacy of p95HER2 TCB mediated tumor cell lysis is dependent on
the p95HER2 expression level. Cells which express naturally p95HER2
at lower amounts are also suitable targets whereas p95HER2 negative
cells are not lysed.
[0423] CD25 and CD69 expression on CD4+ T cells (FIG. 8) and CD8+ T
cells (FIG. 9) upon killing of MCF10A expressing p95HER2 or Vector
or HCC-1954 after 46 hours mediated by p95HER2 TCB is shown in
FIGS. 8 and 9. In line with tumor cell lysis (FIG. 7) there was
significant T cell activation detectable upon p95HER2 TCB-mediated
lysis of MCF10A_p95Her2 cells. CD4+ as well as CD8+ T cells
upregulated CD25 and CD69 dependent on the TCB concentration.
Whereas p95HER2 TCB induced some lysis of HC-1954 (FIG. 7C), there
was no specific T cell activation detectable compared to the
negative control cell line MCF10A_Vector.
Example 4
Lysis of Cardiomyocytes and Subsequent T Cell Activation Induced by
p95HER2 TCB in Comparison to HER2 TCB
[0424] The binding of p95HER2 TCB and HER2 TCB (SEQ ID NOs 24, 31,
32 and 33; analogous structure to p95HER2 TCB) to cardiomyocytes
and MCF10A transfectants was determined prior to functional
activity assays using these cell types as targets for both TCBs
(FIG. 10). The induction of CD3 signaling in Jurkat NFAT (FIG. 11)
as well as the lysis of cardiomyocytes in comparison to
MCF10A_p95Her2 cells (FIG. 12) and subsequent T cell activation
(FIG. 13) mediated by p95HER2 TCB or HER2 TCB was investigated.
[0425] To determine the binding of the TCBs, cardiomyocytes (iCell
Cardiomyocytes, Cellular Dynamics #CMC-100-110-00) were cultured
according to the supplier's instructions. After 10 days of
cultivation, the cardiomyocytes as well as MCF10A transfectants
were harvested with Cell Dissociation Buffer and stained with 20 nM
p95HER2 TCB or HER2 TCB for 30 min at 4.degree. C. After washing, a
1:20 dilution of AF647-conjugated AffiniPure F(ab')2 Fragment goat
anti-human IgG Fcg Fragment Specific (Jackson Immuno Research Lab
#109-606-098) was added to the cells for 30 min at 4.degree. C. in
the dark. After washing, the cells were resuspended in FACS Buffer
containing PI to exclude dead cells from the following measurement
by flow cytometry. Side by side to the binding experiment,
cardiomyocytes grown for 10 days in 96-well plates were used as
targets to determine CD3 signaling, target cell lysis and T cell
activation. Briefly, two days before the CD3 signaling assay,
MCF10A_p95Her2 were harvested with Cell Dissociation Buffer and
seeded (25000 cells per well) in the same plates next to the
cardiomyocytes. After 2 days, Jurkat-NFAT-luc cells were harvested
and 100000 cells were added to the seeded target cells. After
addition of p95HER2 TCB or HER2 TCB (0.4 pM-100 nM, final volume
100 .mu.l/well), the cells were incubated for 5.5 h at 37.degree.
C. in the incubator. 100 .mu.l/well of cell suspension containing
the non-adherent Jurkat-NFAT-luc cells was transferred into
white-walled 96-well plates and 100 .mu.l/well of One Glo substrate
(Promega) was added to the cells. After 5 min incubation at RT, the
luminescence was determined using a Victor Wallac Pro. One day
before the target cell lysis and T cell activation assay,
MCF10A_p95Her2 were harvested with Cell Dissociation Buffer and
seeded (25000 cells per well) in the same plates next to the
cardiomyocytes. PBMCs isolated as described in example 3 were added
with a final E:T ratio of 10:1. TCBs were diluted in assay medium
(RPMI1640+2% FCS+1% Glutamax) and added to the cells. Target cell
lysis was assessed after 47 h of incubation at 37.degree. C., 5%
CO.sub.2 by quantification of LDH released into cell supernatants
by apoptotic/necrotic cells (LDH detection kit, Roche Applied
Science, #11 644 793 001). Maximal lysis of the target cells
(=100%) was achieved by incubation of target cells with 1% Triton
X-100. Minimal lysis (=0%) refers to target cells co-incubated with
effector cells without bispecific construct. For the assessment of
T cell activation occurring upon tumor cell lysis, PBMCs were
transferred to a round-bottom 96-well plate, centrifuged at
400.times.g for 4 min and washed with PBS containing 0.1% BSA.
Surface staining for CD8 (APC anti-human CD8, BD #55536), CD4 (FITC
anti-human CD4, Biolegend #300506), CD69 (BV421 anti-human CD69,
Biolegend #310930) and CD25 (PECy7 anti-human CD25, Biolegend
#302612) was performed according to the suppliers' indications.
Cells were washed twice with 150 .mu.l/well FACS Buffer and fixed
using BD FACS Lysing solution. Samples were analyzed using a BD
FACS CantoII.
[0426] FIG. 10 shows binding of p95HER2-TCB, HER2-TCB and
untargeted control TCB on MCF10A_p95Her2, MCF10A_Vector,
MCF10A_Her2 and cardiomyocytes analyzed by flow cytometry. HER2 TCB
showed significant binding to cardiomyocytes in contrast to p95HER2
TCB.
[0427] FIG. 11 shows CD3 stimulation of Jurkat NFAT cells mediated
by p95HER2 TCB or HER2 TCB in the presence of cardiomyocytes. In
contrast to p95HER2 TCB, HER2 TCB induced significant CD3 signaling
in Jurkat-NFAT-luc using cardiomyocytes as target cells in contrast
to p95HER2 TCB.
[0428] FIG. 12 shows lysis of MCF10A cells stably expressing
p95HER2 and cardiomyocytes after incubation for 47 hours with PBMCs
(effector: target ratio 10:1) and with increasing concentrations of
p95HER2 TCB or HER2 TCB. HER2 TCB induced significant lysis of
MCF10A_Her2 cells as well as cardiomyocytes, in contrast to p95HER2
TCB which only induced detectable lysis of MCF10A_p95Her2
targets.
[0429] FIG. 13 shows CD25 expression level on CD4+ and CD8+ T cells
upon lysis of MCF10A_p95Her2 and cardiomyocytes after incubation
for 47 hours with PBMCs (effector: target ratio 10:1) and
increasing concentrations of p95HER2 TCB or HER2 TCB. HER2 TCB
induced significant T cell activation upon lysis of MCF10A_Her2
cells as well as cardiomyocytes, in contrast to p95HER2 TCB which
only induced detectable T cell activation in the presence of
MCF10A_p95Her2 target cells but not cardiomyocytes.
[0430] These in vitro results suggest that p95HER2 TCB might lead
to reduced cardiac problems in vivo compared to HER2 TCB.
Example 5
In Vitro and In Vivo PDX (Patient-Derived Xenograft) Models for
p95HER2 TCB Characterization
[0431] Human breast tumors used in this study were from surgical
resections at Vall d'Hebron University Hospital (Spain) and were
obtained following institutional guidelines. The institutional
review boards (IRB) at Vall d'Hebron Hospital provided approval for
this study in accordance with the Declaration of Helsinki. Written
informed consent for the performance of tumor molecular studies was
obtained from all patients who provided tissue. For Breast Cancer
PDXs, fragments of patient samples were implanted into the number
four fat pad of the mice. 17 .beta.-estradiol (1 .mu.M)
(Sigma-Aldrich) and Baytril was added to drinking water.
NOD.CB17-Prkdcscid (NOD/SCID) mice were purchased from Charles
River Laboratories (Paris, France). For the establishment of cell
cultures derived from PDXs, tumors were excised and cut into the
smallest pieces possible with scalpel, incubated for 30 minutes
with collagenase IA (Sigma-Aldrich, #C9891-1G), washed and
resuspended in DMEM:F-12, 10% FBS, 4 mmol/L L-glutamine,
Penicillin/Streptomycin (#P4333-Gibco), 10 mM HEPES (Santa Cruz
Biotechnology, #sc-286961) and 1.75 .mu.g/ml Amphotericin B (Gibco,
#15240062) for 6 hours. Then, medium was carefully removed and
changed to 10% FBS-supplemented Mammocult human medium (StemCell
Technologies, #5620) with Penicillin/Streptomycin, 10 mM HEPES and
1.75 .mu.g/ml Amphotericin B for one week in order to facilitate
the growth of epithelial cells with respect to contaminating mouse
fibroblasts. Cells from p95HER2 positive and negative PDXs were
used as targets for p95HER2 TCB-mediated lysis in vitro. Briefly,
target cells were incubated with PBMCs (E:T 10:1) and p95HER2 TCB
for 48 h at 37.degree. C., 5% CO.sub.2 in humidified incubator. LDH
release was determined with CytoTox 96 Non-Radioactive Cytotoxicity
Assay (Promega, #G1780). 45 min before the assay, 20 .mu.l of lysis
solution was added to the maximum release controls. After the 45
min each 96 well plate was centrifuged for 5 min at 420.times.g and
50 .mu.l of each supernatant was transferred to a new 96 well
plate. 50 .mu.l of CytoTox Reagent was added to each well and the
plate was incubated for 30 min, at RT covered from light. Then 50
.mu.l of the Stop solution was added and the absorbance was
measured at 490 nm. Culture medium background was subtracted from
each measure. The percentage of cytotoxicity was calculated as
follows: % Cytotoxicity=(Experimental abs.-Effector Spontaneous
abs.-Target Spontaneous abs.)/(Target Maximum abs.-Target
Spontaneous abs.). For in vivo testing of p95HER2 TCB, PDX173
Tumors were implanted as previously described in NOD.Cg-Prkdcscid
Il2rgtm1WjI/SzJ mice (Charles River Laboratories, Paris, France).
When tumors reached an average size of 150-200 mm.sup.3, NSG mice
were intraperitoneally injected with 10.times.10.sup.6 PBMCs
resuspended in 200 .mu.l of 1.times.PBS. Tumor xenografts were
measured with calipers 3 times a week, and tumor volume was
determined using the formula:
(length.times.width.sup.2).times.(pi/6). Body weight was monitored
twice a week. At the end of the in vivo studies, tumors were
weighted and then excised. To generate single cell suspensions,
tumors were cut in small pieces and passed to a 50 ml tube
containing 50 .mu.l of collagenase (100 mg/ml) and DNAse 50 .mu.l
(2 mg/ml) in 5 ml of media RPMI. This was incubated at 37.degree.
for 1 hour. The mixture was filtered in a 100 .mu.l cell strainer
and then centrifuged for 5 min at 400.times.g. Then, red blood cell
lysis was performed and after a wash with PBS the cells were
resuspended in PBS, 2.5 mM EDTA, 1% BSA and 5% Horse Serum. Twenty
minutes later, samples were centrifuged and cells were incubated
for 45 min with the following antibody mixture: huCD45-PE, clone
HI30, (#304008); msCD45AF488, clone 30-F11 (#103122);
huCD3Percpcy5.5, clone UCHT1 (#300430); CD8 PE-Cy7, clone SK1
(#344712); CD4BV421, clone OKT4 (#317434); all used at 1:300
dilutions (all from BioLegend). After a wash with PBS, samples were
acquired in a LSR Fortessa (BD Bioscience). Data was analyzed in
FlowJo software.
[0432] FIG. 14A shows immunohistochemistry with p95HER2 antibody of
the p95HER2 positive and p95HER2 negative PDXs from which primary
cultures were generated. Primary cultures from PDXs as shown in
FIG. 14A and from a Triple Negative Breast Cancer (TNBC) PDX were
incubated with 2 .mu.g/ml of p95HER2-TCB and analyzed by flow
cytometry (FIG. 14B). Primary cultures from PDXs as shown in FIG.
14A were incubated with PBMCs (effector: target=10:1) and with
increasing concentrations of p95HER2 TCB for 48 hours (FIG. 14C).
Cell lysis was determined by LDH release. The p95HER2 positive
PDX67 was lysed at high concentrations of p95HER2 TCB in the
presence of PBMCs whereas there was no lysis of p95HER2 negative
PDX118. These results confirm the target antigen-specific lysis by
p95HER2 TCB.
[0433] FIG. 15A shows the experimental workflow for in vivo testing
of p95HER2 TCB. PDX173, p95HER2+, was implanted into the mammary
fat pad of NSG mice. When tumors reached an average volume of 200
mm.sup.3 animals were humanized with 10.sup.7 freshly isolated
PBMCs and randomized into the 4 experimental groups. Treatments
started 48 h after PBMC injection. FIG. 15B shows the media of the
percentage change in tumor volume for each of the experimental
groups and for individual animals. FIGS. 15C and 15D show tumor
weights at the end of the experiment. t-test, *p<0.05,
**p<0.01, ***p<0.001. ns, non-significant. Trastuzumab and
p95HER2 TCB both significantly reduced the tumor size in treated
mice.
[0434] FIG. 16 A-D shows determination of tumor-infiltrating immune
cells. Tumors were excised and single cell suspensions were stained
with an antibody mixture containing: msCD45, huCD45, huCD3, huCD4
and huCD8. Samples were analyzed by flow cytometry. t-test,
*p<0.05, **p<0.01, ***p<0.001. ns, non-significant. FIG.
16E shows the percentage of huCD8 in FFPE tumor samples determined
by immunohistochemical analysis. Treatment with p95HER2 TCB and
with Trastuzumab led to enhanced infiltration of CD45 cells as well
as CD8+ and CD4+ T cells into the tumors.
Example 6
Effect of p95HER2 TCB on the Growth of Xenografts of Cells
Expressing p95HER2 and of a Patient-Derived Xenograft (PDX)
Material and Methods
Cell Lines
[0435] MCF7 were obtained from ATCC-LGC Standard and were
maintained at 37.degree. C. and 5% CO.sub.2 within Dulbecco's
minimal essential medium: F12 (DMEM:F12) (1:1) #21331-046
(Gibco-Life Technologies, Rockville, Md., USA) supplemented with
10% fetal bovine serum (FBS) #10270-106 (Gibco-Life Technologies)
and 1% L-glutamine (#M11-004 (PAA Laboratories-GE Healthcare,
Pasching, Austria). MCF7 TetOn-p95HER2 cell line was generated by
lentiviral transduction of pinducer-p95HER2. Briefly, p95HER2
sequence was cloned into pENTR1A Dual Selection Vector from
Invitrogen, using BglII/BamHI (5') and NotI (3') restriction sites,
and used as the Entry vector to introduce the sequence into the
Destination vector pInducer20-Neo-Luc (#44012, Addgene) using
GateWay LR reaction. Polyclonal population was selected and
maintained with 200 .mu.g/ml Geneticin. MCF7 double TetOn for
p95HER2 and shp21 or p95HER2 and sh-nt cell lines were generated by
lentiviral transduction of the previously generated MCF7
TetOn-p95HER2 with pTRIPz-shp21 or pTRIPz-empty vector. Briefly,
short-hairpin sequence for targeting p21 mRNA (NM_000389) was
removed from pGIPZ CDKN1A shRNA from Open Biosystems-Thermo
Scientific (RHS4430-200281172 clone V3LHS-322234) using XhoI and
MluI restriction enzimes, and inserted into the same sites of
pTRIPz vector (Open Biosystems, Thermo Scientific) using standard
cloning techniques. Polyclonal population was selected for at least
48 h with 1 .mu.g/ml puromycin, double resistant population
maintained with 200 .mu.g/ml geneticin and 1 .mu.g/ml
puromycin.
Proliferation Assay
[0436] Proliferation was analyzed by cell counting. Briefly,
1.times.10.sup.5 cells per well were seeded in 6-well plates. At
the indicated times: 0 (10 h was counted as time 0), 24 h, 48 h, 72
h and 144 h cells were detached with trypsin-EDTA and viable cells
were determined by trypan blue dye exclusion and counted on a
Neubauer-chamber.
In Vivo Assay in MCF7-p95HER2 Xenograft
[0437] NSG mice were injected orthotopically with 3.times.10.sup.6
MCF7 Tet-On-p95HER2 sh-p21 cells. Once tumors reached 200 mm.sup.3
animals were injected with 1.times.10.sup.7 PBMCs obtained from
healthy donors. After 48 h animals begun to be treated bi-weekly
with 2.5 mg/kg of p95HER2 TCB (i.v.). The animals were maintained
in the presence of doxycycline (1 g/L) in the drinking water.
In Vivo Assay in Patient-Derived Xenograft (PDX)
[0438] Human tumors used to establish PDXs were from biopsies or
surgical resections at Vall d'Hebron University Hospital (Spain)
and were obtained following institutional guidelines. The
institutional review boards (IRB) at Vall d'Hebron Hospital
provided approval for this study. Written informed consent for the
performance of tumor molecular studies was obtained from all
patients who provided tissue.
[0439] Fragments of patient tumor samples were implanted into the
number four fat pad of NOD.Cg-Prkdc.sup.scid Il2rg.sup.tm1WjI/SzJ
(NSG) (Charles River Laboratories (Paris, France). 17
.beta.-estradiol (1 .mu.M) (#E8875-1G, Sigma-Aldrich) and Baytril
was added to drinking water. Tumor xenografts were measured with
calipers three times a week, and tumor volume was determined using
the formula: (length.times.width).times.(pi/6). Body weight was
monitored twice a week. Once tumors reached a media of 250
mm.sup.3, mice were randomized into the experimental groups and
10.sup.7 PBMCs obtained from healthy donors were injected into mice
(i.p). Treatments were initiated 48 h post-PBMCs injections.
Immune Cell Infiltration in Tumors
[0440] At the end of the in vivo studies, tumors were weighted and
then excised. To generate single cell suspensions, tumors were cut
in small pieces and passed to a 50 ml tube containing 50 .mu.l of
collagenase (100 mg/ml) and DNAse 50 .mu.l (2 mg/ml) in 5 ml of
media RPMI. This was incubated at 37.degree. C. for 1 hour. The
mixture was filtered in a 100 .mu.m cell strainer and then
centrifuged for 5 min at 400 g. Then, red blood cell lysis was
performed and after a wash with 1.times.PBS the cells were
resuspended in 1.times.PBS, 2.5 mM EDTA, 1% BSA and 5% Horse Serum.
Twenty minutes later, samples were centrifuged and cells were
incubated for 45 min with the following antibody mixture:
huCD45-PE, clone HI30, (#304008); msCD45AF488, clone 30-F11
(#103122); huCD3Percpcy5.5, clone UCHT1 (#300430); CD8 PE-Cy7,
clone SK1 (#344712); CD4BV421, clone OKT4 (#317434); all used at
1:300 dilutions (all from BioLegend). After a wash with
1.times.PBS, samples were acquired in a LSR Fortessa (BD
Bioscience). Data was analyzed in FlowJo software.
Immunohistochemistry (IHC)
[0441] Tumor samples were fixed in 4% formaldehyde (#2529311315,
Panreac) and then paraffin included. Stainings were performed on 5
.mu.m paraffin cuts in a Dako Autostainer Plus machine (Dako)
according to the manufacturer's instructions. Antibodies: anti-CD8
(rabbit monoclonal) clone SP57 (#5937248001, Ventana, Roche).
Certified pathologists quantified the percentage of CD8 in tumor
samples, Anti-Human Cytokeratin (monoclonal mouse), clones AE1/AE3
(#M3515, Dako).
Results
[0442] FIG. 17 shows the effect of p95HER2 TCB on the growth of
xenografts of cells expressing p95HER2.
[0443] MCF7 cells were stably transduced with p95HER2 under the
control of a doxycycline-inducible promoter, and a non-targeting
shRNA (sh-NT) or a shRNA targeting p21 (sh-p21) under the control
of an independent doxycycline-inducible promoter (FIG. 17A). As
previously shown (Angelini et al., Cancer Res 73, 450-8 (2013)),
expression of p95HER2 in control MCF7 cells leads to oncogene
induced senescence, and thus, to the inhibition of cell
proliferation (FIG. 17B, sh-NT +Dox) and a profound morphological
change (FIG. 17C, sh-NT +Dox). Downmodulation of p21 overcomes
senescence (FIG. 17B, sh-p21; FIG. 17C, shp21).
[0444] FIG. 17D shows the effect of p95HER2 TCB on the growth MCF7
p95HER2 cells as xenografts. NSG mice (n=6 per group) were injected
with 10.sup.6 MCF7 Tet-On p95HER2 sh-p21 cells. When tumors reached
.about.200 mm.sup.3 (shadowed), human PBMCs from a healthy
volunteer were transferred by i.p. injection (10.sup.7
cells/mouse). Mice were treated with vehicle (control) or 1 mg/kg
of p95HER2 TCB (arrows). Tumor volumes were measured by caliper.
Graphs display averages; error bars correspond to 95% confidence
intervals. P values were calculated using the two-sided Student's t
test; *P<0.05, ** P<0.01.
[0445] FIG. 17E shows levels of human CD45.sup.+ after PBMCs
injection. Leukocytes from mice analyzed in FIG. 17D were obtained
15 days after injection and they were stained with anti-huCD45 and
quantified by flow cytometry. Box plots show the percentage
CD45.sup.+ cells in the mice analyzed in FIG. 17D. Lower and higher
whiskers indicate 10.sup.th and 90.sup.th percentiles,
respectively; lower and higher edges of box indicate 25.sup.th and
75.sup.th percentiles, respectively; the inner line in the box
indicates 50.sup.th percentile.
[0446] FIG. 17F shows the effect of p95HER2 TCB on tumor weight. At
the end of the experiment shown in FIG. 17D, tumors were removed
and weighted. The results are expressed as averages; error bars
correspond to 95% confidence intervals. P values were calculated
using the two-sided Student's t test; *P<0.05.
[0447] FIG. 18 shows the effect of p95HER2 TCB on the growth of a
patient-derived xenograft (PDX).
[0448] FIG. 18A shows the analysis of the expression of p95HER2 by
immunohistochemistry. A sample from the indicated PDX was stained
with specific anti-p95HER2 antibodies as previously described
(ParraPalau et al., Cancer Res 70, 8537-46 (2010)).
[0449] FIG. 18B shows the effect of p95HER2 TCB on tumor growth.
NSG mice (n=6 per group) carrying the indicated PDX were monitored
until tumors reached .about.0.300 mm.sup.3 (shadowed). Then, human
PBMCs from a healthy volunteer were transferred by i.p. injection
(10.sup.7 cells/mouse). Mice were treated with vehicle (control) or
1 mg/kg of p95HER2 TCB (arrows). Tumor volumes were measured by
caliper. Graphs display averages; error bars correspond to 95%
confidence intervals. P values were calculated using the two-sided
Student's t test; *P<0.05.
[0450] FIG. 18C shows levels of human CD45.sup.+ after PBMCs
injection. Leukocytes from mice analyzed in B were obtained 15 days
after injection and they were stained with anti-huCD45 and
quantified by flow cytometry. Box plots show the percentage
CD45.sup.+ cells in the mice analyzed in FIG. 18B. Lower and higher
whiskers indicate 10.sup.th and 90.sup.th percentiles,
respectively; lower and higher edges of box indicate 25.sup.th and
75.sup.th percentiles, respectively; the inner line in the box
indicates 50.sup.th percentile.
[0451] FIG. 18D shows the effect of p95HER2 TCB on tumor weight. At
the end of the experiment shown in FIG. 18B, tumors were removed
and weighted. The results are expressed as averages; error bars
correspond to 95% confidence intervals. P values were calculated
using the two-sided Student's t test; *P<0.05.
[0452] FIG. 18E shows the effect of p95HER2 TCB in T cell
infiltration. At the end of the experiment shown in FIG. 18B, tumor
samples corresponding to the experiment shown in FIG. 18B were
disaggregated to single cells, stained with anti-human CD3, CD8 and
CD4, and the number of positive cells was quantified by flow
cytometry. Box plots show the percentage of the cells positive for
the indicated marker. Lower and higher whiskers indicate 10.sup.th
and 90.sup.th percentiles, respectively; lower and higher edges of
box indicate 25.sup.th and 75.sup.th percentiles, respectively; the
inner line in the box indicates 50.sup.th percentile. P values were
calculated using the two-sided Student's t test; *P<0.05,
**P<0.01.
[0453] FIG. 18F shows the effect of p95HER2 TCB on tumor cells. At
the end of the experiment shown in FIG. 18B, sagittal cuts of
tumors were stained with anti-human cytokeratine antibodies and the
percentage of positive cells was quantified. The results are
expressed as averages; error bars correspond to 95% confidence
intervals. P values were calculated using the two-sided Student's t
test; ***P<0.001. Representative stainings are shown in FIG.
18G.
[0454] These data allow us to conclude that p95HER2 TCB impairs the
growth of a patient-derived xenograft (FIGS. 18B and D) without
increasing the levels of circulating leukocytes (Figure. 18C).
p95HER2 TCB effectively recruits T lymphocytes (both CD4- and
CD8-positive T lymphocytes to tumors) (FIG. 18E).
[0455] The levels of cytokeratin (a marker of mammary tumor cells
in the tumors after the treatment) (FIGS. 18F and 18G) shows that
the measure of tumor volume (FIG. 18B) or tumor weight (FIG. 18D)
leads to the underestimation of the anti-tumor effect of p95HER2
TCB since the remaining lesions in p95HER2 TCB are largely devoid
of tumoral cells (FIGS. 18F and G).
Example 7
Lysis of MCF10A Transfectants and Subsequent T Cell Activation
Induced by p95HER2 TCB in Comparison to HER2 TCB
[0456] The lysis of target cells and subsequent T cell activation
mediated by p95HER2 TCB was assessed using MCF10A_p95Her2,
MCF10A_Her2, MCF10A_p95Her2-Her2 and MCF10A_Vector transfectants as
well as MCF7 cells, essentially as described in the previous
examples. Human PBMCs were used as effectors and tumor lysis was
detected at 46-48 h of incubation with p95HER2 TCB or HER2 TCB.
MCF10A and MCF7 cells were incubated with increasing concentrations
of HER2 TCB (FIG. 19A) or p95HER2 TCB (FIG. 19B) and with PBMCs in
a 10:1 ratio. After 48 h supernatants were collected and lysis was
measured by LDH release. PBMCs from the experiment with
MCF10A-Vector cells were collected, stained for
huCD45/CD8/CD4/CD69/CD25 and analyzed by flow cytometry (FIG.
19C).
Example 8
Binding of p95HER2 TCB to MCF10A Cells Expressing HER2 or HER2
(M611A)
[0457] Despite the clear preference of binding to cells expressing
p95HER2, p95HER2 TCB also bound to HER2 expressing cells (FIG. 5B).
This residual binding could be due to the interaction with the
full-length receptor or, alternatively, to low levels of expression
of p95HER2 in cells overexpressing HER2. Since p95HER2 is
synthesized from the mRNA encoding HER2 through alternative
initiation of translation from the AUG codon encoding methionine
611 (Pedersen et al. (2009) Mol Cell Biol 29, 3319-3331), we
analyzed the binding of p95HER2 TCB to MCF10A cells expressing a
cDNA construct with a methionine to alanine mutation in position
611 (M611A). The results clearly showed that the binding of the
p95HER2-TCB to cells overexpressing HER2 is largely due to the
generation of low levels of p95HER2 synthesized by alternative
initiation of translation from methionine 611 (FIGS. 20 A and B).
This result highlights the specificity of the p95HER2 TCB.
[0458] Although the foregoing invention has been described in some
detail by way of illustration and example for purposes of clarity
of understanding, the descriptions and examples should not be
construed as limiting the scope of the invention. The disclosures
of all patent and scientific literature cited herein are expressly
incorporated in their entirety by reference.
Sequence CWU 1
1
331207PRTHomo sapiens 1Met Gln Ser Gly Thr His Trp Arg Val Leu Gly
Leu Cys Leu Leu Ser1 5 10 15Val Gly Val Trp Gly Gln Asp Gly Asn Glu
Glu Met Gly Gly Ile Thr 20 25 30Gln Thr Pro Tyr Lys Val Ser Ile Ser
Gly Thr Thr Val Ile Leu Thr 35 40 45Cys Pro Gln Tyr Pro Gly Ser Glu
Ile Leu Trp Gln His Asn Asp Lys 50 55 60Asn Ile Gly Gly Asp Glu Asp
Asp Lys Asn Ile Gly Ser Asp Glu Asp65 70 75 80His Leu Ser Leu Lys
Glu Phe Ser Glu Leu Glu Gln Ser Gly Tyr Tyr 85 90 95Val Cys Tyr Pro
Arg Gly Ser Lys Pro Glu Asp Ala Asn Phe Tyr Leu 100 105 110Tyr Leu
Arg Ala Arg Val Cys Glu Asn Cys Met Glu Met Asp Val Met 115 120
125Ser Val Ala Thr Ile Val Ile Val Asp Ile Cys Ile Thr Gly Gly Leu
130 135 140Leu Leu Leu Val Tyr Tyr Trp Ser Lys Asn Arg Lys Ala Lys
Ala Lys145 150 155 160Pro Val Thr Arg Gly Ala Gly Ala Gly Gly Arg
Gln Arg Gly Gln Asn 165 170 175Lys Glu Arg Pro Pro Pro Val Pro Asn
Pro Asp Tyr Glu Pro Ile Arg 180 185 190Lys Gly Gln Arg Asp Leu Tyr
Ser Gly Leu Asn Gln Arg Arg Ile 195 200 2052198PRTMacaca
fascicularis 2Met Gln Ser Gly Thr Arg Trp Arg Val Leu Gly Leu Cys
Leu Leu Ser1 5 10 15Ile Gly Val Trp Gly Gln Asp Gly Asn Glu Glu Met
Gly Ser Ile Thr 20 25 30Gln Thr Pro Tyr Gln Val Ser Ile Ser Gly Thr
Thr Val Ile Leu Thr 35 40 45Cys Ser Gln His Leu Gly Ser Glu Ala Gln
Trp Gln His Asn Gly Lys 50 55 60Asn Lys Glu Asp Ser Gly Asp Arg Leu
Phe Leu Pro Glu Phe Ser Glu65 70 75 80Met Glu Gln Ser Gly Tyr Tyr
Val Cys Tyr Pro Arg Gly Ser Asn Pro 85 90 95Glu Asp Ala Ser His His
Leu Tyr Leu Lys Ala Arg Val Cys Glu Asn 100 105 110Cys Met Glu Met
Asp Val Met Ala Val Ala Thr Ile Val Ile Val Asp 115 120 125Ile Cys
Ile Thr Leu Gly Leu Leu Leu Leu Val Tyr Tyr Trp Ser Lys 130 135
140Asn Arg Lys Ala Lys Ala Lys Pro Val Thr Arg Gly Ala Gly Ala
Gly145 150 155 160Gly Arg Gln Arg Gly Gln Asn Lys Glu Arg Pro Pro
Pro Val Pro Asn 165 170 175Pro Asp Tyr Glu Pro Ile Arg Lys Gly Gln
Gln Asp Leu Tyr Ser Gly 180 185 190Leu Asn Gln Arg Arg Ile
1953125PRTArtificial SequenceCD3 VH 3Glu Val Gln Leu Leu Glu Ser
Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys
Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr 20 25 30Ala Met Asn Trp Val
Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Arg Ile Arg
Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60Ser Val Lys
Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr65 70 75 80Leu
Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 85 90
95Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Phe
100 105 110Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115
120 12545PRTArtificial SequenceCD3 HCDR1 4Thr Tyr Ala Met Asn1
5519PRTArtificial SequenceCD3 HCDR2 5Arg Ile Arg Ser Lys Tyr Asn
Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser1 5 10 15Val Lys
Gly614PRTArtificial SequenceCD3 HCDR3 6His Gly Asn Phe Gly Asn Ser
Tyr Val Ser Trp Phe Ala Tyr1 5 107109PRTArtificial SequenceCD3 VL
7Gln Ala Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly1 5
10 15Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Thr
Ser 20 25 30Asn Tyr Ala Asn Trp Val Gln Glu Lys Pro Gly Gln Ala Phe
Arg Gly 35 40 45Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Thr Pro
Ala Arg Phe 50 55 60Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr
Leu Ser Gly Ala65 70 75 80Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys
Ala Leu Trp Tyr Ser Asn 85 90 95Leu Trp Val Phe Gly Gly Gly Thr Lys
Leu Thr Val Leu 100 105814PRTArtificial SequenceCD3 LCDR1 8Gly Ser
Ser Thr Gly Ala Val Thr Thr Ser Asn Tyr Ala Asn1 5
1097PRTArtificial SequenceCD3 LCDR2 9Gly Thr Asn Lys Arg Ala Pro1
5109PRTArtificial SequenceCD3 LCDR3 10Ala Leu Trp Tyr Ser Asn Leu
Trp Val1 51110PRTArtificial Sequencelinker 1 11Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser1 5 101211PRTArtificial Sequencelinker 2 12Asp
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser1 5 1013225PRTHomo sapiens
13Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly1
5 10 15Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
Met 20 25 30Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
Ser His 35 40 45Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
Val Glu Val 50 55 60His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
Asn Ser Thr Tyr65 70 75 80Arg Val Val Ser Val Leu Thr Val Leu His
Gln Asp Trp Leu Asn Gly 85 90 95Lys Glu Tyr Lys Cys Lys Val Ser Asn
Lys Ala Leu Pro Ala Pro Ile 100 105 110Glu Lys Thr Ile Ser Lys Ala
Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125Tyr Thr Leu Pro Pro
Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 130 135 140Leu Thr Cys
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu145 150 155
160Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
Thr Val 180 185 190Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
Cys Ser Val Met 195 200 205His Glu Ala Leu His Asn His Tyr Thr Gln
Lys Ser Leu Ser Leu Ser 210 215 220Pro225145PRTArtificial
Sequencep95HER2 HCDR1 14Asp Phe Gly Met Ser1 51517PRTArtificial
Sequencep95HER2 HCDR2 15Thr Ile Asn Thr Asn Gly Gly Thr Thr His Tyr
Pro Asp Asn Val Lys1 5 10 15Gly165PRTArtificial Sequencep95HER2
HCDR3 16Glu Gly Leu Asp Tyr1 51711PRTArtificial Sequencep95HER2
LCDR1 17Lys Ala Ser Gln Ser Val Gly Thr Ala Val Ala1 5
10187PRTArtificial Sequencep95HER2 LCDR2 18Ser Ala Ser Asn Arg Phe
Thr1 5199PRTArtificial Sequencep95HER2 LCDR3 19Gln Gln Tyr Ser Thr
Tyr Pro Leu Ala1 520114PRTArtificial Sequencep95HER2 VH 20Glu Val
Gln Leu Val Glu Ser Gly Gly Gly Ile Val Gln Pro Gly Gly1 5 10 15Ser
Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Asp Phe 20 25
30Gly Met Ser Trp Ile Arg Gln Thr Pro Asp Lys Arg Leu Glu Leu Val
35 40 45Ala Thr Ile Asn Thr Asn Gly Gly Thr Thr His Tyr Pro Asp Asn
Val 50 55 60Lys Gly Arg Phe Ser Ile Ser Arg Asp Asn Ala Lys Lys Phe
Val Tyr65 70 75 80Leu Gln Met Ser Ser Leu Lys Ser Asp Asp Thr Ala
Ile Tyr Tyr Cys 85 90 95Pro Arg Glu Gly Leu Asp Tyr Trp Gly Gln Gly
Thr Thr Leu Thr Val 100 105 110Ser Ser21107PRTArtificial
Sequencep95HER2 VL 21Asp Ile Val Leu Thr Gln Ser Gln Lys Phe Met
Ser Thr Ser Val Gly1 5 10 15Asp Arg Val Ser Ile Ile Cys Lys Ala Ser
Gln Ser Val Gly Thr Ala 20 25 30Val Ala Trp Tyr Gln Leu Lys Ala Gly
Gln Ser Pro Lys Leu Leu Ile 35 40 45Tyr Ser Ala Ser Asn Arg Phe Thr
Gly Val Pro Asp Arg Phe Thr Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe
Thr Leu Thr Ile Ser Asn Val Gln Ser65 70 75 80Glu Asp Leu Ala Asp
Tyr Phe Cys Gln Gln Tyr Ser Thr Tyr Pro Leu 85 90 95Ala Phe Gly Ala
Gly Thr Lys Leu Glu Leu Lys 100 10522442PRTArtificial
Sequencep95HER2 VH-CH1(EE)-Fc (hole, P329G LALA) 22Glu Val Gln Leu
Val Glu Ser Gly Gly Gly Ile Val Gln Pro Gly Gly1 5 10 15Ser Leu Lys
Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Asp Phe 20 25 30Gly Met
Ser Trp Ile Arg Gln Thr Pro Asp Lys Arg Leu Glu Leu Val 35 40 45Ala
Thr Ile Asn Thr Asn Gly Gly Thr Thr His Tyr Pro Asp Asn Val 50 55
60Lys Gly Arg Phe Ser Ile Ser Arg Asp Asn Ala Lys Lys Phe Val Tyr65
70 75 80Leu Gln Met Ser Ser Leu Lys Ser Asp Asp Thr Ala Ile Tyr Tyr
Cys 85 90 95Pro Arg Glu Gly Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu
Thr Val 100 105 110Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
Leu Ala Pro Ser 115 120 125Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala
Leu Gly Cys Leu Val Glu 130 135 140Asp Tyr Phe Pro Glu Pro Val Thr
Val Ser Trp Asn Ser Gly Ala Leu145 150 155 160Thr Ser Gly Val His
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu 165 170 175Tyr Ser Leu
Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr 180 185 190Gln
Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val 195 200
205Asp Glu Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro
210 215 220Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe
Leu Phe225 230 235 240Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
Arg Thr Pro Glu Val 245 250 255Thr Cys Val Val Val Asp Val Ser His
Glu Asp Pro Glu Val Lys Phe 260 265 270Asn Trp Tyr Val Asp Gly Val
Glu Val His Asn Ala Lys Thr Lys Pro 275 280 285Arg Glu Glu Gln Tyr
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295 300Val Leu His
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val305 310 315
320Ser Asn Lys Ala Leu Gly Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala
325 330 335Lys Gly Gln Pro Arg Glu Pro Gln Val Cys Thr Leu Pro Pro
Ser Arg 340 345 350Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Ser Cys
Ala Val Lys Gly 355 360 365Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
Glu Ser Asn Gly Gln Pro 370 375 380Glu Asn Asn Tyr Lys Thr Thr Pro
Pro Val Leu Asp Ser Asp Gly Ser385 390 395 400Phe Phe Leu Val Ser
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln 405 410 415Gly Asn Val
Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420 425 430Tyr
Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 44023667PRTArtificial
Sequencep95HER2 VH-CH1(EE)-CD3 VL-CH1-Fc (knob, P329G LALA) 23Glu
Val Gln Leu Val Glu Ser Gly Gly Gly Ile Val Gln Pro Gly Gly1 5 10
15Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Asp Phe
20 25 30Gly Met Ser Trp Ile Arg Gln Thr Pro Asp Lys Arg Leu Glu Leu
Val 35 40 45Ala Thr Ile Asn Thr Asn Gly Gly Thr Thr His Tyr Pro Asp
Asn Val 50 55 60Lys Gly Arg Phe Ser Ile Ser Arg Asp Asn Ala Lys Lys
Phe Val Tyr65 70 75 80Leu Gln Met Ser Ser Leu Lys Ser Asp Asp Thr
Ala Ile Tyr Tyr Cys 85 90 95Pro Arg Glu Gly Leu Asp Tyr Trp Gly Gln
Gly Thr Thr Leu Thr Val 100 105 110Ser Ser Ala Ser Thr Lys Gly Pro
Ser Val Phe Pro Leu Ala Pro Ser 115 120 125Ser Lys Ser Thr Ser Gly
Gly Thr Ala Ala Leu Gly Cys Leu Val Glu 130 135 140Asp Tyr Phe Pro
Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu145 150 155 160Thr
Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu 165 170
175Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr
180 185 190Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr
Lys Val 195 200 205Asp Glu Lys Val Glu Pro Lys Ser Cys Asp Gly Gly
Gly Gly Ser Gly 210 215 220Gly Gly Gly Ser Gln Ala Val Val Thr Gln
Glu Pro Ser Leu Thr Val225 230 235 240Ser Pro Gly Gly Thr Val Thr
Leu Thr Cys Gly Ser Ser Thr Gly Ala 245 250 255Val Thr Thr Ser Asn
Tyr Ala Asn Trp Val Gln Glu Lys Pro Gly Gln 260 265 270Ala Phe Arg
Gly Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Thr 275 280 285Pro
Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr 290 295
300Leu Ser Gly Ala Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Ala
Leu305 310 315 320Trp Tyr Ser Asn Leu Trp Val Phe Gly Gly Gly Thr
Lys Leu Thr Val 325 330 335Leu Ser Ser Ala Ser Thr Lys Gly Pro Ser
Val Phe Pro Leu Ala Pro 340 345 350Ser Ser Lys Ser Thr Ser Gly Gly
Thr Ala Ala Leu Gly Cys Leu Val 355 360 365Lys Asp Tyr Phe Pro Glu
Pro Val Thr Val Ser Trp Asn Ser Gly Ala 370 375 380Leu Thr Ser Gly
Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly385 390 395 400Leu
Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly 405 410
415Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys
420 425 430Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His
Thr Cys 435 440 445Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro
Ser Val Phe Leu 450 455 460Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
Ile Ser Arg Thr Pro Glu465 470 475 480Val Thr Cys Val Val Val Asp
Val Ser His Glu Asp Pro Glu Val Lys 485 490 495Phe Asn Trp Tyr Val
Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 500 505 510Pro Arg Glu
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 515 520 525Thr
Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 530 535
540Val Ser Asn Lys Ala Leu Gly Ala Pro Ile Glu Lys Thr Ile Ser
Lys545 550 555 560Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
Leu Pro Pro Cys 565 570 575Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
Leu Trp Cys Leu Val Lys 580 585 590Gly Phe Tyr Pro Ser Asp Ile Ala
Val Glu Trp Glu Ser Asn Gly Gln 595 600 605Pro Glu Asn Asn Tyr Lys
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 610 615 620Ser Phe Phe Leu
Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln625 630 635 640Gln
Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 645 650
655His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 660
66524232PRTArtificial SequenceCD3 VH-CL 24Glu Val Gln Leu Leu Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser
Cys Ala Ala Ser Gly Phe Thr Phe
Ser Thr Tyr 20 25 30Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly
Leu Glu Trp Val 35 40 45Ser Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala
Thr Tyr Tyr Ala Asp 50 55 60Ser Val Lys Gly Arg Phe Thr Ile Ser Arg
Asp Asp Ser Lys Asn Thr65 70 75 80Leu Tyr Leu Gln Met Asn Ser Leu
Arg Ala Glu Asp Thr Ala Val Tyr 85 90 95Tyr Cys Val Arg His Gly Asn
Phe Gly Asn Ser Tyr Val Ser Trp Phe 100 105 110Ala Tyr Trp Gly Gln
Gly Thr Leu Val Thr Val Ser Ser Ala Ser Val 115 120 125Ala Ala Pro
Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 130 135 140Ser
Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg145 150
155 160Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly
Asn 165 170 175Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
Thr Tyr Ser 180 185 190Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp
Tyr Glu Lys His Lys 195 200 205Val Tyr Ala Cys Glu Val Thr His Gln
Gly Leu Ser Ser Pro Val Thr 210 215 220Lys Ser Phe Asn Arg Gly Glu
Cys225 23025214PRTArtificial Sequencep95HER2 VL-CL(RK) 25Asp Ile
Val Leu Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly1 5 10 15Asp
Arg Val Ser Ile Ile Cys Lys Ala Ser Gln Ser Val Gly Thr Ala 20 25
30Val Ala Trp Tyr Gln Leu Lys Ala Gly Gln Ser Pro Lys Leu Leu Ile
35 40 45Tyr Ser Ala Ser Asn Arg Phe Thr Gly Val Pro Asp Arg Phe Thr
Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val
Gln Ser65 70 75 80Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser
Thr Tyr Pro Leu 85 90 95Ala Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
Arg Thr Val Ala Ala 100 105 110Pro Ser Val Phe Ile Phe Pro Pro Ser
Asp Arg Lys Leu Lys Ser Gly 115 120 125Thr Ala Ser Val Val Cys Leu
Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140Lys Val Gln Trp Lys
Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln145 150 155 160Glu Ser
Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170
175Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr
Lys Ser 195 200 205Phe Asn Arg Gly Glu Cys 21026442PRTArtificial
Sequencep95HER2 VH-CH1-Fc (hole, P329G LALA) 26Glu Val Gln Leu Val
Glu Ser Gly Gly Gly Ile Val Gln Pro Gly Gly1 5 10 15Ser Leu Lys Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Asp Phe 20 25 30Gly Met Ser
Trp Ile Arg Gln Thr Pro Asp Lys Arg Leu Glu Leu Val 35 40 45Ala Thr
Ile Asn Thr Asn Gly Gly Thr Thr His Tyr Pro Asp Asn Val 50 55 60Lys
Gly Arg Phe Ser Ile Ser Arg Asp Asn Ala Lys Lys Phe Val Tyr65 70 75
80Leu Gln Met Ser Ser Leu Lys Ser Asp Asp Thr Ala Ile Tyr Tyr Cys
85 90 95Pro Arg Glu Gly Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr
Val 100 105 110Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
Ala Pro Ser 115 120 125Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu
Gly Cys Leu Val Lys 130 135 140Asp Tyr Phe Pro Glu Pro Val Thr Val
Ser Trp Asn Ser Gly Ala Leu145 150 155 160Thr Ser Gly Val His Thr
Phe Pro Ala Val Leu Gln Ser Ser Gly Leu 165 170 175Tyr Ser Leu Ser
Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr 180 185 190Gln Thr
Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val 195 200
205Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro
210 215 220Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe
Leu Phe225 230 235 240Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
Arg Thr Pro Glu Val 245 250 255Thr Cys Val Val Val Asp Val Ser His
Glu Asp Pro Glu Val Lys Phe 260 265 270Asn Trp Tyr Val Asp Gly Val
Glu Val His Asn Ala Lys Thr Lys Pro 275 280 285Arg Glu Glu Gln Tyr
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295 300Val Leu His
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val305 310 315
320Ser Asn Lys Ala Leu Gly Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala
325 330 335Lys Gly Gln Pro Arg Glu Pro Gln Val Cys Thr Leu Pro Pro
Ser Arg 340 345 350Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Ser Cys
Ala Val Lys Gly 355 360 365Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
Glu Ser Asn Gly Gln Pro 370 375 380Glu Asn Asn Tyr Lys Thr Thr Pro
Pro Val Leu Asp Ser Asp Gly Ser385 390 395 400Phe Phe Leu Val Ser
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln 405 410 415Gly Asn Val
Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420 425 430Tyr
Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 44027685PRTArtificial
Sequencep95HER2 VH-CH1-CD3 VH-CL-Fc (knob, P329G LALA) 27Glu Val
Gln Leu Val Glu Ser Gly Gly Gly Ile Val Gln Pro Gly Gly1 5 10 15Ser
Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Asp Phe 20 25
30Gly Met Ser Trp Ile Arg Gln Thr Pro Asp Lys Arg Leu Glu Leu Val
35 40 45Ala Thr Ile Asn Thr Asn Gly Gly Thr Thr His Tyr Pro Asp Asn
Val 50 55 60Lys Gly Arg Phe Ser Ile Ser Arg Asp Asn Ala Lys Lys Phe
Val Tyr65 70 75 80Leu Gln Met Ser Ser Leu Lys Ser Asp Asp Thr Ala
Ile Tyr Tyr Cys 85 90 95Pro Arg Glu Gly Leu Asp Tyr Trp Gly Gln Gly
Thr Thr Leu Thr Val 100 105 110Ser Ser Ala Ser Thr Lys Gly Pro Ser
Val Phe Pro Leu Ala Pro Ser 115 120 125Ser Lys Ser Thr Ser Gly Gly
Thr Ala Ala Leu Gly Cys Leu Val Lys 130 135 140Asp Tyr Phe Pro Glu
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu145 150 155 160Thr Ser
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu 165 170
175Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr
180 185 190Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr
Lys Val 195 200 205Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Gly Gly
Gly Gly Ser Gly 210 215 220Gly Gly Gly Ser Glu Val Gln Leu Leu Glu
Ser Gly Gly Gly Leu Val225 230 235 240Gln Pro Gly Gly Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Phe Thr 245 250 255Phe Ser Thr Tyr Ala
Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly 260 265 270Leu Glu Trp
Val Ser Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr 275 280 285Tyr
Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp 290 295
300Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu
Asp305 310 315 320Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn Phe
Gly Asn Ser Tyr 325 330 335Val Ser Trp Phe Ala Tyr Trp Gly Gln Gly
Thr Leu Val Thr Val Ser 340 345 350Ser Ala Ser Val Ala Ala Pro Ser
Val Phe Ile Phe Pro Pro Ser Asp 355 360 365Glu Gln Leu Lys Ser Gly
Thr Ala Ser Val Val Cys Leu Leu Asn Asn 370 375 380Phe Tyr Pro Arg
Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu385 390 395 400Gln
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp 405 410
415Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr
420 425 430Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly
Leu Ser 435 440 445Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
Asp Lys Thr His 450 455 460Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
Ala Gly Gly Pro Ser Val465 470 475 480Phe Leu Phe Pro Pro Lys Pro
Lys Asp Thr Leu Met Ile Ser Arg Thr 485 490 495Pro Glu Val Thr Cys
Val Val Val Asp Val Ser His Glu Asp Pro Glu 500 505 510Val Lys Phe
Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 515 520 525Thr
Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser 530 535
540Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
Lys545 550 555 560Cys Lys Val Ser Asn Lys Ala Leu Gly Ala Pro Ile
Glu Lys Thr Ile 565 570 575Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
Gln Val Tyr Thr Leu Pro 580 585 590Pro Cys Arg Asp Glu Leu Thr Lys
Asn Gln Val Ser Leu Trp Cys Leu 595 600 605Val Lys Gly Phe Tyr Pro
Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 610 615 620Gly Gln Pro Glu
Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser625 630 635 640Asp
Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 645 650
655Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
660 665 670His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 675
680 68528214PRTArtificial SequenceCD3 VL-CH1 28Gln Ala Val Val Thr
Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly1 5 10 15Thr Val Thr Leu
Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Thr Ser 20 25 30Asn Tyr Ala
Asn Trp Val Gln Glu Lys Pro Gly Gln Ala Phe Arg Gly 35 40 45Leu Ile
Gly Gly Thr Asn Lys Arg Ala Pro Gly Thr Pro Ala Arg Phe 50 55 60Ser
Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Ala65 70 75
80Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn
85 90 95Leu Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ser Ser
Ala 100 105 110Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser
Ser Lys Ser 115 120 125Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu
Val Lys Asp Tyr Phe 130 135 140Pro Glu Pro Val Thr Val Ser Trp Asn
Ser Gly Ala Leu Thr Ser Gly145 150 155 160Val His Thr Phe Pro Ala
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu 165 170 175Ser Ser Val Val
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr 180 185 190Ile Cys
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys 195 200
205Val Glu Pro Lys Ser Cys 21029214PRTArtificial Sequencep95HER2
VL-CL 29Asp Ile Val Leu Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val
Gly1 5 10 15Asp Arg Val Ser Ile Ile Cys Lys Ala Ser Gln Ser Val Gly
Thr Ala 20 25 30Val Ala Trp Tyr Gln Leu Lys Ala Gly Gln Ser Pro Lys
Leu Leu Ile 35 40 45Tyr Ser Ala Ser Asn Arg Phe Thr Gly Val Pro Asp
Arg Phe Thr Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
Ser Asn Val Gln Ser65 70 75 80Glu Asp Leu Ala Asp Tyr Phe Cys Gln
Gln Tyr Ser Thr Tyr Pro Leu 85 90 95Ala Phe Gly Ala Gly Thr Lys Leu
Glu Leu Lys Arg Thr Val Ala Ala 100 105 110Pro Ser Val Phe Ile Phe
Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125Thr Ala Ser Val
Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140Lys Val
Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln145 150 155
160Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys
Val Tyr 180 185 190Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
Val Thr Lys Ser 195 200 205Phe Asn Arg Gly Glu Cys 21030645PRTHomo
sapiens 30Met Pro Ile Trp Lys Phe Pro Asp Glu Glu Gly Ala Cys Gln
Pro Cys1 5 10 15Pro Ile Asn Cys Thr His Ser Cys Val Asp Leu Asp Asp
Lys Gly Cys 20 25 30Pro Ala Glu Gln Arg Ala Ser Pro Leu Thr Ser Ile
Ile Ser Ala Val 35 40 45Val Gly Ile Leu Leu Val Val Val Leu Gly Val
Val Phe Gly Ile Leu 50 55 60Ile Lys Arg Arg Gln Gln Lys Ile Arg Lys
Tyr Thr Met Arg Arg Leu65 70 75 80Leu Gln Glu Thr Glu Leu Val Glu
Pro Leu Thr Pro Ser Gly Ala Met 85 90 95Pro Asn Gln Ala Gln Met Arg
Ile Leu Lys Glu Thr Glu Leu Arg Lys 100 105 110Val Lys Val Leu Gly
Ser Gly Ala Phe Gly Thr Val Tyr Lys Gly Ile 115 120 125Trp Ile Pro
Asp Gly Glu Asn Val Lys Ile Pro Val Ala Ile Lys Val 130 135 140Leu
Arg Glu Asn Thr Ser Pro Lys Ala Asn Lys Glu Ile Leu Asp Glu145 150
155 160Ala Tyr Val Met Ala Gly Val Gly Ser Pro Tyr Val Ser Arg Leu
Leu 165 170 175Gly Ile Cys Leu Thr Ser Thr Val Gln Leu Val Thr Gln
Leu Met Pro 180 185 190Tyr Gly Cys Leu Leu Asp His Val Arg Glu Asn
Arg Gly Arg Leu Gly 195 200 205Ser Gln Asp Leu Leu Asn Trp Cys Met
Gln Ile Ala Lys Gly Met Ser 210 215 220Tyr Leu Glu Asp Val Arg Leu
Val His Arg Asp Leu Ala Ala Arg Asn225 230 235 240Val Leu Val Lys
Ser Pro Asn His Val Lys Ile Thr Asp Phe Gly Leu 245 250 255Ala Arg
Leu Leu Asp Ile Asp Glu Thr Glu Tyr His Ala Asp Gly Gly 260 265
270Lys Val Pro Ile Lys Trp Met Ala Leu Glu Ser Ile Leu Arg Arg Arg
275 280 285Phe Thr His Gln Ser Asp Val Trp Ser Tyr Gly Val Thr Val
Trp Glu 290 295 300Leu Met Thr Phe Gly Ala Lys Pro Tyr Asp Gly Ile
Pro Ala Arg Glu305 310 315 320Ile Pro Asp Leu Leu Glu Lys Gly Glu
Arg Leu Pro Gln Pro Pro Ile 325 330 335Cys Thr Ile Asp Val Tyr Met
Ile Met Val Lys Cys Trp Met Ile Asp 340 345 350Ser Glu Cys Arg Pro
Arg Phe Arg Glu Leu Val Ser Glu Phe Ser Arg 355 360 365Met Ala Arg
Asp Pro Gln Arg Phe Val Val Ile Gln Asn Glu Asp Leu 370 375 380Gly
Pro Ala Ser Pro Leu Asp Ser Thr Phe Tyr Arg Ser Leu Leu Glu385 390
395 400Asp Asp Asp Met Gly Asp Leu Val Asp Ala Glu Glu Tyr Leu Val
Pro 405 410 415Gln Gln Gly Phe Phe Cys Pro Asp Pro Ala Pro Gly Ala
Gly Gly Met 420 425 430Val His His Arg His Arg Ser Ser Ser Thr Arg
Ser Gly Gly Gly Asp 435 440 445Leu Thr Leu Gly Leu Glu Pro Ser Glu
Glu Glu Ala Pro Arg Ser Pro 450
455 460Leu Ala Pro Ser Glu Gly Ala Gly Ser Asp Val Phe Asp Gly Asp
Leu465 470 475 480Gly Met Gly Ala Ala Lys Gly Leu Gln Ser Leu Pro
Thr His Asp Pro 485 490 495Ser Pro Leu Gln Arg Tyr Ser Glu Asp Pro
Thr Val Pro Leu Pro Ser 500 505 510Glu Thr Asp Gly Tyr Val Ala Pro
Leu Thr Cys Ser Pro Gln Pro Glu 515 520 525Tyr Val Asn Gln Pro Asp
Val Arg Pro Gln Pro Pro Ser Pro Arg Glu 530 535 540Gly Pro Leu Pro
Ala Ala Arg Pro Ala Gly Ala Thr Leu Glu Arg Pro545 550 555 560Lys
Thr Leu Ser Pro Gly Lys Asn Gly Val Val Lys Asp Val Phe Ala 565 570
575Phe Gly Gly Ala Val Glu Asn Pro Glu Tyr Leu Thr Pro Gln Gly Gly
580 585 590Ala Ala Pro Gln Pro His Pro Pro Pro Ala Phe Ser Pro Ala
Phe Asp 595 600 605Asn Leu Tyr Tyr Trp Asp Gln Asp Pro Pro Glu Arg
Gly Ala Pro Pro 610 615 620Ser Thr Phe Lys Gly Thr Pro Thr Ala Glu
Asn Pro Glu Tyr Leu Gly625 630 635 640Leu Asp Val Pro Val
64531448PRTArtificial SequenceHER2 VH-CH1(EE)-Fc (hole, P329G LALA)
31Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1
5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp
Thr 20 25 30Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
Trp Val 35 40 45Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala
Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys
Asn Thr Ala Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp
Thr Ala Val Tyr Tyr Cys 85 90 95Ser Arg Trp Gly Gly Asp Gly Phe Tyr
Ala Met Asp Tyr Trp Gly Gln 100 105 110Gly Thr Leu Val Thr Val Ser
Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125Phe Pro Leu Ala Pro
Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140Leu Gly Cys
Leu Val Glu Asp Tyr Phe Pro Glu Pro Val Thr Val Ser145 150 155
160Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
165 170 175Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr
Val Pro 180 185 190Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn
Val Asn His Lys 195 200 205Pro Ser Asn Thr Lys Val Asp Glu Lys Val
Glu Pro Lys Ser Cys Asp 210 215 220Lys Thr His Thr Cys Pro Pro Cys
Pro Ala Pro Glu Ala Ala Gly Gly225 230 235 240Pro Ser Val Phe Leu
Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255Ser Arg Thr
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270Asp
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280
285Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg
290 295 300Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
Gly Lys305 310 315 320Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
Gly Ala Pro Ile Glu 325 330 335Lys Thr Ile Ser Lys Ala Lys Gly Gln
Pro Arg Glu Pro Gln Val Cys 340 345 350Thr Leu Pro Pro Ser Arg Asp
Glu Leu Thr Lys Asn Gln Val Ser Leu 355 360 365Ser Cys Ala Val Lys
Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380Glu Ser Asn
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val385 390 395
400Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val Asp
405 410 415Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
Met His 420 425 430Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
Ser Leu Ser Pro 435 440 44532673PRTArtificial SequenceHER2
VH-CH1(EE)-CD3 VL-CH1-Fc (knob, P329G LALA) 32Glu Val Gln Leu Val
Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30Tyr Ile His
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ala Arg
Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val 50 55 60Lys
Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr65 70 75
80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly
Gln 100 105 110Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
Pro Ser Val 115 120 125Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
Gly Gly Thr Ala Ala 130 135 140Leu Gly Cys Leu Val Glu Asp Tyr Phe
Pro Glu Pro Val Thr Val Ser145 150 155 160Trp Asn Ser Gly Ala Leu
Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175Leu Gln Ser Ser
Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190Ser Ser
Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200
205Pro Ser Asn Thr Lys Val Asp Glu Lys Val Glu Pro Lys Ser Cys Asp
210 215 220Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Ala Val Val
Thr Gln225 230 235 240Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr
Val Thr Leu Thr Cys 245 250 255Gly Ser Ser Thr Gly Ala Val Thr Thr
Ser Asn Tyr Ala Asn Trp Val 260 265 270Gln Glu Lys Pro Gly Gln Ala
Phe Arg Gly Leu Ile Gly Gly Thr Asn 275 280 285Lys Arg Ala Pro Gly
Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly 290 295 300Gly Lys Ala
Ala Leu Thr Leu Ser Gly Ala Gln Pro Glu Asp Glu Ala305 310 315
320Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn Leu Trp Val Phe Gly Gly
325 330 335Gly Thr Lys Leu Thr Val Leu Ser Ser Ala Ser Thr Lys Gly
Pro Ser 340 345 350Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
Gly Gly Thr Ala 355 360 365Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe
Pro Glu Pro Val Thr Val 370 375 380Ser Trp Asn Ser Gly Ala Leu Thr
Ser Gly Val His Thr Phe Pro Ala385 390 395 400Val Leu Gln Ser Ser
Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 405 410 415Pro Ser Ser
Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His 420 425 430Lys
Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys 435 440
445Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly
450 455 460Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
Leu Met465 470 475 480Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val
Val Asp Val Ser His 485 490 495Glu Asp Pro Glu Val Lys Phe Asn Trp
Tyr Val Asp Gly Val Glu Val 500 505 510His Asn Ala Lys Thr Lys Pro
Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 515 520 525Arg Val Val Ser Val
Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 530 535 540Lys Glu Tyr
Lys Cys Lys Val Ser Asn Lys Ala Leu Gly Ala Pro Ile545 550 555
560Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
565 570 575Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln
Val Ser 580 585 590Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
Ile Ala Val Glu 595 600 605Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
Tyr Lys Thr Thr Pro Pro 610 615 620Val Leu Asp Ser Asp Gly Ser Phe
Phe Leu Tyr Ser Lys Leu Thr Val625 630 635 640Asp Lys Ser Arg Trp
Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 645 650 655His Glu Ala
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 660 665
670Pro33214PRTArtificial SequenceHER2 VL-CL(RK) 33Asp Ile Gln Met
Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val
Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala 20 25 30Val Ala
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr
Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55
60Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65
70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro
Pro 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val
Ala Ala 100 105 110Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Arg Lys
Leu Lys Ser Gly 115 120 125Thr Ala Ser Val Val Cys Leu Leu Asn Asn
Phe Tyr Pro Arg Glu Ala 130 135 140Lys Val Gln Trp Lys Val Asp Asn
Ala Leu Gln Ser Gly Asn Ser Gln145 150 155 160Glu Ser Val Thr Glu
Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175Ser Thr Leu
Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190Ala
Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200
205Phe Asn Arg Gly Glu Cys 210
* * * * *